8-K
Enovis CORP false 0001420800 0001420800 2023-10-19 2023-10-19

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): October 19, 2023

 

 

Enovis Corporation

(Exact name of registrant as specified in its charter)

 

 

Commission File Number: 001-34045

 

Delaware   001-34045   54-1887631

(State or other jurisdiction

of incorporation)

 

(Commission

File Number)

 

(IRS Employer

Identification No.)

 

2711 Centerville Road, Suite 400

Wilmington, DE

  19808
(Address of principal executive offices)   (Zip Code)

Registrant’s telephone number, including area code: (302) 252-9160

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Securities registered pursuant to 12(b) of the Act:

 

Title of Each Class

 

Trading
Symbols

 

Name of Each Exchange
on Which Registered

Common Stock, par value $0.001 per share   ENOV   New York Stock Exchange

 

 

 


Item 2.02.

Results of Operations and Financial Condition.

On October 19, 2023, Enovis Corporation (the “Company”) released the following preliminary information about its performance for the third quarter ended September 29, 2023.

Revenues for the three months ended September 29, 2023 are expected to be between $414 and $418 million, compared to approximately $383 million for the three months ended September 30, 2022, representing an increase of approximately 8 to 9%.

Adjusted EBITDA for the three months ended September 29, 2023 is expected to be between $64 and $66 million, compared to approximately $57 million for the three months ended September 30, 2022, representing an increase of approximately 12 to 15%.

The foregoing preliminary financial estimates reflect management’s current views and may change as a result of management’s review of results and other factors, including a wide variety of significant business, economic and competitive risks and uncertainties. Such preliminary financial information is subject to the finalization and closing of the accounting books and records of the Company (which have yet to be performed) and should not be viewed as a substitute for full quarterly financial statements prepared in accordance with U.S. GAAP. In the course of preparing and finalizing the financial statements for the three months ended September 29, 2023, the preliminary estimates for the three months ended September 29, 2023 will be subject to change and the Company may identify items that will require it to make adjustments to the Company’s preliminary estimates described above. Any such changes could be material. For these or other reasons, the preliminary financial estimates for the three months ended September 29, 2023 may not ultimately be indicative of the Company’s results for such periods and actual results may differ materially from those described above. No independent registered public accounting firm has audited, reviewed or compiled, examined or performed any procedures with respect to these preliminary results, nor have they expressed any opinion or any other form of assurance on these preliminary estimated results.

Adjusted EBITDA is not prepared in accordance with U.S. GAAP and is included in this Current Report on Form 8-K because it is used by the Company’s management to assess its operating performance. The table below provides a reconciliation of preliminary adjusted EBITDA to the closest comparable U.S. GAAP financial measure, net income (loss) from continuing operations, for the three months ended September 29, 2023.

Adjusted EBITDA represents net income or loss from continuing operations excluding taxes, depreciation and amortization, stock-based compensation costs and restructuring and other charges, European Union Medical Device Regulation and other costs, strategic transaction costs, insurance settlement (gain) loss, and inventory step up costs. Adjusted EBITDA should not be considered in isolation from, or as a substitute for, net income (loss) from continuing operations or other measures calculated in accordance with U.S. GAAP.

 

Dollars in millions

(Unaudited)

 
     Three Months Ended September 29, 2023  
       Low(1)                 High(2)    

Net Income (Loss) from continuing operations (GAAP)

   $ (20.1       $ (19.4

Income tax benefit

     (6.0         (6.2

Other Income

        (0.8   

Interest expense, net

        5.8     
  

 

 

       

 

 

 

Operating loss (GAAP)

     (21.1         (20.6

Adjusted to Add:

        

Restructuring and other charges

     5.1           5.6  

Medical Device Regulation (MDR) and other costs(3)

     6.0           6.5  

Strategic transaction costs(4)

     10.3           10.8  

Stock-based compensation

        8.4     

Depreciation and other amortization

        21.5     

Amortization of acquired intangibles

        34.0     

Inventory step-up

        —      
  

 

 

       

 

 

 

Adjusted EBITDA

   $ 64.0         $ 66.0  
  

 

 

       

 

 

 

 

(1)

Assumes a GAAP tax rate of 23%.

(2)

Assumes a GAAP tax rate of 24.2%.

(3)

Primarily related to costs specific to compliance with medical device reporting regulations and other requirements of the European Union MDR. These costs are classified as Selling, general and administrative expense on our Consolidated Statements of Operations.

(4)

Strategic transaction costs includes costs related to the Separation from ESAB Corporation and certain transaction and integration costs related to recent acquisitions.

 

Item 7.01

Regulation FD Disclosure.

In this Current Report on Form 8-K, the Company is furnishing the following information of LimaCorporate S.p.A. (the “Lima”), which it plans to provide to certain investors: (i) audited consolidated financial statements of Lima as of and for the year ended December 31, 2022, attached hereto as Exhibit 99.1 and incorporated by reference in this Item 7.01; (ii) unaudited condensed interim consolidated financial statements of Lima as of and for the six months ended June 30, 2023, attached hereto as Exhibit 99.2 and incorporated by reference in this Item 7.01; and (iii) preliminary unaudited pro forma condensed combined financial statements of the Company and Lima as of and for the six months ended June 30, 2023 and for the year ended December 31, 2022, in each case, that give effect to the Company’s planned acquisition of Lima, attached hereto as Exhibit 99.3 and incorporated by reference in this Item 7.01.

The Company cautions that Lima’s financial statements have been prepared in accordance with International Financial Reporting Standards, as issued by the International Accounting Standards Board and, to the extent audited, have been audited in accordance with International Auditing Standards. These standards differ from generally accepted accounting principles in the United States and the auditing standards promulgated by the PCAOB and American Institute of Certified Public Accountants. The Lima financial statements were not audited or reviewed in accordance with generally accepted accounting standards in the United States or the auditing standards promulgated by the PCAOB and American Institute of Certified Public Accountants. As a result, the pro forma financial information does not comply with Article 11 of Regulation S-X under the Securities Act of 1933, as amended (the “Securities Act”). You should not place undue reliance on such financial statements or on the pro forma financial statements that rely on such financial statements.

The information in this report (including the exhibits) furnished pursuant to Item 7.01 shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section. This report will not be deemed an admission as to the materiality of any information in the report that is required to be disclosed solely by Regulation FD. Furthermore, the information provided in Exhibits 99.1, 99.2 and 99.3 shall not be deemed to be incorporated by reference into the filings of the Company under the Securities Act, unless such incorporation by reference is specifically referenced therein.

 

Item 8.01

Other Events

On October 19, 2023, the Company issued a press release announcing its intention to offer convertible senior notes due 2028 (the “Notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act. The Company also expects to grant the initial purchasers of the Notes an option to purchase additional Notes within a 13-day period beginning on, and including, the initial closing date. A copy of the press release is attached hereto as Exhibit 99.4 and is incorporated herein by reference.

This Current Report on Form 8-K does not constitute an offer to purchase securities or a solicitation of an offer to sell any securities or an offer to sell or the solicitation of an offer to purchase any securities nor does it constitute an offer or solicitation in any jurisdiction in which such offer or solicitation is unlawful.


Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

Exhibit

Number

  

Description

99.1    Audited Consolidated Financial Statements of Lima as of and for the year ended December 31, 2022.
99.2    Unaudited Condensed Consolidated Interim Financial Statements of Lima as of and for the six months ended June 30, 2023.
99.3    Preliminary Unaudited Pro Forma Condensed Combined Financial Statements of the Company and Lima as of and for the Six Months ended June 30, 2023 and for the year ended December 31, 2022.
99.4    Press Release dated October 19, 2023.
104    Cover Page Interactive Data File, formatted in Inline XBRL, and included as Exhibit 101.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: October 19, 2023   ENOVIS CORPORATION
    By:  

/s/ Phillip B. Berry

    Name:   Phillip B. Berry
    Title:  

Senior Vice President

and Chief Financial Officer

EX-99.1

Exhibit 99.1

 

LOGO

KPMG S.p.A.

Revisione e organizzazione contabile

Piazza Salvemini, 20

35131 PADOVA PD

Telefono +39 049 8249101

Email it-fmauditaly@kpmg.it

PEC kpmgspa@pec.kpmg.it

Independent auditors’ report

To the board of directors of

Limacorporate S.p.A.

Report on the audit of the consolidated financial statements

Opinion

We have audited the accompanying consolidated financial statements of the Limacorporate Group (the “group”), which comprise the statement of financial position as at 31 December 2022, the income statement and statements of comprehensive income, cash flows and changes in equity for the year then ended and notes thereto, which include a summary of the significant accounting policies.

In our opinion, the accompanying consolidated financial statements give a true and fair view of the financial position of the Limacorporate Group as at 31 December 2022 and of its financial performance and cash flows for the year then ended in accordance with the International Financial Reporting Standards issued by International Accounting Standards Board (“IFRS issued by the IASB”).

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (ISA). Our responsibilities under those standards are further described in the “Auditors’ responsibilities for the audit of the consolidated financial statements” section of our report. We are independent of Limacorporate S.p.A. (the “parent”) in accordance with the ethics and independence rules and standards applicable in Italy to audits of financial statements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter – IFRS issued by the IASB adoption and error correction

We draw attention to Note 4.1 “Transition to IFRS issued by IASB“ to the consolidated financial statements, which indicates the group has corrected an error related to the payback mechanism accounted in compliance with IFRS 15 that was reported prior to the group’s adoption of the IFRS issued by IASB. Our opinion is not modified in respect of this matter.

Other Matter

The consolidated financial statements of Limacorporate Group as at 31 December 2022 has been prepared for its inclusion in the offering memorandum drawn up by Enovis Corporation as part of its potential issue of notes.

 

 

 

KPMG S.p.A. è una società per azioni di diritto italiano e fa parte del

network KPMG di entità indipendenti affiliate a KPMG International

Limited, società di diritto inglese.

  

Ancona Bari Bergamo Bologna Bolzano Brescia

Catania Como Firenze Genova

Lecce Milano Napoli Novara Padova Palermo Parma Perugia  

Pescara Roma Torino Treviso

Trieste Varese Verona

  

Società per azioni

Capitale sociale

Euro 10.415.500,00 i.v.

Registro Imprese Milano Monza Brianza Lodi    

e Codice Fiscale N. 00709600159

R.E.A. Milano N. 512867

Partita IVA 00709600159

VAT number IT00709600159

Sede legale: Via Vittor Pisani, 25

20124 Milano MI ITALIA


LOGO

Limacorporate Group

Independent auditors’ report

31 December 2022

 

Responsibilities of the parent’s directors and board of statutory auditors (“Collegio Sindacale”) for the consolidated financial statements

The directors are responsible for the preparation of consolidated financial statements that give a true and fair view in accordance with the International Financial Reporting Standards issued by International Accounting Standards Board and, within the terms established by the Italian law, for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

The directors are responsible for assessing the group’s ability to continue as a going concern and for the appropriate use of the going concern basis in the preparation of the consolidated financial statements and for the adequacy of the related disclosures. The use of this basis of accounting is appropriate unless the directors believe that the conditions for liquidating the parent or ceasing operations exist, or have no realistic alternative but to do so.

The Collegio Sindacale is responsible for overseeing, within the terms established by the Italian law, the group’s financial reporting process.

Auditors’ responsibilities for the audit of the consolidated financial statements

Our objectives are to obtain reasonable assurance about whether the consolidated financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors’ report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISA will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these consolidated financial statements.

As part of an audit in accordance with ISA, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

 

 

identify and assess the risks of material misstatement of the consolidated financial statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control;

 

 

obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the group’s internal control;

 

 

evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the directors;

 

 

conclude on the appropriateness of the directors’ use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the group’s ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors’ report to the related disclosures in the consolidated financial statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors’ report. However, future events or conditions may cause the group to cease to continue as a going concern;

 

2


LOGO

Limacorporate Group

Independent auditors’ report

31 December 2022

 

 

evaluate the overall presentation, structure and content of the consolidated financial statements, including the disclosures, and whether the consolidated financial statements represent the underlying transactions and events in a manner that achieves fair presentation;

 

 

obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the group to express an opinion on the consolidated financial statements. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with those charged with governance, identified at the appropriate level required by ISA, regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

Padua, 5 October 2023

KPMG S.p.A.

 

LOGO

Silvia Di Francesco

Director

 

3


LOGO

Consolidated financial statements as at 31 December 2022

 

LOGO


Contents

 

Consolidated financial statements as at 31 December 2022

  

Consolidated financial statements as at 31 December 2022 of the Limacorporate Group

     6  

Notes to the consolidated financial statements as at 31 December 2022

     11  

Other information

     51  

 

5


Consolidated financial statements as at 31 December 2022 of the Limacorporate Group

Statement of financial position

 

(€‘000)

                        

ASSETS

   Note     31/12/2022     31/12/2021     01/01/2021  

Non-current assets

        

Other intangible assets

     [3.1     58,234       53,595       44,477  

Goodwill

     [3.2     384,216       398,305       396,900  

Property, plant and equipment

     [3.3     79,837       81,773       85,288  

Equity investments

     [3.4     2       2       402  

Deferred tax assets

     [3.5     31,709       33,462       31,895  

Other non-current assets

     [3.6     861       705       663  
    

 

 

   

 

 

   

 

 

 

Total non-current assets

       554,859       567,843       559,625  
    

 

 

   

 

 

   

 

 

 

Current assets

        

Inventories

     [3.7     86,728       87,421       84,166  

Trade receivables

     [3.8     70,161       66,891       63,070  

Current tax assets

     [3.9     2,087       2,554       4,361  

Other current assets

     [3.10     14,192       11,247       11,469  

Cash and cash equivalents

     [3.11     25,920       21,503       26,273  
    

 

 

   

 

 

   

 

 

 

Total current assets

       199,088       189,617       189,340  
    

 

 

   

 

 

   

 

 

 

TOTAL ASSETS

       753,947       757,461       748,965  
    

 

 

   

 

 

   

 

 

 

EQUITY AND LIABILITIES

        

Equity

        

Share capital

     [3.12     9,868       9,868       9,868  

Share premium reserve

     [3.12     14,425       14,425       14,425  

Other reserves

     [3.12     323,510       317,570       310,762  

Retained earnings (accumulated deficit)

     [3.12     (21,966     (18,862     (6,380

Profit (loss) for the year

     [3.12     (19,273     (2,539     (12,482
    

 

 

   

 

 

   

 

 

 

Total equity attributable to the owners of the parent

       306,564       320,463       316,194  
    

 

 

   

 

 

   

 

 

 

Total equity

       306,564       320,463       316,194  
    

 

 

   

 

 

   

 

 

 

Non-current liabilities

        

Non-current financial liabilities

     [3.15     10,165       283,573       287,407  

Employee benefits

     [3.14     1,296       1,442       1,421  

Deferred tax liabilities

     [3.5     19,275       17,296       12,986  

Provisions for risks and charges

     [3.13     17,156       15,314       12,847  

Other non-current liabilities

     [3.16     649       5,250       5,476  
    

 

 

   

 

 

   

 

 

 

Total non-current liabilities

       48,541       322,875       320,137  
    

 

 

   

 

 

   

 

 

 

Current liabilities

        

Current financial liabilities

     [3.15     336,659       61,536       61,156  

Trade payables

     [3.17     36,564       32,343       28,941  

Current tax liabilities

     [3.18     877       202       491  

Other current liabilities

     [3.19     24,742       20,041       22,047  
    

 

 

   

 

 

   

 

 

 

Total current liabilities

       398,842       114,123       112,635  
    

 

 

   

 

 

   

 

 

 

TOTAL EQUITY AND LIABILITIES

       753,947       757,461       748,965  
    

 

 

   

 

 

   

 

 

 

 

6


Income statement

 

(€‘000)

                  
     Note     2022     2021  

Revenue

     [3.20     245,669       210,543  

Other revenues and income

     [3.20     5,798       3,973  
    

 

 

   

 

 

 

Total revenue and income

       251,467       214,517  
    

 

 

   

 

 

 

Raw materials, consumables, supplies and goods

     [3.21     (56,391     (53,530

Services

     [3.22     (81,645     (69,910

Change in w.i.p., semi-finished products and finished goods

     [3.23     (887     2,058  

Personnel expenses

     [3.24     (76,858     (60,773

Amortisation and Depreciation

     [3.25     (35,408     (32,517

Impairment losses on trade receivables

     [3.25     (502     (429

Impairment losses on fixed assets

     [3.25     (16,152     (209

Other operating costs

     [3.26     (1,857     (1,509

Internal work capitalised

     [3.27     13,532       16,250  
    

 

 

   

 

 

 

Operating costs

       (256,167     (200,570
    

 

 

   

 

 

 

Operating profit

       (4,700     13,947  
    

 

 

   

 

 

 

Financial income

     [3.28     14,561       7,829  

Financial expense

     [3.28     (22,609     (20,785
    

 

 

   

 

 

 

Net financial expense

       (8,048     (12,956
    

 

 

   

 

 

 

Pre-tax income (loss)

       (12,748     991  
    

 

 

   

 

 

 

Income tax benefit (expense)

     [3.29     (6,526     (3,529
    

 

 

   

 

 

 

Profit (loss) for the year

       (19,273     (2,539
    

 

 

   

 

 

 

of which attributable to the owners of the parent

       (19,273     (2,539
    

 

 

   

 

 

 

 

7


Statement of comprehensive income

 

(€‘000)

                  
     Note     2022     2021  

Profit (loss) for the year

       (19,273     (2,539
    

 

 

   

 

 

 

Other comprehensive income (expense)

      

Items that will never be reclassified to profit or loss (A)

      

Remeasurements of the net defined benefit liability (asset)

     [3.14     71       3  

Related tax

     [3.14     (17     (1
    

 

 

   

 

 

 
       54       2  
    

 

 

   

 

 

 

Items that are or may be reclassified to profit or loss (B)

      

Exchange differences on translation of foreign operations

     [3.12     871       1,842  
    

 

 

   

 

 

 
       871       1,842  
    

 

 

   

 

 

 

Other comprehensive income (expense), net of tax (A+B)

       925       1,844  
    

 

 

   

 

 

 

Comprehensive income (expense) for the year

       (18,348     (695
    

 

 

   

 

 

 

Comprehensive income (expense) attributable to:

      

Owners of the parent

       (18,348     (695
    

 

 

   

 

 

 

 

8


Statement of changes in equity

 

(€‘000)

                                                                       
    Note     Share
capital
    Share
premium
reserve
    Legal
reserve
    Merger
reserve
    Equity
Injections
    Translation
reserve
    Actuarial
reserve
    Other
reserves
    Retained earnings
including Profit (loss)
for the year
    Total equity
attributable to
the owners of
the parent
    Total equity  

At 1 January 2021

      9,868       14,425       2,101       288,261       23,088       (334     (25     (2,328     (18,862     316,194       316,194  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Statement of comprehensive income

                       

Profit for the year

    [3.12     —        —        —        —        —        —        —        —        (2,539     (2,539     (2,539

Other comprehensive income

    [3.12     —        —        —        —        —        1,842       2       —        —        1,844       1,844  

Comprehensive income

      —        —        —        —        —        1,842       2       —        (2,539     (694     (694

Owner transactions

                       

Allocation of the loss for the previous year

    [3.12     —        —        —        —        —        —        —        —        —        —        —   

Other owner transactions

    [3.12     —        —        —        —        4,963       —        —          —        4,963       4,963  

Total owner transactions

      —        —        —        —        4,963       —        —        —        —        4,963       4,963  

Other changes

    [3.12     —        —        —        —        —        —        —        —        —        —        —   
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

At 31 December 2021

      9,868       14,425       2,101       288,261       28,051       1,508       (23     (2,328     (21,401     320,463       320,463  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Statement of comprehensive income

                       

Profit for the year

    [3.12     —        —        —        —        —        —        —        —        (19,273     (19,273     (19,273

Other comprehensive income

    [3.12     —        —        —        —        —        871       54       —        —        925       925  

Comprehensive income

      —        —        —        —        —        871       54       —        (19,273     (18,349     (18,349

Owner transactions

                       

Allocation of the loss for the previous year

    [3.12     —        —        —        —        —        —        —        565       (565     —        —   

Other owner transactions

    [3.12     —        —        —        —        —        —        —          —        —        —   

Total owner transactions

      —        —        —        —        —        —        —        565       (565     —        —   

Other changes

    [3.12     —        —        —        —        —        —        —        4,450       —        4,450       4,450  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

At 31 December 2022

      9,868       14,425       2,101       288,261       28,051       2,379       31       2,687       (41,239     306,564       306,564  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

9


Statement of cash flows

 

(€‘000)

                  
     Note     2022     2021  

Operating activities

      

Profit (loss) for the year

     [3.12]       (19,273     (2,539

Income tax (benefit)/expense

     [3.29]       6,526       3,529  

Net financial (income)/expense

     [3.28]       10,809       13,979  

Amortisation, depreciation and impairment losses

     [3.25]       50,649       32,726  

Accruals/(Release) to provisions

     [3.26]       1,842       3,204  

Net (gains)/loss on disposals

     [3.20] [3.26]       (629     (550

FX on contingent consideration

     [3.28]       1,031       1,384  

Cash flows from operating activities before changes in working capital

       50,955       51,734  

Change in inventories

     [3.7]       693       (3,255

Change in trade receivables

     [3.8]       (3,270     (3,502

Change in trade payables

     [3.17]       4,220       3,402  

Change in other assets/liabilities

     [3.10] [3.16] [3.19]       316       523  

Change in non-current assets

     [3.6]       (156     358  

Income taxes paid

       (2,019     (846
    

 

 

   

 

 

 

Cash flows from operating activities A)

       50,739       48,414  
    

 

 

   

 

 

 

Investing activities

      

Acquisitions of property, plant and equipment

     [3.3]       (25,234     (21,983

Disposal of property, plant and equipment

     [3.3]       1,418       2,108  

Acquisitions of intangible assets

     [3.1]       (12,229     (14,229

Disposal of intangible assets

     [3.1]       955       47  
    

 

 

   

 

 

 

Cash flows used in investing activities B)

       (35,090     (34,056
    

 

 

   

 

 

 

Financing activities

      

Third party funds

      

Net change in current financial liabilities

     [3.15]       8,916       805  

Gross change in non-current financial liabilities

     [3.15]       (0     (572

Decrease in lease liabilities

     [3.15]       (4,401     (3,384

Net interest income

     [3.28]       163       154  

Net interest paid

     [3.28]       (15,911     (16,131
    

 

 

   

 

 

 

Cash flows from (used in) in financing activities C)

       (11,231     (19,127
    

 

 

   

 

 

 

Increase (decrease) in liquid funds (A ± B ± C)

       4,417       (4,770
    

 

 

   

 

 

 

Opening cash and cash equivalent

       21,503       26,273  

Closing cash and cash equivalent

       25,920       21,503  
    

 

 

   

 

 

 

Increase (decrease) in cash and cash equivalents

       4,417       (4,770
    

 

 

   

 

 

 

 

10


Notes to the consolidated financial statements as at 31 December 2022

[2.1] General information

The Limacorporate Group (the “group”) designs, creates and sells joint implants and repair solutions in the medical sector.

The parent, Limacorporate S.p.A. (“Limacorporate” or the “parent”), was set up and is domiciled in Italy. Its registered office is at Via Nazionale 52, San Daniele del Friuli (Udine) and its company registration number is 173824.

The group carries out most of its business at its registered office while some activities are also performed by the subsidiaries.

The consolidated financial statements as at and for the year ended 31 December 2022 include the financial statements of the parent and the subsidiaries (together the “group”).

These consolidated financial statements as at 31 December 2022 were approved by the parent’s board of directors at its meeting on 3 October 2023.

The parent is managed and coordinated by Emil Holding II S.à.r.l., whose details are provided below:

 

   

Registered office: 26A, Boulevard Royal, L-2449 Luxembourg.

 

   

Legal form: limited liability company.

 

   

Description of its business activities and main operations: holding company

 

   

Ultimate parent’s name: Emil NewCo S.à.r.l.

 

   

Name of the ultimate indirect parent: EQT Luxembourg Management S.à r.l.

[2.2] Basis of presentation

The consolidated financial statements as at 31 December 2022 is prepared in accordance with the IFRS issued by International Accounting Standards Board (IASB) applying IFRS 1 – First-time Adoption of International Financial Reporting Standards.

Following the adoption of the IFRS issued by IASB, the Group’s equity and profit for the year previously determined under the IFRS endorsed by the European Union, were corrected due to a correction of error related to the payback mechanism accounted in compliance with IFRS 15, retrospectively, as reduction of revenue (variable consideration). The note [4.1] Transition to IFRS issued by IASB describes the corrected error and transition criteria and includes the reconciliation schedules of the Group’s equity and profit for the year for the comparative periods.

These consolidated financial statements as at 31 December 2022 comprise the statement of financial position, income statement, statement of comprehensive income, statement of changes in equity, statement of cash flows and these notes. They comply with the provisions of IAS 1 Presentation of financial statements and the general principle of historical cost, except for those items that, pursuant to the IFRS, are measured at fair value, as explained in the accounting policies of the individual captions in note 2.4 Basis of preparation. The statement of financial position has been prepared by separating assets and liabilities into current and non-current, whereas costs are classified in the income statements on the basis of their nature. The statement of cash flows has been prepared using the indirect method.

The notes to the consolidated financial statements as at 31 December 2022 include the information generally required by ruling legislation and the IFRS, suitably presented with reference to the financial statements schedules used.

The consolidated financial statements as at 31 December 2022 have been prepared on a going concern basis, as the related assumptions are deemed to be met.

All figures are in thousands of Euros, unless indicated otherwise. The Euro is the parent’s functional and presentation currency. For each financial statements caption, the corresponding amount of the previous year is provided for comparative purposes.

 

11


The consolidated financial statements of Limacorporate Group as at 31 December 2022 has been prepared for its inclusion in the offering memorandum drawn up by Enovis Corporation as part of its potential issue of notes.

[2.3] Consolidation scope

The consolidated financial statements of the Limacorporate Group as at 31 December 2022 include the financial statements of the parent and the Italian and foreign subsidiaries at 31 December 2022.

Subsidiaries are those companies over which the group has control, as defined by IFRS 10 Consolidated financial statements as at 31 December 2022. Control exists when the group has the power to, directly or indirectly, govern the financial and operating policies of an entity so as to obtain benefits from its activities. The financial statements of subsidiaries are included in the consolidated financial statements as at 31 December 2022 starting from when control is assumed and until such control ceases to exist.

The table below lists the companies included in the consolidation scope at 31 December 2022.

Subsidiaries are included in the consolidation scope from when the group acquires control, as defined above, and are excluded from when the group no longer has control.

Amounts in thousands (of the stated currency)

 

   

Registered office

  Currency   Share/quota
capital
    Equity     Profit (Loss)
for the year
    %  

LIMA AUSTRIA GmbH

  Seestadtstrasse 27 Top 6-7, 1220 Vienna (Austria)    (EUR)     35       1,278       172       100

LIMA BELGIUM SRL

  Chaussée de Wavre 504, boîte 5A - 1390 Grez Doiceau (Belgium)   (EUR)     30       -1,250       289       100

LIMA CZ s.r.o.

  Do Zahràdek I., 157/5 - 155 21 Praha 5 - Třebonice - (Czech Republic)   (CZK)     200       116,390       16,178       100

LIMA DENMARK ApS

  Lyngebaekgards Alle 2, 2990 Niva (Denmark)   (DKK)     500       427       142       100

LIMA DEUTSCHLAND GmbH

  Kapstadtring 10, - 22297 Hamburg - (Germany)   (EUR)     25       5,291       1,674       100

LIMA DO BRASIL LTDA

  Al. Campinas, 728 – 2° andar salas 201, 202, 203 e 204.- Jardim Paulista - Sao Paulo - SP - CEP:01404- 001 (Brazil)   (BRL)     1,500       -10,475       7,754       100

LIMA FRANCE Sas

  1, Allée des Alisiers - Immeuble “Le Galilée” - 69500 Bron - (France)   (EUR)     40       440       161       100

LIMA IMPLANTES PORTUGAL S.U. LDA

  Rua Pêro Vaz de Caminha 8 E 2660-441 Stº António Cavaleiros - (Portugal)   (EUR)     5       2,357       125       100

LIMA IMPLANTES Slu

  C/ Manuel Tovar, 33-35 28034 Madrid - (Spain)   (EUR)     200       1,089       29       100

LIMA JAPAN K.K.

  Tokyo Front Terrace 13F 2-3-14 Higashi Shinagawa, Shinagawa, Tokyo, 140-0002 , (Japan)   (JPY)     10,000       -984,102       -34,681       100

LIMA KOREA Co., Ltd

  Zero Building 11th Floor, 14 Teheran Ro 84 Gil, Gangnam Gu, Seoul 06178 - (Korea)   (KRW)     100,000       -1,932,158       299,988       100

LIMA NETHERLANDS B.V.

  Bergweg 153A, 3707AC Zeist - (Netherlands)   (EUR)     18       1,007       232       100

LIMA O.I. d.o.o. - ORTOPEDIJA I IMPLANTATI

  Ante Kovačića, 3 - 10000 Zagreb - (Croatia)   (HRK)     300       32,024       1,586       100

LIMA ORTHOPAEDICS AUSTRALIA Pty Ltd

  Unit 1, 40 Ricketts Road - Mt Waverley, 3149 Victoria - (Australia)   (AUD)     0       21,875       405       100

LIMA ORTHOPAEDICS NEW ZEALAND Pty Ltd

  20 Crummer Rd Grey Lynn 1021 Auckland 1021 - New Zealand   (NZD)     0       10,014       195       100

LIMA ORTHOPAEDICS SOUTH AFRICA (PTY) LTD

  Northlands Deco Park, Stand 326, 10 Newmarket Street, Design Boulevard, Northriding, 2186 (South Africa)   (ZAR)     0       -11,459       -92       100

LIMA ORTHOPAEDICS UK Ltd

  4 Office Village Forder Way Cygnet Park Hampton Peterborough Peterborough PE7 8GX (United Kingdom)   (GBP)     0       6,932       947       100

LIMA POLSKA SP. z.o.o.

  ul. Ul Lopuszanska 95 - 02-457 Warsaw (Poland)   (PLN)     5       472       1,126       100

LIMA SK S.r.o.

  Cesta na Stadiòn 7 - 97404 Banska Banska Bystrica - (Slovakia)   (EUR)     7       6,371       313       100

LIMA SWEDEN AB

  Box 180 - SE-184 22 Akersberga - (Sweden)   (SEK)     100       1,678       666       100

LIMA SWITZERLAND SA

  Birkenstrasse, 49 - 6343 Rotkreuz - Zug - (Switzerland)   (CHF)     100       2,084       328       100

TASFIYE HALINDE LIMA TURKEY ORTOPEDI AS

  Serifali Mah. Hendem Cad.No: 54 Canan Residence OFIS A-2,34775 - UMRANIYE - Istanbul - (Turkiye)   (TRY)     50       -13,713       -11,252       100

LIMA USA Inc.

  2001 NE Green Oaks Blvd, Suite 100 - Arlington, TX 76006 - (United States)   (USD)     20       79,420       -1,368       100

LIMA SM S.p.A. in liquidazione

  Strada Borrana, 38 - Serravalle 47899 - (Repubblica di San Marino)   (EUR)     2,701       4,051       -1,174       100

TechMah Medical LLC

  2099 Thunderhead Road, Suite 302 - Knoxville, TN 37922 - (United States)   (USD)     29,084       961       -8,268       100

LIMA (BEIJING) MEDICAL DEVICES CO., LTD.

  Room 616, 6/F, Building 1, No.1, Lize Zhong 2 Road, Chaoyang District, Beijing, China   (CNY)     3,014       -3,784       -2,761       100

LIMA ORTHOPAEDICS CANADA INC.

  3715 Laird Road Suite Unit 9, Mississauga, ON, Canada   (CAD)     200       221       28       100

 

12


Lima Orthopaedics Canada Inc. incorporated under Canadian law in October 2021 was included in the consolidation scope in 2022. It began operations in the first half of 2022 and was not consolidated in 2021 as it was not yet up and running and was immaterial.

For consolidation purposes, the figures of the individual companies at the reporting date were restated to comply with the IFRS adopted by the group. The reporting date of all of the consolidated companies is 31 December.

The basis of consolidation is set out below:

 

   

Adopting the line-by-line method, showing the portions of equity and profit or loss for the year attributable to non-controlling interests and recognising assets, liabilities, revenue and costs regardless of the percentage held in the subsidiaries.

 

   

Eliminating items deriving from intragroup transactions involving consolidated companies, including any unrealised gains and losses arising from intragroup transactions and recognising the resulting deferred tax effects.

 

   

Eliminating intragroup dividends and reallocating them to opening equity reserves.

 

   

Eliminating the carrying amount of investments in consolidated companies and the relevant portion of equity, allocating the resulting positive and negative differences to the relevant captions (assets, liabilities and equity), as defined at the time of acquisition of the investment and considering any subsequent variations. After control is acquired, any acquisitions of non-controlling interests or sales of shares to non-controlling interests that do not entail loss of control are recognised as owner transactions and the relevant effects are taken directly to equity. Any differences between the change in equity attributable to non-controlling interests and cash and cash equivalents exchanged are recognised under changes in equity attributable to the owners of the parent.

 

   

The financial statements of foreign operations are translated into Euros using the annual average rate for income statement items and the closing rate for statement of financial position items. The difference between the two rates along with the translation differences deriving from changes in opening and closing exchange rates are recognised as changes in equity.

The following rates were applied in translating the financial statements of foreign operations:

 

Currency

   Average Rate      Closing Rate  

AUD - Australian Dollar

     1.51670        1.56930  

BRL - Brazilian Real

     5.43990        5.63860  

CAD - Canadian Dollar

     1.36950        1.44400  

CHF - Swiss Franc

     1.00470        0.98470  

CZK - Czech Koruna

     7.07880        7.35820  

CNY - Yuan Renminbi

     24.56590        24.11600  

DKK - Danish Krone

     7.43960        7.43650  

GBP - Pound Sterling

     0.85276        0.88693  

HRK - Croatian Kuna

     7.53490        7.53650  

JPY - Japanese Yen

     138.0274        140.66  

KRW - South Korean Won

     1,358.07        1,344.09  

NZD - New Zealand Dollar

     1.65820        1.67980  

PLN - Polish Zloty

     4.68610        4.6808  

SEK - Swedish Krona

     10.62960        11.12180  

TRY - Turkish Lira

     17.40880        19.96490  

USD - US Dollar

     1.05300        1.06660  

ZAR - South African Rand

     17.20860        18.0986  

[2.4] Basis of preparation

 

13


[2.4.1] Business combinations and goodwill

Business combinations are recognised using the acquisition method under IFRS 3. To this end, the identifiable assets acquired and the liabilities assumed are recognised at their respective acquisition-date fair value. The consideration transferred in a business combination is the aggregate of the fair value, at the date of exchange, of assets acquired, liabilities assumed and equity instruments issued by the acquirer, in exchange for control of the acquiree.

Goodwill is the positive difference between the consideration transferred, increased by both the fair value at the acquisition date of any non-controlling interests already held in the acquiree and the amount of non-controlling interests held in the acquiree by third parties (measured at fair value or based on the present value of the acquiree’s identifiable net assets), and the fair value of such assets and liabilities.

At the acquisition date, goodwill is allocated to each of the largely independent cash-generating units that are expected to benefit from the synergies of the business combination.

If the difference between the consideration transferred (increased by the above components) and the fair value of the net assets acquired is negative, this is recognised as a gain from a bargain purchase in the income statement in the year of acquisition.

Any goodwill related to non-controlling interests is included in the carrying amount of the relevant equity investments.

After initial recognition, goodwill is not amortised and is recognised net of any cumulative impairment losses, calculated using the methods set out in section [2.4.6] Impairment losses.

As set out in section [3.2] Goodwill of this report, the market multiples method is used to determine the fair value of goodwill, using listed comparable companies (these multiples are compared with the implicit multiple calculated using the group’s actual figures), except for CGU TechMah for which the value in use is defined using estimated future cashflows by applying a discount rate.

IFRS 3 is not applied retrospectively to business combinations that took place prior to 1 January 2018, i.e., the date of the parent’s transition to the IFRS. Accordingly, the amount of goodwill determined under the previous reporting standards, i.e., the carrying amount at such date, is maintained for such business combinations, subject to the recognition of any impairment losses.

[2.4.2] Intangible assets

An intangible asset is an identifiable asset without physical substance, controlled by the group and that generates future economic benefits, in addition to goodwill when acquired against consideration.

Identifiability is defined with reference to the possibility of distinguishing the intangible asset acquired from goodwill. An intangible asset is identifiable when it: (i) arises from a legal or contractual right or (ii) is separable, i.e., can be sold, transferred, licensed, rented, or exchanged, either individually or together with a related contract. An entity controls an asset if it has the power to obtain the future economic benefits flowing from the underlying resource and to restrict the access of others to such benefits.

Intangible assets are stated at cost, which is determined in the same manner as for property, plant and equipment.

Intangible assets with finite useful lives are amortised over their estimated useful lives starting from when they are available for use.

 

14


The amortisation rates adopted in 2022 are shown in the following table by asset category:

 

     2022  

Development expenditure

     5 - 10 years  

Industrial patents and intellectual property rights

     10 - 20 years  

Concessions, licences, trademarks and similar rights

     3 - 4 - 5 years  

Other

     Contract term / maximum 6 years  

Development expenditure

Development expenditure is expensed when incurred.

Development expenditure incurred for a specific project is only capitalised when the group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use and for sale, its intention to complete such asset and use or sell it, how the intangible asset will generate probable future economic benefits, the availability of adequate technical, financial and other resources to complete the development and its ability to measure reliably the expenditure attributable to the intangible asset during its development.

Subsequent to initial recognition, development expenditure is measured at cost less any accumulated amortisation and any accumulated impairment losses. Amortisation of the asset starts from when the development phase has been completed and the asset is available for use. The asset is amortised over the period for which the underlying project is expected to generate revenue for the group.

Industrial patents and intellectual property rights

Industrial patents and intellectual property rights refer to costs for patents owned by Limacorporate S.p.A..

Concessions, licences, trademarks and similar rights

This caption refers to costs to file and register trademarks and costs incurred to acquire commercial licences. The acquisition costs are amortised over a period equal to the useful life of the acquired right.

Other intangible assets

This caption refers to leasehold improvements. The capitalised costs are amortised on the basis of the residual term of the relevant lease contract.

[2.4.3] Property, plant and equipment

Property, plant and equipment are recognised at acquisition or production cost including directly attributable costs incurred to ready the asset for its intended use. Such cost includes costs to replace parts of equipment and plant when they are incurred if they meet the recognition requirements.

Assets acquired under business combinations before 1 January 2018 (the date of the parent’s transition to the IFRS) are recognised at their pre-existing carrying amount, determined within such business combinations in accordance with the previous reporting standards, i.e., at deemed cost.

The carrying amount (cost less accumulated depreciation and cumulative impairment losses) of the replaced parts of equipment and plant is taken to profit or loss at the time of replacement.

Maintenance and repair costs, which do not add to the value of the assets and/or prolong their residual useful lives, are expensed when incurred. Otherwise they are capitalised.

Property, plant and equipment are stated net of any accumulated depreciation and any cumulative impairment losses determined using the methods set out below. Depreciation is calculated on a straight-line basis over the estimated useful life of the asset for the group.

 

15


The depreciation rates used are shown in the following table by asset category:

 

     2022  

Buildings

     3%  

Light constructions

     10%  

General and specific plant

     10% - 15.5%  

Machinery

     15.5%  

Sundry and small equipment

     25%  

Production equipment

     10%  

Office furniture and machines

     12%  

Electronic office machines

     20%  

Transport vehicles

     20%  

Cars

     25%  

Right-of-use assets

     Lease term  

The residual value of the assets, the useful life and the depreciation method applied are reviewed at each year end and adjusted prospectively if necessary.

If significant parts of an item of property, plant and equipment have different useful lives, such parts are recognised separately. Land, free of construction or annexed to buildings, is recognised separately and is not depreciated since it has an unlimited useful life.

The carrying amount of an item of property, plant and equipment and every significant part initially recognised is eliminated on disposal or when no future economic benefits are expected from its use or disposal. The gain or loss arising from the derecognition of the item (calculated as the difference between the carrying amount of the asset and the net disposal proceeds) is included in profit or loss when the item is derecognised.

[2.4.4] Leases

IFRS 16 defines the recognition, measurement, presentation and disclosure requirements for leases. Under IFRS 16, lessees are required to recognise all leases using a single accounting model similar to that used to recognise finance leases under IAS 17.

If a contract contains a lease, at the commencement date, the lessee shall recognise an asset representing its right to use the underlying leased asset and a lease liability representing its obligation to make lease payments. The lessee shall recognise interest on the lease liability and depreciation of the right-of-use asset separately. At inception of a contract, the entity shall assess whether the contract is, or contains, a lease. The contract is, or contains, a lease if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration. An entity shall determine the lease term as the non-cancellable period of a lease, together with both periods covered by an option to extend the lease if the lessee is reasonably certain to exercise that option and periods covered by an option to terminate the lease if the lessee is reasonably certain not to exercise that option.

[2.4.5] Equity investments

Investments in associates and joint ventures are measured using the equity method, recognising the group’s share of the profits or losses for the year in the income statement, with the exception of the effects related to other changes in the equity of the investee, other than owner transactions, that are directly recognised in other comprehensive income.

In the event of losses exceeding the carrying amount of the equity investment, the excess is recognised in a specific provision to the extent the parent is obliged to fulfil legal or constructive obligations to the investee or to cover its losses.

Investments in other companies are measured at fair value and the fair value gains and losses are taken to equity. If fair value cannot be reliably determined, they are measured at cost, adjusted for any impairment losses.

 

16


[2.4.6] Impairment losses

At the reporting date, the carrying amount of property, plant and equipment, intangible assets, financial assets and equity investments is tested for indicators of impairment. Should such indicators exist, the group estimates the recoverable amount of the asset to check the recoverability of the carrying amount and determine any impairment loss to be recognised. Intangible assets with indefinite useful lives or not yet available for use are tested for impairment at least annually, irrespective of whether any indication of impairment exists, or more frequently if an indication of impairment exists.

In order to identify impairment losses, assets are grouped into the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets (the cash-generating unit, CGU). Reference should be made to section [3.2] Goodwill for details of the group’s CGU. The goodwill generated by business combinations is allocated to the CGU that is expected to benefit from the combinations’ synergies. The recoverable amount of an asset or a CGU is the higher of its value in use and its fair value less costs to sell.

Multiples are compared with the implicit multiple calculated using the group’s actual figures. When the carrying amount of an asset or a CGU exceeds its recoverable amount, the group recognises an impairment loss in profit or loss. Impairment losses on the CGU are allocated first to reduce the carrying amount of any goodwill allocated to it and then to the other assets of the CGU pro rata on the basis of their carrying amounts. Impairment losses on goodwill cannot be reversed. Impairment losses on other assets are reversed to the carrying amount that would have been determined (net of amortisation and depreciation) had no impairment losses been recognised in prior years.

The market multiples method is used to determine the value in use using listed comparable companies for the group’s CGU except for TechMah CGU where the value in use of the CGU Techmah is defined using estimated future cashflows by applying a discount rate (weighted average cost of capital).

[2.4.7] Financial instruments

The financial instruments held by the group are described below.

Financial assets

Financial assets include equity investments, current securities, loans and borrowings, as well as derivatives with a positive fair value, trade receivables and other assets, in addition to cash and cash equivalents.

Specifically, cash and cash equivalents include cash, bank deposits and highly marketable securities that are readily convertible to cash and are subject to an immaterial risk of changes in value.

Current securities include short-term or marketable securities which represent temporary investments of available funds and do not meet the requirements to be classified as cash and cash equivalents. Financial assets represented by debt instruments are classified in the consolidated financial statements as at 31 December 2022 and measured using the business model adopted by the group for managing financial assets and based on the cash flows related to each financial asset. Financial assets also include equity investments not held for trading. Such assets are strategic investments and the group has opted to recognise fair value gains or losses thereon through profit or loss (fair value through profit or loss, FVTPL).

Financial assets are tested for impairment using a model based on expected credit losses.

Financial liabilities

Financial liabilities include loans and borrowings, as well as derivatives with a negative fair value, trade payables and other liabilities.

Financial liabilities are classified and measured at amortised cost, with the exception of those initially measured at fair value, e.g., financial liabilities related to earn-out considerations for business combinations and derivatives and financial liabilities for options on non-controlling interests.

 

17


Derecognition of financial assets and liabilities

A financial asset or liability (or, where applicable, part of a financial asset/liability or part of a group of similar financial assets/liabilities) is derecognised when the group unconditionally transfers the contractual rights to receive the cash flows of the financial asset or the obligation to make payments or fulfil other obligations related to the liability.

[2.4.8] Inventories

Raw materials and packaging are measured at the lower of purchase cost and estimated replacement value based on market trends. The cost is calculated using the weighted average cost for the year.

Semi-finished products and finished goods are measured at purchase or production cost, considering their stage of completion, or their realisable value based on market trends, if lower. The production cost includes the reasonably attributable portion of direct and indirect manufacturing costs.

The resulting amount is written down through the allowance for inventory write-down to account for items whose expected realisable value is lower than their cost.

[2.4.9] Trade receivables and other assets and trade payables and other liabilities

Trade receivables and other assets that derive from the supply of credit facilities, goods or services to third parties are classified under current assets, except when they are due after one year of the reporting date with reference to loans and receivables. If they have a set due date, current and non-current loan assets, other current and non-current assets and trade receivables, with the exception of derivatives, are measured at amortised cost calculated using the effective interest method. If they do not have a set due date, financial assets are measured at cost. Loans and receivables due after one year that are non-interest bearing or accruing interest lower than market rates are discounted using market rates.

The above financial assets are measured using the expected credit loss impairment model introduced by IFRS 9.

Trade payables and other liabilities that arise from the acquisition of credit facilities, goods or services from a third party supplier are classified under current liabilities, except when they are due after one year of the reporting date with reference to loans and borrowings.

On initial recognition, current and non-current loans and borrowings, other current and non-current liabilities and trade payables are stated at fair value, which normally coincides with the transaction price including transaction costs. Subsequently, all financial liabilities are measured at amortised cost calculated using the effective interest method.

[2.4.10] Employee benefits

The liability related to short-term employee benefits paid during the employment relationship is recognised on an accruals basis at the amount accrued at the reporting date.

The liability related to employee benefits paid upon or after termination of the employment relationship via defined benefit plans, is recognised at the amount accrued at the reporting date.

The liability related to employee benefits paid upon or after termination of the employment relationship via defined benefit plans, net of any plan assets and advances granted, is calculated using actuarial assumptions and recognised on an accruals basis in line with the service needed to obtain the benefits. Such liability is calculated by independent actuaries. The gain or loss deriving from the actuarial calculation is fully recognised in the statement of comprehensive income for the relevant year.

Defined benefit plan liabilities are measured using the actuarial assumptions set out in section [3.14] Employee benefits of the notes to the consolidated financial statements as at 31 December 2022.

 

18


[2.4.11] Provisions for risks and charges

The provisions for risks and charges are recognised when the group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the expenditure required to settle the present obligation or transfer it to third parties at the reporting date. Where the effect of the discounting is material, the provisions are calculated by discounting the estimated future cash flows at a rate that reflects current market assessments of the time value of money. When discounting is used, the carrying amount of the provision increases to reflect the passage of time and this increase is recognised as borrowing cost.

[2.4.12] Share-based payments

The grant-date fair value of equity-settled share-based payment arrangements agreed with employees is generally recognised as an expense, with a corresponding increase in equity, over the vesting period of the awards. The amount recognised as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognised is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. For share-based payment awards with non-vesting conditions, the grant-date fair value of the share-based payment is measured to reflect such conditions. With regard to non-vesting conditions, any differences between expected and actual outcomes do not have an impact on the consolidated financial statements as at 31 December 2022.

The fair value of the amount payable to employees in respect of cash-settled share-based payments is recognised as an expense with a corresponding increase in liabilities, over the period during which the employees become unconditionally entitled to payment. The liability is remeasured at each reporting date and at the settlement date based on the fair value of the share-based payments. Any fair value gains or losses are recognised in profit or loss.

The parent has had agreements with some managers for the award of options and/or shares for several years (see section [4.8] Incentive plans).

[2.4.13] Revenue and expense

Based on the five-step model introduced by IFRS 15, the group recognises revenue after identifying the contract(s) with a customer and the performance obligations in the contract (transfer of goods and/or services), determining the transaction price to which it expects to be entitled in exchange for fulfilling performance obligations (at a point in time or over time). Revenue is measured on the basis of the transaction price excluding amounts collected on behalf of third parties. Based on the group’s internal analysis of contracts with customers, the group has not identified any performance obligations that are satisfied over time and, therefore, the group recognises revenue upon the transfer of control of the promised goods or services to the customer. Revenue is measured to the extent that it is probable that the economic benefits will flow to the group and the amount can be measured reliably.

Revenue is adjusted for any discounts and volume rebates allowed by the group in contracts with customers and for the payback (variable considerations) see [3.20] Revenue and other revenue and income and [3.13] Provisions for risks and charges for payback system.

Expense is recognised when the goods and services are sold or consumed during the year or by systematic allocation, or when it is not possible to identify their future use.

Expense items are classified by nature in accordance with the applicable IFRS.

[2.4.14] Government grants

Grants related to income are taken to profit or loss in the year in which the relevant expense is recognised.

 

19


Grants related to assets received for projects and development activities are recognised under liabilities and subsequently recognised under operating revenue in line with the amortisation and depreciation of the relevant assets.

Grants due for investments in research and development are recognised in line with the progress of the research, calculated on the basis of the progress reports issued to the relevant bodies and the stage of completion reported by those in charge of the research, if all requirements for their disbursement are met.

[2.4.15] Financial income and expense

Financial income and expense are recognised on an accruals basis on the basis of interest accrued on the net amount of the relevant financial assets and liabilities, using the effective interest method.

[2.4.16] Dividends

Dividends are recognised when the shareholder’s right to receive payment is established.

[2.4.17] Income taxes

Income taxes recognised in profit or loss are the sum of current and deferred taxes.

Income taxes for the year are determined on the basis of ruling legislation. They are recognised in profit or loss, except for those related to items recognised directly in equity, for which the tax effect is accounted for directly in equity.

Income tax liabilities are recognised under current tax liabilities, net of advances paid. Any tax credits are recognised under current tax assets.

Deferred tax assets and liabilities are calculated on the temporary differences between the carrying amounts of assets and liabilities (resulting from the application of the accounting policies set out in note [2.4] Basis of preparation) and their tax bases (deriving from the application of the tax legislation ruling in the country of the subsidiaries). Current and deferred tax assets and liabilities are offset when the group has the legally enforceable right to offset.

Deferred taxes are calculated using the tax rates expected to be enacted in the years in which the temporary differences will be recovered or settled. Deferred tax assets and liabilities are not discounted.

Deferred tax assets are recognised on temporary differences and to the extent that it is probable the group will have future taxable profits that will allow their recovery.

[2.4.18] Fair value

IFRS 13 is a common framework for fair value measurement and relevant disclosure when this measurement is required or allowed by other IFRS. Specifically, the standard sets out the definition of fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

IFRS 13 establishes a hierarchy that categorises the inputs used in the valuation techniques adopted to measure fair value into different levels, as follows:

 

   

level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity has the ability to access at the measurement date;

 

   

level 2: inputs other than quoted prices included in level 1 that are observable for the assets or liabilities, either directly or indirectly;

 

   

level 3: unobservable inputs for the assets or liabilities.

 

20


In some cases, the inputs used to measure the fair value of an asset or a liability might be categorised within different levels of the fair value hierarchy. In those cases, the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The group recognises transfers among the different levels of the fair value hierarchy at the end of the year in which the transfer took place.

Reference should be made to the notes to the individual financial statements items for the definition of the fair value hierarchy level used to classify the individual instruments measured at fair value or whose fair value is disclosed.

The fair value of derivatives is calculated by discounting estimated cash flows using the market interest rates at the reporting date and the credit default swaps issued by the counterparty and group companies, to include the non-performance risk explicitly provided for under IFRS 13.

Where market prices are not available, the fair value of non-derivative medium/long-term financial instruments is calculated by discounting estimated cash flows using the market interest rates at the reporting date and considering counterparty risk for financial assets and credit risk for financial liabilities.

[2.4.19] Use of estimates

In preparing the consolidated financial statements as at 31 December 2022, the directors were required to apply accounting policies that are, at times, based on judgements or past experience or assumptions deemed reasonable and realistic at the time, depending on the relevant circumstances. The application of such estimates and assumptions impacts the carrying amounts recognised in the statement of financial position, income statement, statement of comprehensive income and statement of cash flows, in addition to the disclosure provided. The end results of the assessments in which such estimates and assumptions were used may differ from those recognised in the consolidated financial statements as at 31 December 2022 due to the inherent uncertainty of the assumptions and the conditions underlying the estimates.

Actual results may differ from those estimated. Estimates and assumptions are reviewed on an ongoing basis. The effect of a change in accounting estimates is recognised in profit or loss in the period of the change, if the change affects that period only, or the period of the change and future periods, if the change affects both.

Estimates mainly refer to the following captions:

 

   

Impairment losses on non-current assets and goodwill;

 

   

loss allowance;

 

   

allowance for inventory write-down;

 

   

recoverability of deferred tax assets;

 

   

estimate of the provisions for risks and contingent liabilities;

 

   

financial liabilities;

 

   

employee incentive plans.

Impairment losses on non-current assets and goodwill

Non-current assets include property, plant and equipment, intangible assets including goodwill and other financial assets.

Management periodically revises the carrying amount of non-current assets held and used and assets held for sale when events and circumstances require such revision. This is performed using the estimates of cash flows the group expects to derive from using or selling the asset and suitable discount rates for calculating the present value.

When the carrying amount of a non-current asset has been impaired, the group recognises an impairment loss equal to the excess between the carrying amount and the amount to be recovered through use or sale of the asset, determined using the parent’s or group’s most recent plans. Reference should be made to note [2.4.6] Impairment losses.

 

21


Loss allowance

The loss allowance is management’s best estimate of the potential credit losses on trade receivables from end customers. Reference should be made to note [2.4.8] Trade receivables and other assets and trade payables and other liabilities for a description of the criteria used in estimating the allowance.

Allowance for inventory write-down

Inventories of slow-moving raw materials and finished goods are periodically analysed on the basis of historical data and the possibility of selling them at prices lower than normal market transactions. If, as a result, the carrying amount of inventories needs to be written down, the group recognises a specific allowance for inventory write-down.

Recoverability of deferred tax assets

The group pays taxes in numerous countries and some estimates are required to calculate the taxes in each jurisdiction. It recognises deferred tax assets to the extent that it is probable that future taxable profits will be available and over a period of time compatible with the time horizon implicit in the management estimates.

Estimate of the provisions for risks and contingent liabilities

The group could be subject to legal and tax disputes regarding a vast range of issues that are subject to the jurisdiction of various countries. Disputes and litigation against the group are subject to a different degree of uncertainty, including the facts and circumstances inherent to each dispute, the jurisdiction and different applicable laws. In the ordinary course of business, management consults its legal consultants and legal and tax experts. The group recognises a liability for such disputes when it is deemed probable that they will result in an outflow of resources and when the amount of the resulting losses can be reasonably estimated. If an outflow of resources is possible but the amount cannot be determined, such fact is disclosed in the notes to the consolidated financial statements as at 31 December 2022.

Employee incentive plans and financial liabilities

Reference is made to section [4.8] Incentive plans for a description of the calculation of the fair value of share-based payments as part of group management incentive plans. Section [3.15] Current and non-current financial liabilities provides details of the calculation of fair value of the group’s financial liabilities.

[2.4.20] Translation of foreign currency items

The financial statements of each consolidated company are prepared using the functional currency related to the economy where each company operates. Transactions in currencies other than the functional currency are recognised at the exchange rate at the date of the transaction. Foreign currency monetary assets and liabilities are subsequently translated at the closing rate and any exchange differences are taken to profit or loss. Foreign currency non-monetary assets and liabilities recognised at historical cost are translated using the exchange rate at the date of the transaction.

For consolidation purposes, the foreign currency reporting packages of consolidated companies are translated using the closing rates for asset and liability captions, including goodwill and consolidation adjustments, and the average rate for the year (if similar to the respective transaction-date rates) or the period under consolidation, if lower, for income statement captions. The relevant exchange differences are taken directly to the statement of comprehensive income and reclassified to profit or loss when control over the investee is lost and, thus, it is deconsolidated.

[2.4.21] Operating segments

An operating segment is a component of an entity:

 

   

that engages in business activities from which it may earn revenue and incur expenses (including revenue and expenses relating to transactions with other components of the same entity);

 

   

whose operating results are regularly reviewed by the entity’s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance; and

 

   

for which discrete financial information is available.

 

22


Note [4.2] Operating segments provides information about the single operating segment identified.

[2.4.22] New standards and interpretations, revisions and amendments to existing standards

As required by IAS 8 Accounting policies, changes in accounting estimates and errors, below are the new standards and interpretations, in addition to amendments to existing and applicable standards and interpretations, applicable starting from 1 January 2022 and not yet in effect at the reporting date.

[2.4.22.1] New standards and interpretations applicable from 1 January 2022

The amendments to the IFRS adopted during the year included:

On 14 May 2020, the IASB published the following amendments:

 

   

Amendments to IFRS 3 Business combinations: which update the reference in IFRS 3 to the revised conceptual framework without significantly changing its requirements.

 

   

Amendments to IAS 16 Property, plant and equipment: which prohibit deducting from the cost of an item of property, plant and equipment any proceeds from selling items produced during the testing of such item. An entity recognises the proceeds from selling such items, and the cost of producing those items, in profit or loss.

 

   

Amendments to IAS 37 Provisions, contingent liabilities and contingent assets: which specify that the cost of fulfilling a contract comprises the costs that relate directly to the contract. Costs that relate directly to a contract can either be incremental costs of fulfilling that contract (e.g., direct labour, materials) or an allocation of other costs that relate directly to fulfilling contracts (e.g., the allocation of the depreciation charge for an item of property, plant and equipment used in fulfilling the contract).

 

   

Annual Improvements 2018-2020: which amend IFRS 1 First-time adoption of International Financial Reporting Standards, IFRS 9 Financial instruments, IAS 41 Agriculture and the illustrative examples of IFRS 16 Leases.

All of the amendments are effective for annual periods beginning on or after 1 January 2022.

The adoption of the other standards and interpretations detailed above has not had a material impact on the measurement of the group’s asset, liabilities, costs and revenue.

[2.4.22.2] Standards, amendments and interpretations not yet mandatory and not adopted early at 31 December 2022

On 18 May 2017, the IASB published IFRS 17 Insurance contracts which will replace IFRS 4 Insurance contracts.

The objective of the new standard is to ensure that an entity provides relevant information that faithfully represents the rights and obligations deriving from insurance contracts issued. The IASB developed the standard to eliminate inconsistencies and deficiencies in existing accounting standards, providing a single principle-based framework covering all types of insurance contracts, including reinsurance contracts held by an insurance company.

The new standard also sets out presentation and disclosure requirements to improve the comparability between entities operating in the insurance industry.

Under IFRS 17, an entity measures an insurance contract using a general accounting model or a simplified version called the premium allocation approach.

The main features of the general model are:

 

   

estimates and assumptions of future cash flows are always current;

 

   

measurement reflects the time value of money;

 

23


   

estimates make maximum use of observable market data;

 

   

there is a current and explicit measurement of risk;

 

   

expected profit is deferred and aggregated in groups of insurance contracts at initial recognition; and

 

   

expected profit is recognised over the coverage period after adjustments from changes in the cash flows assumptions related to each group of contracts.

Under the premium allocation approach, an entity measures the liability for the remaining coverage of a group of insurance contracts on the condition that, at initial recognition, the entity reasonably expects that this will be an approximation of the general model. Contracts with a coverage period of one year or less are automatically eligible for PAA. The simplifications arising from PAA do not apply to the measurement of the liability for incurred claims, measured under the general model. However, there is no need to discount those cash flows if the balance is expected to be paid or received in one year or less from the date the claims are incurred.

An entity shall apply the new standard to issued insurance contracts, including reinsurance contracts issued, reinsurance contracts held and also to investment contracts with a discretionary participation feature (DPF).

The standard is effective for annual periods beginning on or after 1 January 2023. Early application is permitted only for entities that apply IFRS 9 Financial instruments and IFRS 15 Revenue from contracts with customers.

The directors do not expect the adoption of this standard to have a significant effect on the group’s consolidated financial statements as at 31 December 2022.

On 9 December 2021, the IASB published “Amendments to IFRS 17 Insurance contracts: Initial application of IFRS 17 and IFRS 9 – Comparative information”. The amendment is a transition option relating to comparative information about financial assets presented on initial application of IFRS 17. The amendment is aimed at helping entities to avoid temporary accounting mismatches between financial assets and insurance contract liabilities, and therefore improve the usefulness of comparative information for users of financial statements. IFRS 17 incorporating the amendment is effective for annual reporting periods beginning on or after 1 January 2023.

On 12 February 2021, the IASB published “Disclosure of accounting policies—Amendments to IAS 1 and IFRS Practice statement 2” and “Definition of accounting estimates—Amendments to IAS 8”. These amendments will help companies improve accounting policy disclosures so that they provide more useful information to investors and other primary users of the financial statements and distinguish changes in accounting estimates from changes in accounting policies. The amendments are effective for annual reporting periods beginning on or after 1 January 2023 and early adoption is permitted.

On 7 May 2021, the IASB published “Amendments to IAS 12 Income taxes: Deferred tax related to assets and liabilities arising from a single transaction” which clarify how companies account for deferred tax on transactions such as leases and decommissioning obligations. The amendments are effective for annual reporting periods beginning on or after 1 January 2023 and early adoption is permitted.

Limacorporate S.p.A. did not opt for early adoption of these standards.

Other standards, amendments and interpretations

 

   

On 23 January 2020, the IASB published “Amendments to IAS 1 Presentation of financial statements: classification of liabilities as current or non-current” and, on 31 October 2022, “Amendments to IAS 1 Presentation of financial statements: non-current liabilities with covenants which clarify how an entity classifies debt and other financial liabilities as current or non-current. The amendments are effective for annual reporting periods beginning on or after 1 January 2024 and early adoption is permitted.

 

   

On 22 September 2022, the IASB published “Amendments to IFRS 16 Leases: lease liability in a sale and leaseback” which requires a seller-lessee to measure lease liabilities arising from a sale and leaseback in a way that it does not recognise any amount of the gain or loss that relates to the right of use it retains. The amendments are effective for annual reporting periods beginning on or after 1 January 2024 and early adoption is permitted.

 

24


   

On 30 January 2014, the IASB published IFRS 14 Regulatory deferral accounts permits a first-time adopter of IFRS Standards to continue to recognise its rate regulation activities in accordance with its previous GAAP. As the parent and group are not a first-time adopter, this standard is not applicable.

The group will adopt such new standards and amendments, on the basis of the relevant application date, and will assess the potential impacts on the consolidated financial statements as at 31 December 2022 when they are endorsed by IASB.

 

25


[3] Notes to the consolidated financial statements as at 31 December 2022

Below are comments on the statement of financial position captions as at 31 December 2022. For details on statement of financial position captions deriving from related party transactions, reference should be made to note [4.6] Related party transactions.

[3.1] Other intangible assets

Other intangible assets at 31 December 2022 amount to €58,234 thousand, up €4,639 thousand on the previous year end (€53,595 thousand). Changes in other intangible assets in 2021 and 2022 and a breakdown of historical cost, accumulated amortisation and any cumulative impairment losses are summarised in the following tables.

 

(€‘000)

                                                
     01/01/2021      Exchange
difference
     Increases      Reclassifications      Decreases      Amortisation      31/12/2021  

Development expenditure

     664        1,414        7,322        28,340        0        -3,858        33,882  

Industrial patents and intellectual property rights

     1,181        0        413        924        0        -455        2,063  

Concessions, licences, trademarks and similar rights

     5,016        10        2,411        1,722        0        -2,914        6,245  

Assets under development and payments on account

     37,267        1,041        3,893        -30,987        -38        0        11,176  

Other

     349        2        53        1        -9        -167        229  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     44,477        2,467        14,092        0        -47        -7,394        53,595  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

(€‘000)

                                                
     31/12/2021      Exchange
difference
     Increases      Reclassifications      Decreases      Amortisation      31/12/2022  

Development expenditure

     33,882        2,057        5,132        943        0        -4,896        37,118  

Industrial patents and intellectual property rights

     2,063        0        485        0        0        -339        2,208  

Concessions, licences, trademarks and similar rights

     6,245        51        2,322        446        0        -3,165        5,900  

Assets under development and payments on account

     11,176        19        3,911        -1,646        -953        0        12,507  

Other

     229        2        271        257        -2        -257        500  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     53,595        2,129        12,121        0        -955        -8,657        58,234  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

€‘000

      
     01/01/2021  
     Historical cost      Accumulated amortisation      Carrying amount  

Development expenditure

     1,639        975        664  

Industrial patents and intellectual property rights

     2,984        1,802        1,181  

Concessions, licences, trademarks and similar rights

     18,905        13,889        5,016  

Assets under development and payments on account

     37,267        —         37,267  

Other

     1,207        859        348  
  

 

 

    

 

 

    

 

 

 

Total

     62,002        17,525        44,477  
  

 

 

    

 

 

    

 

 

 

 

€‘000

      
     31/12/2021  
     Historical cost      Accumulated amortisation      Carrying amount  

Development expenditure

     38,593        4,711        33,882  

Industrial patents and intellectual property rights

     3,904        1,841        2,063  

Concessions, licences, trademarks and similar rights

     21,272        15,027        6,245  

Assets under development and payments on account

     11,176        0        11,176  

Other

     1,246        1,017        229  
  

 

 

    

 

 

    

 

 

 

Total

     76,191        22,596        53,595  
  

 

 

    

 

 

    

 

 

 

 

26


€‘000

      
     31/12/2022  
     Historical cost      Accumulated amortisation      Carrying amount  

Development expenditure

     46,425        9,307        37,118  

Industrial patents and intellectual property rights

     3,663        1,455        2,208  

Concessions, licences, trademarks and similar rights

     22,359        16,458        5,901  

Assets under development and payments on account

     12,507        0        12,507  

Other

     1,731        1,231        500  
  

 

 

    

 

 

    

 

 

 

Total

     86,685        28,451        58,234  
  

 

 

    

 

 

    

 

 

 

Intangible assets with an indefinite useful life only comprise goodwill, while the other assets (development expenditure, industrial patents and intellectual property, concessions, licences, trademarks and similar rights, other intangible assets and assets under development and payments on account) all have a finite life. More information on each item is provided below.

Development expenditure, amounting to €37,118 thousand, comprises:

 

   

€1,060 thousand incurred by the parent mainly related to Physica and Hybrid Glenoid;

 

   

€14,424 thousand related to the allocation of part of the goodwill arising on consolidation transferred at the acquisition date for TechMah Medical LLC (resulting from a step acquisition achieved in stages but consolidated at 100% as per the anticipated acquisition method). Such goodwill was partly allocated to development expenditure and partly to goodwill. The relevant estimated useful life is ten years;

 

   

€1,382 thousand for the recognition of the additional new milestone agreed with the sellers of such company in June 2020 via an addendum to the initial agreement, for the development of an additional implant technology to those agreed at the acquisition;

 

   

€20,252 thousand related to costs capitalised by TechMah Medical LLC for the development of its products which will enrich the group’s portfolio with digital solutions designed to assist surgeons with operations. The same applies as for the second point regarding amortisation.

The significant increase on the previous year end is due to the costs incurred by TechMah Medical LLC in 2022 to develop products. The recoverability of TechMah costs is supported by the result of the discounted cash flow method applied to test the TechMah CGU; based on the impairment test exercise at 31 December 2022 the VIU is lower than the carrying amount of the CGU so, as provided for IAS 36, management fully impaired firstly the goodwill. The carrying amount of the CGU after the impairment of goodwill is recoverable by the VIU defined.

In summer 2023 the Management of Limacorporate took the strategic decision to stop the Spart Space project (TechMah business). All digital activities and resources have been refocused on other projects (please refer to Events after the reporting date paragraph).

Amortisation of this caption amounts to €4,896 thousand.

Industrial patents and intellectual property rights, amounting to €2,208 thousand, are comprised of costs incurred by Limacorporate S.p.A. to acquire patents in 2022 and previous years.

Concessions, licences, trademarks and similar rights of €5,900 thousand are comprised of costs incurred by:

 

   

the parent (€2,861 thousand) for costs to register Lima products on the European, US, Chinese, Korean and Japanese markets;

 

   

other group companies (€448 thousand) for costs mainly to register products on the Brazilian market;

 

   

the parent (€2,336 thousand) for costs incurred to purchase commercial licences (€1,146 thousand), software programs (€1,086 thousand) and to register trademarks (€104 thousand);

 

   

other group companies (€255 thousand).

Amortisation of this caption amounts to €3,165 thousand.

 

27


Assets under development and payments on account, amounting to €12,507 thousand, is comprised of the following:

 

   

€12,107 thousand for costs incurred by Limacorporate S.p.A. for development activities, payments on account for software licences, costs to register the Lima products and costs incurred to acquire patents;

 

   

€400 thousand related to other group companies.

“Other”, amounting to €500 thousand, refers to the following companies for leasehold improvements:

 

   

Limacorporate S.p.A. for €19 thousand;

 

   

Lima USA for €269 thousand;

 

   

Lima Orthopaedics Australia for €23 thousand;

 

   

Lima Implantes for €56 thousand;

 

   

Lima Korea for €115 thousand;

 

   

other group companies for €18 thousand.

The capitalised costs are amortised over the residual term of the relevant lease contract and amortisation of this caption amounts to €257 thousand.

Total amortisation of intangible assets taken to profit or loss amounts to €8,657 thousand.

[3.2] Goodwill

Goodwill amounts to €384,216 thousand.

Pursuant to IAS 36, goodwill is not subject to amortisation, but is tested for impairment at least annually or more frequently if events or circumstances indicate that it might be impaired. With regard to testing goodwill for impairment, the group identified two CGUs for its operations,-one for the Group except TechMah (“Group CGU”) and one related to TechMah . It considered the sources of information set out by IAS 36 such as the fact that management monitors the group’s performance and takes strategic decisions about its product offering and investments at group level, except for TechMah business which is a separate CGU.

The goodwill recognised in the consolidated financial statements as at 31 December 2022 in relation to the above-mentioned merger, together with other items of goodwill, was tested for impairment at the reporting date. Specifically, the recoverable amount of the group’s assets was calculated by estimating their fair value and comparing it with the carrying amount of consolidated net invested capital at 31 December 2022 in order to examine whether recognised amounts had been impaired.

The market multiples method is used to determine the fair value of goodwill of the Group CGU, using listed comparable companies. These multiples are compared with the implicit multiple calculated using the group’s actual figures. The market multiples analysis based on companies operating in sectors comparable to those of Limacorporate (performed on the date the impairment test was carried out on seven comparable companies) provides supporting evidence about the carrying amount of goodwill recognised in the 2022 consolidated financial statements as at 31 December 2022. This is because the market multiples (which show an average enterprise value of between 15 and 17 times gross operating profit) are higher and/or in line with the multiple obtained by comparing the group’s actual net invested capital at the end of 2022 (i.e., including goodwill) to consolidated gross operating profit.

As a result of such checks, based on market references (i.e., market multiples) compared with the group’s implicit multiple, no impairment indicators have been detected to date for goodwill allocated to the Group CGU.

The group separately measured TechMah Medical LLC’s business related to the Smart SPACE digital solution.

The recoverable value of the TechMah CGU was determined as its value in use, on the basis of the cashflows discounted using a rate that reflects the risk conditions (WACC of 13.5%). The recoverable amount determined with aforementioned method led to the full impairment of goodwill (€ 15,109 thousand) allocated to the CGU.

 

28


[3.3] Property, plant and equipment

Property, plant and equipment and other assets amount to €79,837 thousand, down €1,936 thousand compared to 31 December 2021 (€81,773 thousand).

Changes in property, plant and equipment in 2021 and 2022 and a breakdown of historical cost, accumulated depreciation and any cumulative impairment losses are summarised in the following tables:

 

     01/01/2021      Exchange
difference
     Increases      Decreases      Depreciation      Reclassifications      Other
changes
     31/12/2021  

Land and buildings

     15,907        0        508        0        -703        34        0        15,746  

Leased land and buildings

     9,364        377        827        -78        -2,539        0        -880        7,071  

Plant and equipment

     17,945        14        1,753        -754        -4,282        343        0        15,019  

Leased plant and equipment

     26        0        0        0        -15        0        2        13  

Industrial and commercial equipment

     35,489        670        15,676        -626        -14,967        578        0        36,820  

Leased industrial and commercial equipment

     15        0        935        0        -315        0        0        635  

Other assets

     1,605        35        643        -22        -576        0        0        1,683  

Other leased assets

     2,695        7        1,221        0        -1,726        0        -52        2,145  

Assets under construction and payments on account

     2,244        81        1,349        -78        0        -955        0        2,641  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     85,288        1,184        22,912        -1,558        -25,123        0        -930        81,773  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

     31/12/2021      Exchange
difference
     Increases      Reclassifications      Decreases      Other
changes
     Depreciation      31/12/2022  

Land and buildings

     15,746        0        456        35        -67        0        -674        15,496  

Leased land and buildings

     7,071        226        2,087        0        -5        623        -3,247        6,755  

Plant and equipment

     15,019        0        3,601        2,255        -17        0        -4,442        16,416  

Leased plant and equipment

     13        0        82        0        0        0        -16        79  

Industrial and commercial equipment

     36,820        258        14,647        -63        -1,156        0        -15,832        34,674  

Leased industrial and commercial equipment

     635        0        0        0        0        -58        -558        19  

Other assets

     1,683        15        706        3        -20        0        -600        1,787  

Other leased assets

     2,145        2        1,577        0        0        90        -1,514        2,299  

Assets under construction and payments on account

     2,641        64        1,991        -2,231        -154        0        0        2,311  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     81,773        566        25,145        0        -1,418        655        -26,884        79,837  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

     01/01/2021  
     Historical cost      Accumulated
depreciation
     Accumulated
impairment losses
     Carrying amount  

Land and buildings

     24,082        7,610        565        15,907  

Leased land and buildings

     18,471        9,107        —         9,364  

Plant and equipment

     53,382        35,437        —         17,945  

Leased plant and equipment

     117        91        —         26  

Industrial and commercial equipment

     116,513        80,857        167        35,489  

Leased industrial and commercial equipment

     30        15        —         15  

Other assets

     6,727        5,122        —         1,605  

Other leased assets

     6,176        3,481        —         2,695  

Assets under construction and payments on account

     2,244        —         —         2,244  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     227,741        141,720        733        85,288  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     31/12/2021  
     Historical cost      Accumulated
depreciation
     Accumulated
impairment losses
     Carrying amount  

Land and buildings

     24,624        8,313        565        15,746  

Leased land and buildings

     17,344        10,273        0        7,071  

Plant and equipment

     54,318        39,299        0        15,019  

Leased plant and equipment

     119        106        0        13  

Industrial and commercial equipment

     132,183        95,196        167        36,820  

Leased industrial and commercial equipment

     966        331        0        635  

Other assets

     7,257        5,574        0        1,683  

Other leased assets

     6,016        3,871        0        2,145  

Assets under construction and payments on account

     2,641        0        0        2,641  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     245,468        162,963        733        81,773  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

29


     31/12/2022  
     Historical cost      Accumulated
depreciation
     Accumulated
impairment losses
     Carrying amount  

Land and buildings

     23,870        8,374        0        15,496  

Leased land and buildings

     19,868        13,113        0        6,755  

Plant and equipment

     59,135        42,719        0        16,416  

Leased plant and equipment

     202        122        0        80  

Industrial and commercial equipment

     141,939        107,009        256        34,674  

Leased industrial and commercial equipment

     66        47        0        19  

Other assets

     7,937        6,150        0        1,787  

Other leased assets

     5,069        2,770        0        2,299  

Assets under construction and payments on account

     2,311        0        0        2,311  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     260,397        180,304        256        79,837  
  

 

 

    

 

 

    

 

 

    

 

 

 

The €456 thousand increase in land and buildings during the year is chiefly due to costs incurred by the parent to build the new electrical substation at the Villanova production facility and to acquire land to extend the production facility.

The increase in plant and machinery mainly refers to the construction of plant for the new electrical substation, the completion of the new packaging line and investments made to purchase production machinery, specifically additive manufacturing machines.

Industrial and commercial equipment amounts to €34,674 thousand and is chiefly comprised of surgical instruments capitalised during the current and previous years.

Other assets include office furniture and machines, electronic office machines, transport vehicles and cars. Investments, amounting to €706 thousand, refer to purchases of electronic office machines and furniture.

The €1,991 thousand increase in assets under construction and payments on account during the year is chiefly due to costs incurred to expand the Villanova production facility and for the purchase of production equipment and machinery.

Some plant and machinery are subject to a special lien at the reporting dates. Additional information is provided in note [3.15] Current and non-current financial liabilities.

Changes in right-of-use assets deriving from the application of IFRS 16 are set out in the following tables, where such changes are shown for each asset category along with details on the historical cost and accumulated depreciation:

 

     01/01/2021      Exchange
difference
     Increases      Decreases      Depreciation      Other
changes
     31/12/2021  

Right-of-use assets

                    

Leased land and buildings

     9,364        377        827        -78        -880        -2,539        7,071  

Leased plant and equipment

     26        0        0        0        2        -15        13  

Leased industrial and commercial equipment

     15        0        935        0        0        -315        635  

Other leased assets

     2,695        7        1,221        0        -52        -1,726        2,145  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     12,100        384        2,983        -78        -930        -4,595        9,864  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

     31/12/2021      Exchange
difference
     Increases      Decreases      Depreciation      Other
changes
     31/12/2022  

Right-of-use assets

                    

Leased land and buildings

     7,071        226        2,087        -5        623        -3,247        6,755  

Leased plant and equipment

     13        0        82        0        0        -16        79  

Leased industrial and commercial equipment

     635        0        0        0        -58        -558        19  

Other leased assets

     2,145        2        1,577        0        90        -1,514        2,300  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     9,864        228        3,746        -5        655        -5,335        9,153  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Lease liabilities deriving from the application of IFRS 16 are included under current and non-current financial liabilities (analysed in note [3.15] Current and non-current financial liabilities). Changes in current and non-current lease liabilities from 1 January 2021 to 31 December 2022 are set out below:

 

30


     01/01/2021      Increases      Decreases      Reclassifications      31/12/2021  

Lease liabilities as per IFRS 16 - non-current portion

     6,573        1,369        0        -3,518        4,423  

Lease liabilities as per IFRS 16 - current portion

     3,384        0        -3,384        3,518        3,518  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

TOTAL

     9,957        1,369        -3,384        0        7,941  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

     01/01/2022      Exchange
difference
     Increases      Decreases      Other
changes
     Reclassifications      31/12/2022  

Lease liabilities as per IFRS 16 - non-current portion

     4,423        83        3,663        0        655        -4,273        4,552  

Lease liabilities as per IFRS 16 - current portion

     3,518        -7        40        -4,559        0        4,273        3,265  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

TOTAL

     7,941        76        3,703        -4,559        655        0        7,817  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

[3.4] Equity investments

Equity investments amount to €2 thousand at 31 December 2022.

The following information is provided on direct and indirect equity investments in subsidiaries, associates and other companies.

Subsidiaries

All of the subsidiaries are included in the consolidation scope.

Other companies

Equity investments in other companies amount to €2 thousand and refer to CAAF Interregionale dipendenti S.r.l., Consorzio Friuli Energia, Terra degli Elimi and CE.R.ME.T..

[3.5] Deferred tax assets and liabilities

Deferred tax assets and liabilities are only offset when this is legally provided for within the same tax jurisdiction. The group recognised deferred tax assets and liabilities on the temporary differences between carrying amounts and tax bases. The latter were calculated using the rates ruling when the temporary differences will reverse in the different countries where the group operates.

Deferred tax assets and liabilities are broken down as follows at 31 December 2022 and 2021:

 

     31/12/2022      31/12/2021      01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Deferred tax assets

     11,558        11,947        12,758        -390        -811  

Deferred tax assets arising on consolidation

     20,151        21,515        19,137        -1,364        2,378  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     31,709        33,462        31,895        -1,754        1,567  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

     31/12/2022      31/12/2021      01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Deferred tax liabilities

     9,414        7,931        5,461        1,483        2,470  

Deferred tax liabilities arising on consolidation

     9,861        9,364        7,525        497        1,839  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     19,275        17,295        12,986        1,980        4,309  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Reference should be made to section [3.29] of these notes for more details on deferred tax assets and liabilities and the differences that generated them.

The recoverability of DTA accrued at 31 December 2022 was based on the business plan prepared by the management which shows the recoverability considering the future taxable incomes.

 

31


[3.6] Other non-current assets

Other non-current assets, amounting to €861 thousand, mainly refer to guarantee deposits for lease contracts taken out by the group and prepayments (€162 thousand), mostly for insurance and maintenance.

[3.7] Inventories

A breakdown of inventories at 31 December 2022 and 2021 is provided below:

 

     31/12/2022      31/12/2021      01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Raw materials and supplies

     6,272        6,094        6,106        178        -12  

Work in progress and semi-finished products

     11,533        12,861        14,344        -1,328        -1,483  

Contract work in progress

     0        0        0        0        0  

Finished goods

     79,583        77,993        74,875        1,590        3,118  

Payments on account

     0        0        0        0        0  

Goods in transit

     831        647        177        184        470  

Allowance for inventory write-down

     -11,492        -10,174        -11,336        -1,318        1,162  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     86,728        87,421        84,166        -693        3,255  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Inventories were measured using the cost of the production company for the consolidated companies.

The allowance for inventory write-down, amounting to €11,492 thousand at 31 December 2022, changed as follows during the year:

 

Balance at 01/01/2021

     11,336  

Exchange difference

     74  

Utilisations

     -1,952  

Accruals

     716  
  

 

 

 

Balance at 31/12/2021

     10,174  
  

 

 

 

Exchange difference

     54  

Utilisations

     -1,883  

Accruals

     3,146  
  

 

 

 

Balance at 31/12/2022

     11,491  
  

 

 

 

Utilisations of the allowance refer to the scrapping of obsolete goods by Limacorporate S.p.A. and subsidiaries during the year.

[3.8] Trade receivables

Trade receivables at 31 December 2022 amount to €70,161 thousand, compared to €66,891 thousand at the previous year end, and are broken down as follows:

 

     Gross amount      Loss allowance      Carrying amount
31/12/2021
 

Trade receivables - third parties

     68,971        2,082        66,889  

Trade receivables - related parties

     2        —         2  
  

 

 

    

 

 

    

 

 

 

Total

     68,973        2,082        66,891  
  

 

 

    

 

 

    

 

 

 

 

     Gross amount      Loss allowance      Carrying amount
31/12/2022
 

Trade receivables - third parties

     72,527        2,387        70,140  

Trade receivables - related parties

     21        —         21  
  

 

 

    

 

 

    

 

 

 

Total

     72,548        2,387        70,161  
  

 

 

    

 

 

    

 

 

 

 

32


Trade receivables originate from group activities and are broken down by geographical segment as follows:

 

     Total Italy
31/12/2021
     Total EU
31/12/2021
     Rest of world
31/12/2021
     Total
31/12/2021
 

Trade receivables

     21,642        20,938        24,309        66,889  

From subsidiaries

     0        0        2        2  

From associates

     0        0        0        0  

From parents

     0        0        0        0  

From subsidiaries of parents

     0        0        0        0  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     21,642        20,938        24,311        66,891  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

     Total Italy      Total EU      Rest of world      Total  
     31/12/2022      31/12/2022      31/12/2022      31/12/2022  

Trade receivables

     23,021        20,681        26,438        70,140  

From subsidiaries

     0        0        0        0  

From associates

     0        0        0        0  

From parents

     0        21        0        21  

From subsidiaries of parents

     0        0        0        0  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     23,021        20,702        26,438        70,161  
  

 

 

    

 

 

    

 

 

    

 

 

 

Trade receivables in foreign currency are detailed in section [4.2] Financial instruments – Fair value and risk management under Other information, to which reference should be made.

The loss allowance amounts to €2,387 thousand at 31 December 2022 (31 December 2021: €2,082 thousand).

The loss allowance is management’s estimate of the expected credit losses on trade receivables from customers. The estimate is based on the group’s expected credit losses, determined using past experience with similar receivables, current and historical overdue amounts, losses and collections, a careful monitoring of credit quality and forecasts of economic and market conditions.

Changes in the loss allowance in 2022 and 2021 are as follows:

 

     2022      2021  

Opening balance

     2,082        1,940  

Exchange difference

     33        10  

Accruals

     519        544  

Utilisations

     -247        -412  
  

 

 

    

 

 

 

Closing balance

     2,387        2,082  
  

 

 

    

 

 

 

Specifically:

 

     Receivables
impaired
individually
     Receivables
impaired
collectively
     Total  

01/01/2021

     1,660        280        1,940  

Utilisations

     -398        -14        -412  

Accruals

     406        138        544  

Exchange difference

     11        0        11  
  

 

 

    

 

 

    

 

 

 

31/12/2021

     1,679        403        2,082  
  

 

 

    

 

 

    

 

 

 

Utilisations

     -230        -17        -247  

Accruals

     324        195        519  

Exchange difference

     -10        43        33  
  

 

 

    

 

 

    

 

 

 

31/12/2022

     1,763        624        2,387  
  

 

 

    

 

 

    

 

 

 

 

33


A breakdown of the loss allowance by past due category is as follows:

 

     Not yet due      Overdue      Total  
            <30 days      30 - 90 days      90 - 180 days      Over 180 days         

Gross trade receivables at 01 January 2021

     38,238        6,112        5,375        4,306        10,968        64,998  

Loss allowance

     0        0        0        64        1,876        1,940  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net trade receivables at 01 January 2021

     38,238        6,112        5,375        4,242        9,092        63,058  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Gross trade receivables at 31 December 2021

     41,111        6,422        5,362        4,622        11,454        68,971  

Loss allowance

     0        0        0        24        2,059        2,082  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net trade receivables at 31 December 2021

     41,111        6,422        5,362        4,598        9,396        66,889  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Gross trade receivables at 31 December 2022

     47,181        7,324        6,108        4,519        7,394        72,526  

Loss allowance

     0        0        1        1        2,385        2,387  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net trade receivables at 31 December 2022

     47,181        7,324        6,109        4,520        9,779        74,913  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

[3.9] Current tax assets

Tax assets at 31 December 2022 amount to €2,087 thousand and include direct taxes, particularly in relation to the parent’s IRES and IRAP for €1,619 thousand.

[3.10] Other current assets

Other current assets at 31 December 2022 amount to €14,192 thousand, compared to €11,247 thousand at the previous year end, and are broken down as follows:

 

     31/12/2022      31/12/2021      01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Grants

     5,281        4,976        4,807        305        169  

Other tax assets

     827        758        1,024        69        -266  

Advances to agents

     776        779        964        -3        -185  

VAT

     1,317        1,340        923        -23        417  

Advances to suppliers

     1,327        939        804        388        135  

Hire and maintenance

     873        657        669        216        -12  

Other sundry

     1,354        420        489        934        -69  

VAT to be offset

     325        118        461        207        -343  

Insurance premiums and sureties

     574        507        396        67        111  

Other

     676        239        349        437        -110  

VAT claimed for reimbursement

     289        289        289        0        0  

Other tax credit

     0        0        104        0        -104  

Rent

     32        112        88        -80        24  

Deductible taxes

     0        50        50        -50        0  

Social security institutions

     20        20        21        0        -1  

IRAP-IRES reimbursement

     18        18        18        0        0  

Tax withholdings

     2        8        7        -6        1  

Factoring interest

     40        10        3        30        7  

Accrued income

     3        3        3        0        0  

Tax assets - interest

     454        0        0        454        0  

Leasing fees

     0        0        0        0        0  

IRPEF reimbursement

     4        5        0        -1        5  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     14,192        11,248        11,469        2,944        -221  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Grants chiefly refer to the amount accrued by the parent (€5,281 thousand) and are broken down as follows:

 

   

SIB grant (€4,630 thousand);

 

   

MCBEES grant (€258 thousand);

 

   

AIM grant (€40 thousand);

 

   

IAREPAM grant (€158 thousand;

 

   

PROST3SIS grant (€195 thousand).

 

34


Other assets also include guarantee deposits on gas and electricity consumption (€472 thousand).

[3.11] Cash and cash equivalents

Cash and cash equivalents at 31 December 2022 amount to €25,920 thousand, compared to €21,503 thousand at the previous year end. This caption shows the group’s liquidity at the reporting date.

Reference should be made to the statement of cash flows for an analysis of changes in cash and cash equivalents.

 

     31/12/2022      31/12/2021      31/12/2020      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Bank and postal accounts

     25,903        21,486        26,257        4,417        -4,771  

Cash-in-hand and cash equivalents

     17        17        16        0        1  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     25,920        21,503        26,273        4,417        -4,770  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

[3.12] Equity

Equity attributable to the owners of the parent amounts to €306,564 thousand, and is broken down as follows:

 

(€‘000)

                                  
     31/12/2022      31/12/2021      01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Share capital

     9,868        9,868        9,868        0        0  

Share premium reserve

     14,425        14,425        14,425        0        0  

Legal reserve

     2,101        2,101        2,101        0        0  

Equity injections

     28,051        28,051        23,088        0        4,963  

Merge reserve

     288,261        288,261        288,261        0        0  

Actuarial reserve

     31        -23        -25        54        2  

Translation reserve

     2,379        1,508        -334        871        1,842  

Other reserves

     2,687        -2,329        -2,329        5,016        0  

Retained earnings (losses carried forward)

     -21,966        -18,862        -6,380        -3,104        -12,482  

Profit (loss) for the year

     -19,273        -2,539        -12,482        -16,735        9,943  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Equity

     306,564        320,463        316,194        -13,899        4,269  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

The share capital at 31 December 2022 is €9,868 thousand and is fully subscribed and paid up. It is comprised of 9,989,718 ordinary shares without a nominal amount. It is unchanged on the previous year end.

The share premium reserve amounts to €14,425 thousand and is unchanged on the previous year end.

The legal reserve amounts to €2,101 thousand. This reserve is not distributable and did not change during the year.

Negative goodwill, amounting to €288,261 thousand, comprises the effects of the reverse merger between the parent and Emil Holding III S.p.A. in October 2016 on equity.

Capital injections for capital increase, amounting to €28,051 thousand, comprise the contribution in kind made in 2021 by the shareholder for the acquisition of TechMah Medical (€4,963 thousand), the capital injection made by the shareholder in June 2020 (€20,000 thousand) and the effects of a contribution in kind made in 2019 by the shareholder in relation to the transaction carried out by the subsidiary Lima USA with Hospital for Special Surgery (HSS) (€3,088 thousand).

The contribution in kind made by the shareholder in 2021 is directly related to the shared-based payment of certain milestones regarding the acquisition of TechMah Medical. Under the agreement signed in 2018, the subsidiary Lima USA would allocate the founding shareholders of TechMah Medical a set number of new EmilNewCo Sarl (indirect parent of Limacorporate S.p.A. with a 100% interest) shares upon reaching set targets regarding the development of new products benefiting the group.

 

35


The above-mentioned allocation of shares in October 2021 led to a share capital increase for EmilNewCo and the recognition of an amount due from the founding shareholders of TechMah Medical equal to the liability recognised by Lima USA for the contractual milestones to be settled. The two transactions between the founding shareholders of Techmah Medical and Lima Group (EmilNewCo Sarl, Limacorporate S.p.A. and Lima USA) were offset using claim notes, which generated the capital injection referred to above.

With a similar transaction, the collaboration agreement signed with HSS in January 2019 for the production of implants within the hospital led to the following agreements:

 

   

a six-year lease for the premises where Lima USA will produce the implants for HSS, of which payment for the first three years has been made by awarding HSS a fixed number of new EmilNewCo Sarl shares and the second three years will be paid by monthly instalments;

 

   

a clause which establishes that HSS will bear an agreed amount of the cost of any leasehold improvements made by Lima USA and will receive an agreed number of new EmilNewCo Sarl shares in return.

The above-mentioned allocation of shares led to a share capital increase for EmilNewCo and the recognition of an amount due from HSS. The prepaid lease instalments and the set amount related to the leasehold improvements generated a liability for Lima USA towards HSS. The two transactions between HSS and Lima Group (EmilNewCo, Limacorporate S.p.A. and Lima USA) have been offset using claim notes, which generated the capital injection referred to above.

Other reserves also include:

 

   

the revaluation reserve, which arose from the merger of Lima S.p.A., amounts to €111 thousand and is recognised in compliance with Law no. 413 of 30 December 1991 in relation to deferred tax on the revalued amount of land and industrial buildings. There were no changes in the reserve during the year;

 

   

the reserve deriving from the application of IAS 19 Employee benefits amounting to €31 thousand;

 

   

the IFRS 2 reserve amounting to €4,650 thousand deriving from the accounting treatment of cash-settled share-based payment and equity-settled share-based payment arrangements;

 

   

the reserve for unrealised exchange rate gains of €1,764 thousand, comprising the net unrealised gains on the allocation of the parent’s profit for the previous year;

 

   

the translation reserve, with a positive balance of €2,379 thousand, reflects the changes in the group’s share of the equity of consolidated companies due to changes in exchange rates of such companies’ functional currencies compared to the presentation currency of the consolidated financial statements as at 31 December 2022.

The correction of error on payback for €6.945 thousand has been recorded on retained earnings / losses carried forward (see section “Transition to IFRS issued by IASB”).

The following table provides information on the possibility of use and distribution of each of the parent’s equity items, along with their utilisations in the last three years:

 

36


Description

   Amount      Possibility
of use
     Available
portion
     Utilisation in the
previous three
years to cover
losses
     Utilisation in the
previous three
years for other
reasons
 

Share capital

     9,868        B           

Share premium reserve

     14,425        A, B        14,425        

Legal reserve

     2,101        B        2,101        

Capital injections for capital increase

     28,051        A, B, C        28,051        9,215     

Merge reserve

     288,261        A, B, C        288,288        246     

Actuarial reserve

     31              

Translation reserve

     2,379              

Other reserves

     2,687              

Retained earnings (losses carried forward)

     -21,966           10,770        
  

 

 

       

 

 

    

 

 

    

 

 

 

TOTAL

     325,838           343,635        9,461        0  
  

 

 

       

 

 

    

 

 

    

 

 

 

Non-Distributable Portion (Legal Reserve)

           2,101        

Non-Distributable Portion (Reserve For Unrealised Exchange Rate Gains)

           1,199        

Capitalised Start-Up And Development Costs)

           14,387        
        

 

 

       

Residual Distributable Amount

           325,949        
        

 

 

       

 

*

A: for capital increases; B: to cover losses; C: dividends

The following supplementary information is provided on the parent’s reserves:

1) Reserves or other provisions that do not contribute to the taxable profit of shareholders in the event of distribution regardless of when they are formed.

 

     31/12/2022      31/12/2021      01/01/2021  

Emil Holding III merger reserve

     288,261        288,261        288,261  

Capital injections for capital increase

     28,051        28,051        23,088  

Share premium reserve

     14,425        14,425        14,425  
  

 

 

    

 

 

    

 

 

 

Total

     330,737        330,737        325,774  
  

 

 

    

 

 

    

 

 

 

2) Reserves or other provisions that do contribute to the taxable profit of the parent in the event of distribution regardless of when they are formed.

 

     31/12/2022      31/12/2021      01/01/2021  

Revaluation reserve as per Law no. 413/1991

     111        111        111  

Reserve as per article 55 of Presidential decree no. 917/86

     —         —         —   
  

 

 

    

 

 

    

 

 

 

Total

     111        111        111  
  

 

 

    

 

 

    

 

 

 

3) Reserves included in share capital.

Reserves or other provisions that contribute to the taxable profit of shareholders in the event of distribution, irrespective of when they were set up, for a free share capital increase by using the reserve as per the shareholders’ resolution of 15 October 1999.

 

     31/12/2022      31/12/2021      01/01/2021  

Extraordinary reserve

     540        540        540  
  

 

 

    

 

 

    

 

 

 

Total

     540        540        540  
  

 

 

    

 

 

    

 

 

 

[3.13] Provisions for risks and charges

Details of this caption and changes therein during 2021 and 2022 are provided below:

 

37


(€‘000)

                                         
     01/01/2021      Exchange
differences
     Increases      Decreases      Reclassification      31/12/2021  

Pension and similar provisions

     889        0        198        -162        0        925  

Other provisions

     11,958        -4        4,226        -1,222        -569        14,389  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     12,847        -4        4,424        -1,384        -569        15,314  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

(€‘000)

                                         
     01/01/2022      Exchange
differences
     Increases      Decreases      Reclassification      31/12/2022  

Pension and similar provisions

     925        0        236        -576        0        585  

Other provisions

     14,389        14        4,166        -1,997        0        16,571  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     15,314        14        4,402        -2,573        0        17,156  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Agents’ termination indemnity (€585 thousand) is the estimated liability deriving from the application of ruling legislation and the contractual clauses in relation to the termination of agency contracts. Unlike accruals to the provision for risks, guarantees and other provisions, accruals to agents’ termination indemnity are classified by nature among costs for services. The decreases of the year refer to utilisations of the provision following the termination of agency contracts and the release of the provision when not due.

Other provisions, amounting to €16,571 thousand, are comprised as follows:

 

   

the provision for charges of €1,859 thousand, of which €1,460 thousand related to commission expense on revenue yet to be invoiced; and €399 thousand related to highly probable non-competition agreements the payment date of which is not yet known;

 

   

the provision related to the payback system for €14.3 million;

 

   

compensation for damage caused by products of €300 thousand;

 

   

other disputes/contingent liabilities of €95 thousand.

The decreases of the year mainly refer to the release of a provision following the signing of a settlement agreement with an agent.

The accruals of the year mainly refer to the best estimate of the amounts due under the payback system.

The market in which the Group operates is strictly controlled by laws and regulations such as, e.g., the EU Medical Devices Regulation (‘MDR’) in Europe and the Federal Food, Drug and Cosmetic Act (‘FDCA’) in USA. In order to demonstrate adherence to regulatory requirements and to maintain the ability to sell its products, the Group must obtain and maintain authorisations and certifications from the relevant authorities. Discussions are currently underway with the Australian authority, the Therapeutic Goods Administration (the ‘TGA’), which has been provided with clarification regarding an observation made by the TGA on the high revision rate of certain elements of the ‘SMR’ shoulder solution.

[3.14] Employee benefits

Employee benefits chiefly refer to post-employment benefits recognised by the parent. These are defined benefit plans in accordance with IAS 19. Changes in the caption during the two years were as follows:

 

38


     31/12/2022      31/12/2021      Variation  

Balance at 1 January

     1,442        1,421        21  

Exchange difference

     -13        0        -13  

Benefits settled/advances paid

     -189        -123        -66  

Accruals

     1,716        1,651        65  

Cometa Fund, other pension funds

     -1,599        -1,376        -223  

Post-employment benefits - Substitute tax on revaluation

     0        -132        132  

Interest

     10        4        6  

Actuarial gain

     -71        -3        -68  
  

 

 

    

 

 

    

 

 

 

TOTAL

     1,296        1,442        -146  
  

 

 

    

 

 

    

 

 

 

The main actuarial assumptions used in determining the present value of post-employment benefits are set out below:

 

    

31/12/2022

  

31/12/2021

Actual mortality rate    RG48 tables determined by the State general accountant    RG48 tables determined by the State general accountant
Actual invalidity rate    INPS disability/invalidity tables    INPS disability/invalidity tables

Rate of early terminations (dismissals and resignations)

   Constant annual average rate of 5%    Constant annual average rate of 5%

Rate of requests for advances of post-employment benefits

  

- Constant annual average rate of 3%

 

- Average amount of 70% of post-employment benefits accrued

  

- Constant annual average rate of 3%

 

- Average amount of 70% of post-employment benefits accrued

Annual technical discount rate    3.6% - iBoxx index Eur Corporate AA 10    1% - iBoxx index Eur Corporate AA 10+
Annual future inflation rate    2.50%    1.50%
Pension dates    In line with ruling legislation    In line with ruling legislation
Annual increase in post-employment benefits    Fixed rate of 3.38% plus 75% of the inflation rate noted by ISTAT for December of the previous year    Fixed rate of 2.63% plus 75% of the inflation rate noted by ISTAT for December of the previous year

The occurrence of reasonably possible changes in the actuarial assumptions at 31 December 2022 and 2021 would have impacted the defined benefit obligations by the amounts shown below:

 

2021 sensitivity analysis

 
(€‘000)    Defined benefit obligation  
     +      -  

Annual discount rate (+/- 0.50%)

     959        999  

Annual inflation rate (+/- 0.25%)

     991        967  

Annual turnover rate (+/- 2.00%)

     978        979  

2022 sensitivity analysis

 
(€‘000)    Defined benefit obligation  
     +      -  

Annual discount rate (+/- 0.50%)

     890        922  

Annual inflation rate (+/- 0.25%)

     915        896  

Annual turnover rate (+/- 2.00%)

     907        906  

The number of employees by category at the reporting date and the average for the year is set out below:

 

39


Workforce

   31/12/2020      Incoming      Outgoing      Other
changes
     Reclassifications      31/12/2021      2021 average  

Blue collars

     227        11        -18        0        0        220        224  

White collars

     589        108        -104        -1        -1        591        590  

Junior managers

     90        7        -9        0        -12        76        83  

Managers

     32        5        -9        0        13        41        37  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     938        131        -140        -1        0        928        933  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

Workforce

   31/12/2021      Incoming      Outgoing      Other
changes
     Reclassifications      31/12/2022      2022 average  

Blue collars

     220        22        -14        -20        -4        204        212  

White collars

     591        140        -132        1        -2        598        595  

Junior managers

     76        8        -14        15        5        90        83  

Managers

     41        4        -9        4        1        41        41  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     928        174        -169        0        0        933        931  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

[3.15] Current and non-current financial liabilities

Non-current financial liabilities, amounting to €10,165 thousand at 31 December 2022, comprise the portion of loans and borrowings due after one year and are broken down as follows:

 

     31/12/2022      31/12/2021      01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Non-current bank loans and borrowings

     363        746        1,379        -383        -633  

Non-current bank loans and borrowings (due after five years)

     2        0        41        2        -41  

Bonds

     0        272,556        271,136        -272,556        1,420  

Other financial liabilities

     5,248        5,848        8,279        -600        -2,431  

Lease liabilities as per IFRS 16

     4,552        4,423        6,573        129        -2,150  

Derivatives

     0        0        0        0        0  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     10,165        283,573        287,407        -273,408        -3,834  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Current financial liabilities, amounting to €336,659 thousand, comprise the current portion of loans and borrowings and are broken down as follows:

 

     31/12/2022      31/12/2021      01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Credit cards

     383        47,000        40,000        -46,617        7,000  

Advances on exports

     0        7,771        14,817        -7,771        -7,046  

Current bank loans and borrowings

     54,000        3,518        3,384        50,482        134  

Non-current bank loans and borrowings

     386        1,346        1,318        -960        28  

Bonds - current portion

     274,039        882        909        273,157        -27  

Accrued expenses on bonds - due within one year

     1,979        0        0        1,979        0  

Accrued financial expense - due within one year

     298        401        405        -103        -4  

Loans and borrowings with other financial backers

     2,310        280        211        2,030        69  

Lease liabilities as per IFRS 16

     3,265        338        112        2,927        226  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     336,659        61,536        61,156        275,123        380  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Current financial liabilities chiefly include the bonds issued by Limacorporate S.p.A. in 2017 equal to €274,039 thousand at the reporting date. They are senior secured bonds redeemable in 2023 for a total nominal amount of €275 million. The bonds were initially recognised at fair value, net of directly related costs, and measured at amortised cost applying the effective interest rate method.

 

40


The bonds have coupons based on the 3-month Euribor plus a 3.75% spread, with a Euribor floor threshold of 0.00%. They are listed on the Euro MTF market of the Luxembourg Stock Exchange and the professional section of the ExtraMOT market of the Italian Stock Exchange.

The coupons mature every three months on 15 February, 15 May, 15 August and 15 November each year starting from 15 November 2017.

The following guarantees were issued in relation to the bonds:

 

   

pledge on the shares of Limacorporate S.p.A.;

 

   

pledge on the shares of some subsidiaries;

 

   

pledge on some of the current accounts of the parent and some subsidiaries;

 

   

special lien on plant, machinery and other items of property, plant and equipment of the parent;

 

   

lien on certain categories of assets of some subsidiaries;

 

   

guarantees on some categories of assets of the parent and some subsidiaries.

In relation to the refinancing put in place in 2017, as well as the issue of bonds, Limacorporate also finalised an agreement for a new super senior revolving credit facility for a maximum of €60 million. It may also be used partially, in several instalments with set repayment terms. If the financial covenants are complied with, the interest rate is the same as the bonds, i.e., 3-month Euribor plus a 3.75% spread, with a Euribor floor threshold of 0.00%.

The same guarantees provided for the issue of the bonds were granted for this revolving credit facility; specifically:

 

   

pledge on the shares of Limacorporate S.p.A.;

 

   

pledge on the shares of some subsidiaries;

 

   

pledge on some of the current accounts of the parent and some subsidiaries;

 

   

special lien on plant, machinery and other items of property, plant and equipment of the parent;

 

   

lien on certain categories of assets of some subsidiaries;

 

   

guarantees on some categories of assets of the parent and some subsidiaries.

At the reporting date, €54 million of the revolving facility was used (31 December 2021: €47 million).

If more than 35% of the available amount of the revolving facility is used (i.e., draw-downs exceeding €21 million), a covenant related to the ratio of super senior net debt (the amount drawn down from the revolving facility net of liquid funds) to consolidated gross operating profit (as defined in the loan agreement), which cannot exceed 1.83, is activated under the terms of the contract. Such covenant was complied with at 31 December 2022.

On 3 February 2023, the parent issued new senior secured bonds redeemable in February 2028 for a total nominal amount of €295 million. In addition to the bond issue, the parent also signed a new super senior revolving facility for a maximum of €65 million expiring in November 2027.

On 9 March 2023, the parent privately placed additional notes with the same terms and conditions as the bonds, for an amount of €15 million.

The pre-existing bonds and super senior revolving facility were fully redeemed and repaid.

The bonds have coupons based on the 3-month Euribor plus a 5.75% spread, with a Euribor floor threshold of 0.00%. They are listed on the Euro MTF market of the Luxembourg Stock Exchange.

The completion of the refinancing also saw a significant capital injection of €46,295 thousand by the parent’s shareholder.

The management, after having carefully assessed, and positively considered, the effects of the actions in progress have the reasonable expectation that the Company may continue to operate in the foreseeable future, consequently the management have prepared the financial statements as at 31 December 2022 on a going concern basis.

Non-current financial liabilities include loans and borrowings from other financial backers (€185 thousand) related to the amount due in 2024 for the acquisition of a business unit from the group’s Sicilian distributor.

 

41


On 25 September 2017, the parent entered into an agreement with the agency MT Ortho to acquire its business unit comprising the components organised for the marketing, sale and after-sales assistance of Lima medical devices in Sicily and Calabria. Specifically, the business unit included:

 

   

ongoing supply contracts with the healthcare facilities;

 

   

supply contracts under negotiation;

 

   

goodwill.

The consideration of €3.7 million was to be paid as follows:

 

   

€740 thousand when the contract was signed;

 

   

€2,960 thousand in six annual instalments (from 2018 to 2023), the payment of which depends on whether a certain level of sales is maintained in the region until the payment is complete.

The agreement was renegotiated in late 2020, accelerating the payment of the remaining 2021 instalments of €1,645 thousand against a €20 thousand decrease in the liability and the renegotiation of the commissions in the area.

Loans and borrowings from other financial backers also include amounts yet to be paid in relation to the acquisition of TechMah Medical LLC (contingent consideration). The difference on the previous year end is taken to profit or loss under financial income.

The caption also includes the non-current portion of the medium/long-term loans taken out by the parent for the SICAT and IAREPAM projects and by some branches in relation to the relief available for the Covid-19 pandemic, detailed as follows:

 

Description

   Company      Original
amount
    

Rate

   Expiry
date
     Residual
amount at
01/01/2021
     Guarantee  

SICAT sustainable growth fund 1st progress report

     Limacorporate S.p.A.        274      Fixed      30/06/2026        190        None  

SICAT sustainable growth fund 2nd progress report

     Limacorporate S.p.A.        339      Fixed      30/06/2026        251        None  

Covid-19 subsidised loan

     Lima France        500      Fixed      31/05/2024        500       
Government
guarantee
 
 

Covid-19 subsidised loan

     Lima Austria        200     

0% until August 2022,

then a floating loan

     31/12/2024        200        None  

Covid-19 subsidised loan

     Lima Switzerland        407      Fixed      31/03/2025        407        None  
     

 

 

          

 

 

    

Total

        1,720              1,548     
     

 

 

          

 

 

    

Description

   Company      Original
amount
    

Rate

   Expiry
date
     Residual
amount at
31/12/2021
     Guarantee  

SICAT sustainable growth fund 1st progress report

     Limacorporate S.p.A.        274      Fixed      30/06/2026        156        None  

SICAT sustainable growth fund 2nd progress report

     Limacorporate S.p.A.        339      Fixed      30/06/2026        206        None  

Covid-19 subsidised loan

     Lima France        500      Fixed      31/05/2024        512       
Government
guarantee
 
 

Covid-19 subsidised loan

     Lima Austria        200     

0% until August 2022,

then a floating loan

     31/12/2024        150        None  
     

 

 

          

 

 

    

Total

        1,313              1,024     
     

 

 

          

 

 

    

 

Company

  

Description

   Original
amount
    

Rate

   Expiry date      Residual
amount at
31/12/2022
    

Guarantee

Limacorporate S.p.A.

   SICAT sustainable growth fund 1st progress report      274      Fixed      30/06/2026        122      None

Limacorporate S.p.A.

   SICAT sustainable growth fund 2nd progress report      339      Fixed      30/06/2026        161      None

Limacorporate S.p.A.

   Sustainable growth fund “Project IAREPAM – Artificial Intelligence for the Efficient Development of an Implant in Additive Manufacturing” 1st progress report      6      Fixed      30/06/2031        6      None

Lima France

   Covid-19 subsidised loan      500      Fixed      31/05/2024        363     

Government

guarantee

Lima Austria

   Covid-19 subsidised loan      200     

0% until

August 2022, then

a floating loan

     31/12/2024        100      None
     

 

 

          

 

 

    

Total

        1,319              751     
     

 

 

          

 

 

    

Accrued financial expense and accrued expenses on bonds due within one year include interest accrued at each reporting date and not yet paid.

Finally, financial liabilities include lease liabilities deriving from the application of IFRS 16. The discount rate applied in 2022 was revised and modified to take into consideration the higher interest rates compared to previous years.

Changes in lease liabilities from 1 January 2021 to 31 December 2022 are set out below:

 

42


     01/01/2021      Increases      Decreases      Reclassifications      31/12/2021  

Lease liabilities as per IFRS 16 - non-current portion

     6,573        1,369        0        -3,518        4,423  

Lease liabilities as per IFRS 16 - current portion

     3,384        0        -3,384        3,518        3,518  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

TOTAL

     9,957        1,369        -3,384        0        7,941  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

     01/01/2022      Exchange
difference
     Increases      Decreases      Other changes      Reclassifications      31/12/2022  

Lease liabilities as per IFRS 16 - non-current portion

     4,423        83        3,663        0        655        -4,273        4,552  

Lease liabilities as per IFRS 16 - current portion

     3,518        -7        40        -4,559        0        4,273        3,265  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

TOTAL

     7,941        76        3,703        -4,559        655        0        7,817  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Lease liabilities are detailed by due dates as follows:

 

     31/12/2022      31/12/2021      01/01/2021  

Current liabilities - due within one year

     3,265        3,518        3,384  

Non-current liabilities - due from one to five years

     3,997        4,328        6,022  

Non-current liabilities - due after five years

     555        95        551  
  

 

 

    

 

 

    

 

 

 

Total

     7,817        7,941        9,957  
  

 

 

    

 

 

    

 

 

 

[3.16] Other non-current liabilities

Other non-current liabilities, amounting to €649 thousand (31 December 2021: €5,250 thousand), include incentive plans for some managers (€427 thousand) and the non-current portion of deferred income (€221 thousand), chiefly related to insurance costs.

The decrease on the previous year end is chiefly due to the pay-out of amounts to an outgoing manager and the fair value adjustment of the incentive plans.

Reference should be made to note [4.8] incentive plans under section [4] Other information for further information about such plans.

[3.17] Trade payables

Trade payables amount to €36,564 thousand at 31 December 2022 (31 December 2021: €32,343 thousand) and refer to short-term obligations to suppliers of goods and services. They refer to positions payable in the short term and there are no amounts due after one year.

There are no differences between the carrying amount and fair value of such payables.

Trade payables at 31 December 2022 are broken down by geographical segment in the following table:

 

     Total Italy      Total EU      Rest of
world
     Total  

Trade payables

     19,196        8,941        8,077        36,214  

Commercial paper

     —         —         —         —   

Payable to subsidiaries

     —         —         —         —   

Payable to associates

     —         —         —         —   

Payables to parents

     —         350        —         350  

Payables to subsidiaries of parents

     —         —         —         —   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     19,196        9,291        8,077        36,564  
  

 

 

    

 

 

    

 

 

    

 

 

 

 

43


Trade payables at 31 December 2021 are broken down by geographical segment in the following table:

 

     Total Italy      Total EU      Rest of
world
     Total  

Trade payables

     18,297        7,366        6,330        31,993  

Commercial paper

           —         —   

Payable to subsidiaries

     —         —         —         —   

Payable to associates

     —         —         —         —   

Payables to parents

     —         350        —         350  

Payables to subsidiaries of parents

     —         —         —         —   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     18,297        7,716        6,330        32,343  
  

 

 

    

 

 

    

 

 

    

 

 

 

Trade payables at 01 January 2021 are broken down by geographical segment in the following table:

 

     Total Italy      Total EU      Rest of
world
     Total  

Trade payables

     16,316        6,208        5,491        28,016  

Payable to subsidiaries

     —         —         400        400  

Debiti verso Imprese Collegate

     —         —         —         —   

Payables to parents

     —         525        —         525  

Payables to subsidiaries of parents

     —         —         —         —   
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     16,316        6,733        5,891        28,941  
  

 

 

    

 

 

    

 

 

    

 

 

 

Trade payables do not accrue interest. The terms and conditions for related parties do not differ from those applied for third party suppliers. Trade payables in foreign currencies are analysed in section [4.2] Financial risk management Fair value and risk management to which reference should be made.

[3.18] Tax liabilities

Tax liabilities amount to €877 thousand at 31 December 2022 (31 December 2021: €202 thousand). Specifically, the caption is fully comprised of current taxes payable by foreign branches.

[3.19] Other current liabilities

Other current liabilities are broken down in the following table. The main liabilities refer to payments on account, tax liabilities, social security charges payable, amounts due to employees and sundry liabilities mainly related to the payback system.

 

44


     31/12/2022      31/12/2021      01/01/2021      Variation
2022 vs 2021
     Variation
2021 vs 2020
 

Wages and salaries

     1,848        2,347        3,386        -499        -1,039  

Employee and performance bonus

     8,911        6,064        6,197        2,847        -133  

Directors’ fees

     302        82        369        220        -287  

Statutory auditors’ fees

     34        35        18        -1        17  

Liabilities for the purchase of business units

     194        194        194        0        0  

Payables to factors for collections received

     7        2        5        5        -3  

Foreign commissions

     4        0        0        4        0  

Sundry other liabilities

     1,034        1,382        1,396        -348        -14  

Payments on account

     4,380        4,273        4,378        107        -105  

IRPEF withholdings

     1,241        978        812        263        166  

Other tax liabilities

     1,852        632        826        1,220        -194  

VAT

     1,280        1,384        1,344        -104        40  

INPS - Inpdai - Previndai

     2,390        1,616        2,048        774        -432  

INAIL

     19        18        3        1        15  

Cometa Fund, other pension funds

     292        255        226        37        29  

Enasarco for agents

     181        152        142        29        10  

Other social security charges payable

     612        425        442        187        -17  

Accrued expenses:

     0        0        0        0        0  

Insurance premiums

     5        9        10        -4        -1  

Interest on non-current loans

     0        9        0        -9        9  

Other

     80        152        189        -72        -37  

Deferred income:

     0        0        0        0        0  

Grants related to assets

     72        26        42        46        -16  

Rent

     1        0        0        1        0  

Other

     3        6        19        -3        -13  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     24,742        20,041        22,047        4,701        -2,006  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Payments on account amount to €4,380 thousand and include the following:

 

   

PON SIB grant advance of €3,773 thousand, unchanged on the previous year end;

 

   

MC BEES grant advance of €249 thousand, up €33 thousand on the previous year end;

 

   

IAREPAM grant advance of €11 thousand (nil balance at the previous year end);

 

   

advances received from customers of €340 thousand;

 

   

other payments on account of €7 thousand.

Liabilities for the purchase of business units of €194 thousand (unchanged from the previous year) refers to the acquisition of the Lima Brazil business unit. This liability dates back to 2011 when the Brazilian business unit was set up.

Other tax liabilities include taxes, fines and interest which arose from the parent signing a mutually-agreed assessment settlement procedure with the tax authorities (Friuli-Venezia Giulia regional tax authorities).

On 4 December 2019, the company was notified of a preliminary assessment report by tax authorities.

On 3 February 2020, the company replied to such preliminary assessment report, asking the tax authorities to recognize the lack of grounds of some of the allegations set out in the report and, accordingly, not to issue the assessment notices, reserving its right to present further pleadings and start negotiations with the tax authorities.

No issue of the assessment notices has been notified. In this context the risk was difficult to quantify and of an indeterminate amount, in light of the deductions made by the company and the failure to establish a cross-examination on the matter with the Tax Authority.

 

45


The company’s management believed that if taken the claim to court, then it is probable that it will be able to defend its position, however, at the end of 2022 management changed the strategy and intended to take in consideration to settle the claim (although not in agreement on the legitimacy and grounds of the add-backs proposed by the tax authorities), in order to avoid a lengthy dispute and based on its assessments on the cost-effectiveness of the legal procedure.

On 11 January 2023 the tax authorities notified to the company an Invitation (pursuant to article 5-ter of Legislative decree no. 218 of 19 June 1997), the invitation is a communication to appear in order to try to reach an agreement. the Invitation has been issued with year protocol 2022 and notified in early January to the company.

In march 2023 the company decided to accept the amount of the settlement proposed by the tax authorities.

The amount due is of about €1,477 at 31 December 2022 and is included in the caption “Other current liabilities”.

[3.20] Revenue and other revenue and income

Revenue amounts to €245,669 thousand, compared to €210,543 thousand in 2021, a year-on-year increase of 16.7%.

Revenue derives from sales and distribution contracts with group customers essentially related to the sale of orthopaedic implants, mostly for shoulders, hips and knees.

In accordance with IFRS 15, revenues are stated net of discounts and allowances and are constrained in order to only represent the ones that are highly probable to be collected. The constraints related to variable consideration refer to payback, amounting to € 2.9 million at 31 December 2022 (€ 2.3 million at 31 December 2021), established in connection with the activation of the Italian government payback provision as a retroactive rebate (i.e. variable consideration). Such variable considerations were estimated based on the publicly available information. The Italian payback law is a mechanism to obtain from suppliers a contribution to offset variances occurring when Italian government expenditures exceed their ceiling for the purchase of medical devices.

It is broken down by geographical segment as follows:

 

(€‘000)

                    
     31/12/2022      31/12/2021      Variation  

Italy

     45,227        39,950        5,277  

Rest of Europe

     97,948        79,011        18,937  

APAC

     37,652        38,357        (705

United States

     43,111        35,283        7,828  

Rest of world

     21,731        17,942        3,789  
  

 

 

    

 

 

    

 

 

 

Total

     245,669        210,543        35,126  
  

 

 

    

 

 

    

 

 

 

Under Italian healthcare regulations, each region is allocated an annual budget for purchasing medical devices. Upon exceeding the assigned budget, the region can ask suppliers of medical devices to reimburse a portion of the excess amount in proportion to the annual market share of each supplier in the region involved (the payback system). Specifically, pursuant to Decree law no. 115 of 9 August 2022 (converted into Law no. 142/2022), the Ministry for Health, with Ministerial decree published on 15 September 2022 (“Decree 216/2022”), set the amounts exceeding the regional budgets for each year from 2015 to 2018 and, with Ministerial decree published on 6 October 2022 (“Decree 251/2022”), set out guidelines for the Italian regions to follow in requesting reimbursements under the payback system.

Under the payback system, each region issues payment orders to suppliers of medical devices. At the date of these consolidated financial statements as at 31 December 2022, Limacorporate S.p.A. and Lima SM in liquidation received payment orders for reimbursements under the payback system for amounts totalling €8.8 million for 2015, 2016, 2017 and 2018 which were recognised under provisions for risks and charges.

Should a supplier not pay the requested amounts within 30 days, Decree 216/2022 provides that such amounts be offset against any amounts due to such suppliers from each region and/or body partnered with regional healthcare authorities. In addition, under Decree law no. 4 of 11 January 2023, the due date for the payment of such amounts was deferred to 30 April 2023. Decree law no. 34 of 31 March 2023 as modified by Law Decree n 98 of 28 July 2023, then further deferred the payment to 30 October 2023.

 

46


In line with the approach adopted by other suppliers of medical devices, Limacorporate contested Decree 216/2022 and Decree 251/2022 before the Lazio regional administrative court, contesting, inter alia, whether the decrees comply with the constitution. The parent also contested the individual deeds through which the regions involved individually settled and requested the amounts deemed due to it.

Furthermore, as it cannot be excluded that the Italian Ministry for Health may deem that the regional budgets for each year from 2019 to 2022 have been exceeded and, thus, that the Italian regions may issue further payment orders for each of those years, the group has calculated its best estimate of amounts probably due, based on:

 

   

publicly available data on spending by the regions over the relevant budgets

 

   

Limacorporate’s turnover in the various regions;

 

   

Limacorporate’s market share in the various regions.

Other revenue and income are broken down as follows:

 

     2022      2021      Variation  

Service recharges

     2,805        2,048        758  

Lease income

     449        441        8  

Recharges to subsidiaries/associates

     24        1        24  

Gains

     863        675        189  

Release of the provision for risks

     106        0        106  

Other income

     535        489        46  

Grants related to income

     615        475        139  

Grants related to assets

     84        77        7  

Other revenue - previous years

     283        -249        532  

Other revenue

     33        16        17  
  

 

 

    

 

 

    

 

 

 

TOTAL

     5,798        3,973        1,825  
  

 

 

    

 

 

    

 

 

 

The increase in revenue from recharges for services is linked to the rise in turnover and sales.

[3.21] Raw materials, consumables, supplies and goods

This caption amounts to €56,391 thousand, compared to €53,530 thousand in 2021. It is broken down as follows:

 

     2022      2021      Variation  

Purchase of raw materials

     9,350        9,038        312  

Purchase of semi-finished products

     21,353        21,567        -214  

Purchase of finished goods

     10,218        6,136        4,082  

Individual tool components

     13,501        15,135        -1,634  

Opening balance of raw materials, consumables, supplies and goods

     6,094        6,106        -12  

Closing balance of raw materials, consumables, supplies and goods

     -6,272        -6,094        -178  

Other purchases

     2,146        1,642        504  
  

 

 

    

 

 

    

 

 

 

TOTAL

     56,391        53,530        2,860  
  

 

 

    

 

 

    

 

 

 

[3.22] Services

Services amount to €81,645 thousand, up 16.8% on the €69,910 thousand of 2021.

The caption is broken down as follows:

 

47


(€‘000)

                    
     2022      2021      Variation  

Outsourced processing and analyses

     3,310        4,347        -1,037  

Transport costs for sales

     5,551        4,750        801  

Transport costs for purchases

     790        631        159  

Energy, power supply

     3,622        1,194        2,428  

Administrative services

     1,891        1,693        198  

Maintenance and repair

     2,226        1,825        400  

Maintenance of HW/SW/office machines

     2,700        2,071        629  

Technical and commercial consultancy

     5,895        5,535        360  

Non-recurring consultancy

     635        5,386        -4,751  

Conferences and trade fairs

     2,354        1,026        1,328  

Workshops

     2,812        1,414        1,399  

Enasarco (agent social security charges)

     28,074        23,670        4,405  

Travel costs

     4,561        2,670        1,892  

Insurance costs

     3,524        3,078        446  

Directors’ fees

     2,784        799        1,986  

Royalties

     1,360        936        424  

Other

     9,555        8,886        669  
  

 

 

    

 

 

    

 

 

 

Total

     81,645        69,910        11,735  
  

 

 

    

 

 

    

 

 

 

The increase in this caption is chiefly due to fees directly related to the growth in turnover and higher energy costs tied to the rise in utilities costs.

Directors’ fees for 2022 include €941 thousand for management incentive plans (2021: €466 thousand). Reference should be made to section [4.8] Incentive plans for a description of such plans. The increase in directors’ fees is attributable to the costs incurred due to the CEO stepping down.

[3.23] Change in work in progress, semi-finished products and finished goods

This caption shows a negative balance of €887 thousand for 2022 (2021: positive balance of €2,058 thousand).

[3.24] Personnel expenses

Personnel expenses amount to €76,858 thousand, compared to €60,773 thousand in 2021, and are broken down as follows:

 

     2022      2021      Variation  

Wages and salaries

     63,080        48,151        14,928  

Social security contributions

     11,980        10,485        1,495  

Post-employment benefits

     1,716        1,726        -10  

Other costs

     82        411        -329  
  

 

 

    

 

 

    

 

 

 

TOTAL

     76,858        60,773        16,414  
  

 

 

    

 

 

    

 

 

 

Reference should be made to note [3.14] Employee benefits for details on the workforce.

Personnel expenses for 2022 include €3,928 thousand for management incentive plans. Reference should be made to section [4.8] Incentive plans for a description of such plans and the related costs.

 

48


[3.25] Amortisation, depreciation and impairment losses

Amortisation, depreciation and impairment losses amount to €35,408 thousand in 2022, compared to €32,517 thousand in 2021, and include depreciation of right-of-use assets of €5,335 thousand (2021: €4,595 thousand). Reference should be made to note [3.3] Property, plant and equipment for details on the individual categories.

The caption is broken down as follows:

 

     2022      2021      Variation  

Amortisation of intangible assets

     8,657        7,394        1,263  

Depreciation of property, plant and equipment

     21,416        20,528        888  

Depreciation of right-of-use assets

     5,335        4,595        740  
  

 

 

    

 

 

    

 

 

 

TOTAL

     35,408        32,517        2,891  
  

 

 

    

 

 

    

 

 

 

Other impairment losses of €16,152 thousand (2021: €209 thousand) refer to impairment losses on intangible assets and property, plant and equipment for which the related costs are not expected to be recovered as of the date of preparation of these consolidated financial statements as at 31 December 2022. The caption also includes the impairment loss on the goodwill generated by the acquisition of the subsidiary TechMah. Reference should be made to note [3.2] Goodwill for details.

The impairment losses on trade receivables of €502 thousand (2021: €429 thousand) include the net impairment losses on trade receivables recognised pursuant to IFRS 9.

[3.26] Other operating costs

Other operating costs amount to €1,857 thousand in 2022, compared to €1,509 thousand in 2021, and are broken down as follows:

 

(€‘000)

                    
     31/12/2022      31/12/2021      Variation  

Taxes and duties

     1,053        904        149  

Other costs

     18        16        2  

Losses on assets

     52        94        -42  

Gifts and donations

     670        490        180  

Sundry costs - previous years

     234        125        109  

Tax expense - previous years

     0        -51        51  

Provision for risks

     -170        -69        -101  
  

 

 

    

 

 

    

 

 

 

Total

     1,857        1,509        348  
  

 

 

    

 

 

    

 

 

 

[3.27] Internal work capitalised

This caption amounts to €13,532 thousand for 2022 and €16,250 thousand for 2021. It may be broken down as follows:

 

     2022      2021      Variation  

Increases in property, plant and equipment for capitalisation of equipment

     10,291        11,856        -1,565  

Increases in intangible assets for capitalisation of sundry costs

     759        1,826        -1,068  

Increases in property, plant and equipment for internal work

     2,483        2,568        -85  
  

 

 

    

 

 

    

 

 

 

TOTAL

     13,532        16,250        -2,717  
  

 

 

    

 

 

    

 

 

 

Increases in property, plant and equipment for the capitalisation of surgical instruments and internal work both refer to the capitalisation of surgical instruments built internally. These surgical instruments are provided to hospitals on a free loan basis to be used to implant the group’s products.

Increases in non-current assets for capitalisation of costs (€759 thousand) refer to the capitalisation of internal and external costs incurred for product development projects.

 

49


[3.28] Financial income and expense

Net financial expense amounts to €8,048 thousand in 2022, compared to €12,956 thousand in 2021, and is broken down as follows:

 

(€‘000)

                    
     2022      2021      Variation  

Exchange gains

     -7,416        -6,986        -430  

Other interest income

     -163        -154        -9  

Fair value gain on liabilities

     -6,981        -688        -6,293  

Financial income

     -14,561        -7,829        -6,732  

Exchange losses

     6,478        5,645        833  

Interest on bonds

     11,320        10,484        835  

Other interest and financial expenses

     4,811        4,069        742  

Fair value losses on liabilities

     0        586        -586  

Financial expense

     22,609        20,785        1,824  
  

 

 

    

 

 

    

 

 

 

Total

     8,048        12,956        -4,908  
  

 

 

    

 

 

    

 

 

 

The €6,732 thousand increase in financial income during the year is chiefly due to fair value gains on the liability for the acquisition of TechMah.

The higher interest rates on bonds and the revolving credit facility in the second half of the year following the rise in the Euribor led to an increase in net borrowing costs.

[3.29] Income taxes

Income taxes amount to €6,526 thousand compared to €3,529 thousand in 2021. The caption is broken down as follows:

 

€‘000

             
     31/12/2022      31/12/2021  

Pre-tax income (loss)

     -12.748        991  

Income taxes calculated using the the theorical IRES rate (24%)

     3.059        -238  

IRAP

     -252        -809  

Effect of different taxation of foreign companies

     -1.924        -673  

Other taxes differences

     6.885        5.249  

Tax settlement

     -1.477        0  

DTA on fiscal losses

     235        0  
  

 

 

    

 

 

 

Income tax benefit (expense)

     -6.525        -3.529  
  

 

 

    

 

 

 

Taxes relative to previous years refer to taxes for 2016 defined with the mutually-agreed assessment settlement procedure (tax settlement). Reference should be made to section [3.19] Other current liabilities for more information.

The main temporary differences that led to the recognition of deferred tax assets and liabilities are set out in the following table along with relevant effects:

 

50


     31/12/2022      31/12/2021  

Description

   Temporary
differences
     Tax effect      Temporary
differences
     Tax effect  

Change in deferred tax assets:

           

Provision for risks and charges

     14,682        -3,751        13,147        -3,207  

Allowance for inventory write-down

     6,178        -1,483        5,972        -1,443  

Amortisation of trademarks

     149        -42        128        -36  

Amortisation of goodwill

     670        -69        1,386        -387  

Unpaid directors’ fees

     262        -63        40        -10  

Agents’ termination indemnity

     97        -27        268        -75  

Exchange losses

     11,309        -2,713        10,007        -2,402  

Impairment losses on equity investments

     0        0        565        -136  

Impairment losses on intangible assets

     152        -37        222        -57  

ACE deduction

     8,966        -2,152        6,254        -1,501  

Non-deductible interest as per article 96 of the Consolidated income tax act

     0        0        3,103        -745  

Fiscal losses

     979        -235        0        0  

Difference between carrying amount and tax base

     953        -229        640        -154  

IFRS 16

     99        -72        302        -87  

Incentive plans

     0        0        4,217        -1,012  

Post-employment benefits

     37        -19        76        -18  

Other variations

     532        -128        136        -34  

Deferred tax assets - subsidiaries (Lima AU, Lima ES, Lima BR, Lima NZ, Lima DK, Lima PL)

     0        -538        0        -642  

Deferred tax assets on consolidation adjustments

     0        -20,151        0        -21,516  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total change in deferred tax assets

     45,068        -31,709        46,463        -33,462  
  

 

 

    

 

 

    

 

 

    

 

 

 

Change in deferred tax liabilities

           

Taxed grants

     3,692        886        3,754        901  

Exchange gains

     7,874        1,890        7,976        1,914  

Other variations

     641        154        456        117  

Deferred tax liabilities - subsidiaries (Lima AU, Lima ES, Lima CZ, Lima JP, Lima NZ, Lima PL, Lima UK e Lima USA)

     0        6,484        0        5,000  

Deferred tax assets on consolidation adjustments

     0        9,861        0        9,364  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total change in deferred tax liabilities

     12,207        19,275        12,186        17,296  
  

 

 

    

 

 

    

 

 

    

 

 

 

Net change in deferred tax (assets) liabilities

     32,861        -12,434        34,277        -16,166  
  

 

 

    

 

 

    

 

 

    

 

 

 

The deferred tax assets and liabilities includes the taxes calculated on the temporary differences arising between the book value of assets and liabilities and the corresponding tax values (especially for taxed funds and non-deductible interest). Considering 3 years history, 2020,2021, 2022 the fiscal year 2022 was the first year of fiscal losses of the Group. The tax rate for the fiscal year 2022 is mainly impacted by the full impairment of the Goodwill related to TechMah CGU as described in paragraph [3.2].

Other information

[4.1] Transition to IFRS issued by IASB

The accounting policies set out in the relevant section of these notes have been applied to prepare the consolidated financial statements at 31 December 2021 and 31 December 2022 and to prepare the opening IFRS financial statements at 1 January 2021 (transition date).

In preparing the opening IFRS financial statements according to IFRS issued by IASB, the company corrected errors previously presented in the financial statements drawn up in accordance with the IFRS endorsed by European Union.

 

51


As per the IAS.8, par. 49, the table below shows the errors and the amount of the correction in the column’s errors. The error refers to the payback accounted for as variable consideration under IFRS15 instead of IAS37. The correction of error has been accounted for retrospectively at 1 January 2021.

In order to illustrate the effects of the transition on the IFRS-restated consolidated financial statements as at 31 December 2022, the reconciliations required by IFRS 1.24 are provided herein. This information covers the impact of the transition, in 2021, on the financial position and financial performance while no reconciliation schedule of the statement of cash flows for 2021 is presented because the effects of applying IFRS issued by IASB were not significant.

The effect of the error of the opening balances of assets and liabilities to the IFRS issued by IASB was reflected in the opening equity at the transition date (1 January 2021) in retained earnings (accumulated deficit), net of the tax effect.

Reconciliations of the statement of financial position and the statement of profit or loss

 

(€‘000)

                                          

ASSETS

   Note     01/01/2021 EU     Errors     01/01/2021 IASB     31/12/2021 EU     Errors     31/12/2021 IASB  

Non-current assets

              

Other intangible assets

     [3.1     44,477         44,477       53,595         53,595  

Goodwill

     [3.2     396,900         396,900       398,305         398,305  

Property, plant and equipment

     [3.3     85,288         85,288       81,773         81,773  

Equity investments

     [3.4     402         402       2         2  

Deferred tax assets

     [3.5     29,702       2,193       31,895       30,728       2,734       33,462  

Other non-current assets

     [3.6     663         663       705         705  
    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total non-current assets

       557,432       2,193       559,625       565,109       2,734       567,842  
    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Current assets

              

Inventories

     [3.7     84,166         84,166       87,421         87,421  

Trade receivables

     [3.8     63,070         63,070       66,891         66,891  

Current tax assets

     [3.9     4,361         4,361       2,554         2,554  

Other current assets

     [3.10     11,469         11,469       11,247         11,247  

Cash and cash equivalents

     [3.11     26,273         26,273       21,503         21,503  
    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total current assets

       189,340       —        189,340       189,617       —        189,617  
    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

TOTAL ASSETS

       746,772       2,193       748,965       754,726       2,734       757,460  
    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

EQUITY AND LIABILITIES

              

Equity

              

Share capital

     [3.12     9,868         9,868       9,868         9,868  

Share premium reserve

     [3.12     14,425         14,425       14,425         14,425  

Other reserves

     [3.12     310,762         310,762       317,570         317,570  

Retained earnings (accumulated deficit)

     [3.12     565       (6,945     (6,380     (11,917     (6,945     (18,862

Profit (loss) for the year

     [3.12     (12,482       (12,482     (825     (1,713     (2,538
    

 

 

     

 

 

   

 

 

   

 

 

   

 

 

 

Total equity attributable to the owners of the parent

       323,139       (6,945     316,194       329,121       (8,658     320,463  
    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total equity

       323,139       (6,945     316,194       329,121       (8,658     320,463  
    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Non-current liabilities

              

Non-current financial liabilities

     [3.15     287,222         287,222       283,573         283,573  

Employee benefits

     [3.14     1,421         1,421       1,442         1,442  

Deferred tax liabilities

     [3.5     12,986         12,986       17,296         17,296  

Provisions for risks and charges

     [3.13     3,894       9,138       13,032       3,922       11,392       15,314  

Other non-current liabilities

     [3.16     5,476         5,476       5,250         5,250  
    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total non-current liabilities

       310,999       9,138       320,137       311,483       11,392       322,875  
    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Current liabilities

              

Current financial liabilities

     [3.15     59,511         59,511       61,536         61,536  

Trade payables

     [3.17     28,941         28,941       32,343         32,343  

Current tax liabilities

     [3.18     491         491       202         202  

Other current liabilities

     [3.19     23,692         23,692       20,041         20,041  
    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total current liabilities

       112,635       —        112,635       114,122       —        114,122  
    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

TOTAL EQUITY AND LIABILITIES

       746,772       2,193       748,965       754,726       2,734       757,460  
    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

52


(€‘000)

                           
     Note      2021 EU      Errors      2021 IASB  

Revenue

     [3.20      212,798        (2,254      210,543  

Other revenues and income

     [3.20      3,973           3,973  
     

 

 

    

 

 

    

 

 

 

Total revenue and income

        216,771        (2,254      214,517  
     

 

 

    

 

 

    

 

 

 

Raw materials, consumables, supplies and goods

     [3.21      (53,530         (53,530

Services

     [3.22      (69,910         (69,910

Change in w.i.p., semi-finished products and finished goods

     [3.23      2,058           2,058  

Personnel expenses

     [3.24      (60,773         (60,773

Amortisation and Depreciation

     [3.25      (32,517         (32,517

Impairment losses on trade receivables

     [3.25      (429         (429

Impairment losses on fixed assets

     [3.25      (209         (209

Other operating costs

     [3.26      (1,509         (1,509

Internal work capitalised

     [3.27      16,250           16,250  
     

 

 

    

 

 

    

 

 

 

Operating costs

        (200,570      —         (200,570
     

 

 

    

 

 

    

 

 

 

Operating profit

        16,201        (2,254      13,947  
     

 

 

    

 

 

    

 

 

 

Financial income

     [3.28      7,829           7,829  

Financial expense

     [3.28      (20,785         (20,785
     

 

 

    

 

 

    

 

 

 

Net financial expense

        (12,956      —         (12,956
     

 

 

    

 

 

    

 

 

 

Pre-tax income (loss)

        3,245        (2,254      991  
     

 

 

    

 

 

    

 

 

 

Income tax benefit (expense)

     [3.29      (4,070      541        (3,529
     

 

 

    

 

 

    

 

 

 

Profit (loss) for the year

        (825      (1,713      (2,539
     

 

 

    

 

 

    

 

 

 

of which attributable to the owners of the parent

        (825      (1,713      (2,539
     

 

 

    

 

 

    

 

 

 

 

(€‘000)

                           
     Note      2021 EU      Errors      2021 IASB  

Profit (loss) for the year

        (825      (1,713      (2,539
     

 

 

    

 

 

    

 

 

 

Other comprehensive income (expense)

           

Items that will never be reclassified to profit or loss (A)

           

Remeasurements of the net defined benefit liability (asset)

     [3.14      3        —         3  

Related tax

     [3.14      (1      —         (1
     

 

 

    

 

 

    

 

 

 
        2        —         2  
     

 

 

    

 

 

    

 

 

 

Items that are or may be reclassified to profit or loss (B)

           

Exchange differences on translation of foreign operations

     [3.12      1,842        —         1,842  
     

 

 

    

 

 

    

 

 

 
        1,842        —         1,842  
     

 

 

    

 

 

    

 

 

 

Other comprehensive income (expense), net of tax (A+B)

        1,844        —         1,844  
     

 

 

    

 

 

    

 

 

 

Comprehensive income (expense) for the year

        1,019        (1,713      (695
     

 

 

    

 

 

    

 

 

 

Comprehensive income (expense) attributable to:

        —         

Owners of the parent

        1,019        (1,713      (695
     

 

 

    

 

 

    

 

 

 

Notes to the corrected errors

In the consolidated financial statements as of 31 December 2022 prepared in accordance with IFRS issued by IASB, the Group corrected the payback treatment in compliance with IFRS 15 considering it as a variable consideration instead of applying IAS 37.

The effect originated by the restatement on the figures as at 31 December 2022 is a decrease of revenues for an amount equal to €2,925 thousand. The table reported below summarize the effects of the restatement on the financial statements as at 31 December 2022.

 

53


(€‘000)

                           

ASSETS

   Note      31/12/2022 EU      Errors      31/12/2022 IASB  

Non-current assets

           

Other intangible assets

     [3.1      58,234           58,234  

Goodwill

     [3.2      384,216           384,216  

Property, plant and equipment

     [3.3      79,837           79,837  

Equity investments

     [3.4      2           2  

Deferred tax assets

     [3.5      31,694        15        31,709  

Other non-current assets

     [3.6      861           861  
     

 

 

    

 

 

    

 

 

 

Total non-current assets

        554,844        15        554,859  
     

 

 

    

 

 

    

 

 

 

Current assets

           

Inventories

     [3.7      86,728           86,728  

Trade receivables

     [3.8      70,161           70,161  

Current tax assets

     [3.9      2,087           2,087  

Other current assets

     [3.10      14,192           14,192  

Cash and cash equivalents

     [3.11      25,920           25,920  
     

 

 

    

 

 

    

 

 

 

Total current assets

        199,088        —         199,088  
     

 

 

    

 

 

    

 

 

 

TOTAL ASSETS

        753,932        15        753,947  
     

 

 

    

 

 

    

 

 

 

EQUITY AND LIABILITIES

           

Equity

           

Share capital

     [3.12      9,868           9,868  

Share premium reserve

     [3.12      14,425           14,425  

Other reserves

     [3.12      323,510           323,510  

Retained earnings (accumulated deficit)

     [3.12      (13,308      (8,658      (21,966

Profit (loss) for the year

     [3.12      (27,885      8,612        (19,274
     

 

 

    

 

 

    

 

 

 

Total equity attributable to the owners of the parent

        306,610        (47      306,564  
     

 

 

    

 

 

    

 

 

 

Total equity

        306,610        (47      306,564  
     

 

 

    

 

 

    

 

 

 

Non-current liabilities

           

Non-current financial liabilities

     [3.15      10,165           10,165  

Employee benefits

     [3.14      1,296           1,296  

Deferred tax liabilities

     [3.5      19,275           19,275  

Provisions for risks and charges

     [3.13      8,296        8,860        17,156  

Other non-current liabilities

     [3.16      649           649  
     

 

 

    

 

 

    

 

 

 

Total non-current liabilities

        39,680        8,860        48,541  
     

 

 

    

 

 

    

 

 

 

Current liabilities

           

Current financial liabilities

     [3.15      336,659           336,659  

Trade payables

     [3.17      36,564           36,564  

Current tax liabilities

     [3.18      877           877  

Other current liabilities

     [3.19      33,542        (8,800      24,742  
     

 

 

    

 

 

    

 

 

 

Total current liabilities

        407,641        (8,800      398,842  
     

 

 

    

 

 

    

 

 

 

TOTAL EQUITY AND LIABILITIES

        753,932        14        753,946  
     

 

 

    

 

 

    

 

 

 

 

54


(€‘000)

                           
     Note      2022 EU      Errors      2022 IASB  

Revenue

     [3.20      248,594        (2,925      245,669  

Other revenues and income

     [3.20      5,798           5,798  
     

 

 

    

 

 

    

 

 

 

Total revenue and income

        254,392        (2,925      251,467  
     

 

 

    

 

 

    

 

 

 

Raw materials, consumables, supplies and goods

     [3.21      (56,391         (56,391

Services

     [3.22      (81,645         (81,645

Change in w.i.p., semi-finished products and finished goods

     [3.23      (887         (887

Personnel expenses

     [3.24      (76,858         (76,858

Amortisation and Depreciation

     [3.25      (35,408         (35,408

Impairment losses on trade receivables

     [3.25      (502         (502

Impairment losses on fixed assets

     [3.25      (16,152         (16,152

Other operating costs

     [3.26      (16,113      14,256        (1,857

Internal work capitalised

     [3.27      13,532           13,532  
     

 

 

    

 

 

    

 

 

 

Operating costs

        (270,424      14,256        (256,167
     

 

 

    

 

 

    

 

 

 

Operating profit

        (16,032      11,331        (4,700
     

 

 

    

 

 

    

 

 

 

Financial income

     [3.28      14,561           14,561  

Financial expense

     [3.28      (22,609         (22,609
     

 

 

    

 

 

    

 

 

 

Net financial expense

        (8,048      —         (8,048
     

 

 

    

 

 

    

 

 

 

Pre-tax income (loss)

        (24,080      11,331        (12,748
     

 

 

    

 

 

    

 

 

 

Income tax benefit (expense)

     [3.29      (3,806      (2,720      (6,526
     

 

 

    

 

 

    

 

 

 

Profit (loss) for the year

        (27,886      8,612        (19,274
     

 

 

    

 

 

    

 

 

 

of which attributable to the owners of the parent

        (27,886      8,612        (19,274
     

 

 

    

 

 

    

 

 

 

 

(€‘000)

                           
     Note      2022 EU      Errors      2022 IASB  

Profit (loss) for the year

        (27,886      8,612        (19,274
     

 

 

    

 

 

    

 

 

 

Other comprehensive income (expense)

           

Items that will never be reclassified to profit or loss (A)

           

Remeasurements of the net defined benefit liability (asset)

     [3.14      71        —         71  

Related tax

     [3.14      (17      —         (17
     

 

 

    

 

 

    

 

 

 
        54        —         54  
     

 

 

    

 

 

    

 

 

 

Items that are or may be reclassified to profit or loss (B)

           

Exchange differences on translation of foreign operations

     [3.12      871        —         871  
     

 

 

    

 

 

    

 

 

 
        871        —         871  
     

 

 

    

 

 

    

 

 

 

Other comprehensive income (expense), net of tax (A+B)

        925        —         925  
     

 

 

    

 

 

    

 

 

 

Comprehensive income (expense) for the year

        (26,961      8,612        (18,349
     

 

 

    

 

 

    

 

 

 

Comprehensive income (expense) attributable to:

        —         
     

 

 

    

 

 

    

 

 

 

Owners of the parent

        (26,961      8,612        (18,349
     

 

 

    

 

 

    

 

 

 

In the statutory consolidated financial statement as at 31 December 2022 the payback was incorrectly accounted for as operating cost in the profit and loss as of 31 December 2022.

[4.2] Operating segments

The disclosure about operating segments was prepared in accordance with IFRS 8 Operating segments which provides for the presentation of information in line with the measures adopted by the chief operating decision maker to make operating decisions.

At operating level, the group has a matrix organisational structure split by product line, distribution channel and geographical segment providing a coherent strategic vision of the business. This structure can be seen in the way management monitors and directs the group’s activities. Specifically, senior management reviews the group’s results as a whole as it does not have identifiable operating segments. Therefore, the group’s operations are presented as a single segment for IFRS 8 reporting purposes.

A breakdown of revenue earned in 2022 and 2021 by product line, distribution channel and geographical segment is shown below:

 

55


(€‘000)

             

Revenue by PRODUCT LINE

   31/12/2022      31/12/2021  

Hip

     88,142        78,307  

Extremities

     98,537        83,966  

Knee

     49,234        39,700  

Fixation&Other

     9,756        8,570  
  

 

 

    

 

 

 

Total sales revenue

     245,669        210,543  
  

 

 

    

 

 

 

 

(€‘000)

             

Revenue by DISTRIBUTION CHANNEL

   31/12/2022      31/12/2021  

Direct customers

     195,629        178,786  

Indirect channel

     50,040        31,757  
  

 

 

    

 

 

 

Total sales revenue

     245,669        210,543  
  

 

 

    

 

 

 

 

(€‘000)

             

Revenue by GEOGRAPHICAL SEGMENT

   31/12/2022      31/12/2021  

Italy

     45,227        39,960  

Resto of Europe

     97,948        79,001  

APAC

     37,652        38,357  

United States

     43,111        35,283  

Rest of world

     21,731        17,942  
  

 

 

    

 

 

 

Total sales revenue

     245,669        210,543  
  

 

 

    

 

 

 

As required by IFRS 8, it is noted that the group does not have individual customers that generate revenue of 10% or more of its total revenue in 2022 and 2021.

The following table shows non-current assets other than financial assets and deferred tax assets by geographical segment at 31 December 2022 and 2021, allocated in line with the country where they are held. Unallocated non-current assets entirely consist of goodwill.

 

€‘000

             
     31/12/2022      31/12/2021  

Italy

     444,336        442,737  

USA

     50,006        61,606  

Rest of Europe

     15,106        21,593  

APAC

     6,827        7,940  

Rest of world

     6,873        502  
  

 

 

    

 

 

 

Total non-current assets

     523,148        534,379  
  

 

 

    

 

 

 

[4.3] Financial instruments - Fair value and risk management

 

  A.

Accounting classification and fair value

The next table shows the carrying amount and fair value of each financial asset and liability, including their fair value hierarchy level. Information about the fair value of financial assets and liabilities not measured at fair value is not provided as their carrying amount reasonably approximates their fair value.

Trade receivables and other assets and trade payables and other liabilities classified as held for sale are not included in the table. Their carrying amount reasonably approximates their fair value.

 

56


(€‘000)

        Carrying Amount     Fair value  

31/12/2021

  Notes     Fair value –
Hedging
instruments
    Mandatorily
at FVTPL -
other
    FVOCI - debt
instruments
    FVOCI -
equity
instruments
    Financial Assets
measured at
amortised cost
    Other
liabilities
    Total     Level 1     Level 2     Level 3     Total  

Financial assets measured at fair value

                       
      —                  —        —        —        —        —   

Financial assets not measured at fair value

                       

Trade receivables and other assets

    [3.8] [3.10]               78,138         78,138         78,138         78,138  

Cash and cash equivalents

    [3.11]               21,503         21,503         21,503         21,503  
      —        —        —        —        99,642       —        99,642       —        99,641       —        99,641  

Financial liabilities measured at fair value

                       

Liabilities for acquisitions - MT Ortho

    [3.15]                 185       185           185       185  

Liabilities for acquisitions - Techmah

    [3.15]                 13,434       13,434           13,434       13,434  
      —        —        —        —        —        13,619       13,619       —        —        13,619       13,619  

Financial liabilities not measured at fair value

                       

Bank credit facilities

    [3.15]                 1,199       1,199         1,199         1,199  

Secured bank loans

    [3.15]                 47,000       47,000         47,000         47,000  

Undecured bank loans

    [3.15]                 1,024       1,024         1,024         1,024  

Secured bonds - listed bonds

    [3.15]                 272,556       272,556         272,556         272,556  

Lease liabilities - IFRS16

    [3.15]                 7,941       7,941         7,941         7,941  

Trade payables and other liabilities

    [3.18] [3.20]                 52,385       52,385         52,385         52,385  
      —        —        —        —        —        382,105       382,105         382,105         382,105  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

TOTALE

      —        —        —        —        99,642       395,723       495,365       —        481,746       13,619       495,365  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

(€‘000)

      Carrying Amount     Fair value  

31/12/2022

  Notes   Fair value –
Hedging
instruments
    Mandatorily
at FVTPL -

other
    FVOCI - debt
instruments
    FVOCI -
equity
instruments
    Financial Assets
measured at
amortised cost
    Other
liabilities
    Total     Level 1     Level 2     Level 3     Total  

Financial assets measured at fair value

                       
      —                  —        —        —        —        —   

Financial assets not measured at fair value

                       

Trade receivables and other assets

  [3.8] [3.10]             84,353         84,353         84,353         84,353  

Cash and cash equivalents

  [3.11]             25,920         25,920         25,920         25,920  
      —        —        —        —        110,273       —        110,273       —        110,273       —        110,273  

Financial liabilities measured at fair value

                       

Liabilities for acquisitions - MT Ortho

  [3.15]               185       185           185       185  

Liabilities for acquisitions - Techmah

  [3.15]               7,373       7,373           7,373       7,373  
      —        —        —        —        —        7,558       7,558       —        —        7,558       7,558  

Financial liabilities not measured at fair value

                       

Bank credit facilities

  [3.15]               383       383         383         383  

Secured bank loans

  [3.15]               54,000       54,000         54,000         54,000  

Undecured bank loans

  [3.15]               751       751         751         751  

Secured bonds - listed bonds

  [3.15]               274,039       274,039         264,982         264,982  

Lease liabilities - IFRS16

  [3.15]               7,817       7,817         7,817         7,817  

Trade payables and other liabilities

  [3.18] [3.20]               70,105       70,105         70,105         70,105  
      —        —        —        —        —        407,095       407,095         398,038         398,038  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

TOTALE

      —        —        —        —        110,273       414,653       524,926       —        508,311       7,558       515,869  
   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

  B.

Fair value measurement

i. Measurement techniques and significant unobservable inputs

The following tables present the measurement techniques and significant unobservable inputs used to determine the fair value of level 2 and 3 financial instruments in the statement of financial position.

 

57


Financial instruments measured at fair value

 

2021

              

Type

  

Measurement technique

  

Unobservable

significant inputs

  

Relationship between

unobservable sig. inputs

and fair value measurement

Liabilities for TechMah acquisition   

Discounted cash flows:

 

This measurement technique considers the present value of the estimated payments, discounted using a discount rate that reflects the risk.

 

These estimated cash flows are estimated by independent experts that define the net present value of the contract’s future cash outflows; these outflows are partly tied to the group’s business plan assuming the milestones will be achieved as agreed with TechMah’s former owners.

  

•  At 31 December 2021, these milestones have been estimated by independent experts as USD15.2 million.

 

•  At 31 December 2021, independent experts have expected future cash outflows of USD9.3 million if the milestones are reached.

 

•  Discount rate that reflects the risk (31 December 2021: 3.39%).

  

The estimated fair value would decrease if:

 

•  achievement of each milestone does not happen in accordance with the agreed timeline

 

•  the discount rate reflecting the risk is higher

 

2022

              

Type

  

Measurement technique

  

Unobservable

significant inputs

  

Relationship between

unobservable sig. inputs
and fair value measurement

Liabilities for TechMah acquisition   

Discounted cash flows:

 

This measurement technique considers the present value of the estimated payments, discounted using a discount rate that reflects the risk.

 

These estimated cash flows are estimated by independent experts that define the net present value of the contract’s future cash outflows; these outflows are partly tied to the group’s business plan assuming the milestones will be achieved as agreed with TechMah’s former owners.

  

•  At 31 December 2022, these milestones have been estimated by independent experts as USD7.4 million.

 

•  At 31 December 2022, independent experts have expected future cash outflows of USD5.6 million if the milestones are reached.

 

•  Discount rate that reflects the risk (31 December 2022: 7.32%).

  

The estimated fair value would decrease if:

 

•  achievement of each milestone does not happen in accordance with the agreed timeline

 

•  the discount rate reflecting the risk is higher

Financial instruments not measured at fair value

 

Type

  

Measurement technique

    

Secured bonds

Lease liabilities

Secured bank loans

Unsecured bank loans

  

Discounted cash flows:

 

This measurement technique considers the present value of estimated payments, discounted using a discount rate that reflects the risk.

  

 

58


Reconciliation of level 3

 

€‘000

      
     Liability  

Balance at 31 December 2020

     21,265  

Gain (losses)

  

- Net fair value loss (unrealised)

     -680  

- Foreign exchange gains/(losses)

     1,264  

Payments

     -8,415  

Balance at 31 December 2021

     13,434  

Gain (losses)

  

- Net fair value loss (unrealised)

     -6,981  

- Foreign exchange gains/(losses)

     921  

Payments

     0  

Balance at 31 December 2022

     7,374  

Sensitivity analysis

The reasonably possible changes at 31 December 2022 to one of the significant unobservable inputs would have the following effects on the fair value of the consideration:

 

€‘000

                              
     Decrease     31 December 2022     Increase  

Equity value

     -10     -5     0     5     10

Techma liability

     7,362       7,369       7,373       7,383       7,389  

 

  C.

Financial risk management

The group is exposed to the following risks deriving from its use of financial instruments:

 

   

credit risk;

 

   

liquidity risk;

 

   

market risk.

Risk management system

Overall responsibility for the design and oversight of the group’s risk management system lies with the parent’s board of directors, which is in charge of developing and monitoring the group’s risk management policies.

The group’s risk management policies are designed to identify and analyse any risks it is exposed to, establish appropriate limits and controls and monitor the risks and compliance with such limits. The committee regularly revisits the policies and related systems to align them with market developments and the group’s business. The group aims to create a disciplined and constructive control environment through training programmes, standards and management procedures so that its employees are familiar with their roles and responsibilities.

The board of directors ensures compliance with the risk polices and management procedures and checks that the risk management system is appropriate to deal with risks that could affect the group.

The group’s financial instruments comprise cash and cash equivalents, loans, trade receivables and payables, current and non-current assets and liabilities as well as derivatives.

In its normal business operations, the group is exposed to:

 

   

market risk, mainly currency and interest rate risks;

 

59


   

commercial or counterparty credit risks, related to the risk of default on commercial or financial obligations by various counterparties as part of normal business operations or lending, investment and hedging transactions;

 

   

liquidity risk, related to the availability of financial resources and access to the credit market and to the need to meet the group’s financial needs in the short term.

Financial risk management is carried out centrally and essentially ensures that there are enough financial resources to meet business development needs and that resources are suitably invested in profitable activities.

Market risk

Market risk can be broken down into the following components:

 

   

interest rate risk,

 

   

currency risk.

Interest rate risk

The group’s exposure to interest rate risk is chiefly related to cash and cash equivalents, bonds and bank loans and borrowings, especially the revolving credit facility that is managed centrally. At 31 December 2022, the group does not have any interest rate hedges. A 100bps increase in the interest rate applied would have led to an increase of roughly €3.2 million in financial expense.

Currency risk

As the group sells its products in various countries, it is exposed to currency risk. This risk mainly derives from sales in currencies other than the Euro, like the US dollar, British pound, Japanese yen and Australian dollar.

The group regularly assesses its exposure to market financial risks. It does not manage such risks by using derivatives.

Its exposure in relation to foreign currency assets and liabilities is detailed in the following table (countervalue of the respective currencies in Euro):

 

60


€‘000

 
     Currency    Amount in
currency
     Exchange rate      Countervalue in
Euro
 

Trade receivables

           
   AUD      2,493        2        1,588  
   BRL      16,391        6        2,907  
   CHF      479        1        487  
   CZK      32,315        24        1,340  
   DKK      1,219        7        164  
   GBP      2,570        1        2,898  
   HRK      7,526        8        999  
   JPY      527,636        141        3,751  
   KRW      3,980,038        1,344        2,961  
   NZD      971        2        578  
   PLN      14,923        5        3,188  
   SEK      2,914        11        262  
   TRY      3,483        20        174  
   USD      10,596        1        9,935  
   CAD      100        1        69  
   CNY      308        7        42  

Other assets

           
   USD      1,417        1        1,328  
   AUD      234        2        149  
   BRL      5,584        6        990  
   CHF      52        1        53  
   CNY      463        7        63  
   CZK      2,090        24        87  
   DKK      0        7        0  
   GBP      110        1        124  
   HRK      96        8        13  
   JPY      32,436        141        231  
   KRW      389,216        1,344        290  
   NZD      30        2        18  
   PLN      427        5        91  
   SEK      247        11        22  
   TRY      4,172        20        209  
   ZAR      1        18        0  
   CAD      133        1        92  

Cash and cash equivalents

           
   AUD      1,185        2        755  
   BRL      3,845        6        682  
   CHF      187        1        190  
   CZK      21,266        24        882  
   DKK      645        7        87  
   GBP      908        1        1,024  
   HRK      5,773        8        766  
   JPY      37,994        141        270  
   KRW      823,810        1,344        613  
   NZD      594        2        353  
   PLN      3,018        5        645  
   SEK      3,024        11        272  
   TRY      2,280        20        114  
   USD      5,360        1        5,025  
   ZAR      1,447        18        80  
   CAD      328        1        227  
   CNY      1,227        7        167  

 

61


€‘000

 
     Currency    Amount in
currency
     Exchange rate      Countervalue in
Euro
 

Trade payables

           
   AUD      206        2        131  
   CAD      85        1        59  
   CHF      457        1        465  
   CZK      911        24        38  
   DKK      1,428        7        192  
   GBP      606        1        683  
   JPY      77,918        141        554  
   KRW      62,011        1,344        46  
   NZD      252        2        150  
   PLN      2,520        5        538  
   SEK      2,289        11        206  
   TRY      1,133        20        57  
   USD      3,330        1        3,122  
   ZAR      77        18        4  
   HRK      68        8        9  
   BRL      28        6        5  
   CNY      62        7        8  

Financial liabilities

           
   AUD      498        2        318  
   CAD      1        1        0  
   CHF      359        1        364  
   CZK      6,357        24        264  
   GBP      212        1        240  
   JPY      56,134        141        399  
   KRW      159,876        1,344        119  
   NZD      163        2        97  
   TRY      0        20        0  
   USD      10,671        1        10,004  
   HRK      577        8        77  
   BRL      291        6        52  
   CNY      283        7        38  

Other liabilities

           
   AUD      1,049        2        668  
   CAD      3        1        2  
   CHF      804        1        817  
   CZK      4,928        24        204  
   DKK      238        7        32  
   GBP      882        1        995  
   JPY      154,243        141        1,097  
   KRW      110,305        1,344        82  
   NZD      211        2        125  
   SEK      1,111        11        100  
   TRY      4        20        0  
   USD      1,490        1        1,397  
   ZAR      66        18        4  
   HRK      261        8        35  
   BRL      617        6        110  

 

62


Sensitivity analysis of currency risk

The financial assets and liabilities in currencies other than the functional currency of each group company at 31 December 2022 and 2021 were identified to perform the sensitivity analysis of currency risk. The group also considered foreign currency intragroup assets and liabilities to assess the potential effects on the profit or loss for the year.

Two scenarios were considered with a 5% appreciation or depreciation in the nominal exchange rate between the currency in which the caption is expressed and the Euro.

The next table shows the results of the sensitivity analysis:

 

€‘000

 
     5% appreciation      5% depreciation  
     31 December      31 December  

Currency

   2022      2021      2022      2021  

USD

     1,961        2,232        (1,868      (2,126

JPY

     943        1,092        (898      (1,040

PLN

     613        537        (583      (512

KRW

     494        576        (470      (549

GBP

     447        415        (426      (395

BRL

     501        391        (477      (373

CHF

     71        124        (68      (118

AUD

     18        176        (18      (167

TRY

     74        151        (71      (144

SEK

     62        115        (59      (109

CZK

     92        100        (88      (95

DKK

     33        76        (31      (73

HRK

     82        58        (78      (55

Other

     115        74        (110      (70
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     5,507        6,117        (5,245      (5,826
  

 

 

    

 

 

    

 

 

    

 

 

 

Credit risk

Credit risk is the risk that a customer or counterparty to a financial instrument may default on a contractual obligation generating a loss for the group. It mainly arises on trade receivables and debt instruments.

The group’s maximum exposure to this type of risk is the assets’ carrying amount.

Some of the markets on which the group operates have a higher level of risk, such as southern Italy, where the health system is deeply in debt, southern European countries, like Spain and Portugal, and eastern European countries, such as Croatia, the Czech Republic and Slovakia, where collection times are very long.

Most of the group’s receivables are due from public institutions, thus solely linked to the country risk. Moreover, payments from public administrations have improved notably in some cases in recent years thanks to measures taken to cut public entity debt with private companies.

Credit risk is also mitigated by the fact that the group is increasing its sales in countries with shorter average collection times. Therefore, the weight of markets with higher credit risk will be reduced.

At 31 December 2021 and 2022, the group does not have exposures with individual customers for more than 10% of its total trade receivables. Its top ten customers account for around 6% of total trade receivables at 31 December 2021 and 2022.

 

63


The amount of financial assets for which recovery is doubtful is immaterial in terms of the total amount of trade receivables and is, in any case, covered by adequate accruals to the relevant allowances. The following table shows the group’s exposure to credit risk (amounts are inclusive of the loss allowance):

 

            Overdue         
     Not yet due      <30 days      30 - 90 days      90 - 180 days      Over 180 days      Total  

Gross trade receivables at 31/12/2021

     41,111        6,422        5,362        4,622        11,454        68,971  

Loss allowance at 31/12/2021

     0        0        0        24        2,058        2,082  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net trade receivables at 31/12/2021

     41,111        6,422        5,362        4,598        9,396        66,889  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Gross trade receivables at 31/12/2022

     47,181        7,324        6,108        4,519        7,394        72,527  

Loss allowance at 31/12/2022

     0        0        1        1        2,385        2,387  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Net trade receivables at 31/12/2022

     47,181        7,324        6,107        4,518        5,009        70,140  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

The group monitors credit risk by grouping trade receivables by the credit worthiness of the customers, considering whether they belong to the private or public sector, their geographical location, relationship with the group and any previous financial difficulties.

Receivables are broken down by geographical segment as follows:

 

     Total Italy      Total EU      Rest of world      Total  

Trade receivables

     23,021        20,681        26,438        70,140  

From subsidiaries

     0        0        0        0  

From associates

     0        0        0        0  

From parents

     0        21        0        21  

From subsidiaries of parents

     0        0        0        0  
  

 

 

    

 

 

    

 

 

    

 

 

 

TOTAL

     23,021        20,702        26,438        70,161  
  

 

 

    

 

 

    

 

 

    

 

 

 

Liquidity risk

Liquidity risk derives from the ability to obtain financial resources at a sustainable cost to carry out the group’s normal business operations.

The group uses the usual tools to manage current trade receivables, as well as partially using the credit facilities available.

Moreover:

 

   

the group has debt instruments and credit lines to deal with liquidity requirements;

 

   

there are no significant concentrations of liquidity risk with regard to financial assets.

The table below summaries the ageing of financial liabilities at 31 December 2022 on the basis of non-discounted contractual payments. The refinancing completed in the first quarter of 2023 guarantees enough liquid funds to the group to make the liquidity risk in the medium term immaterial.

 

     Within one year      After one year      After five
years
     Total  

Credit cards

     383        0        0        383  

Advances on exports

     0        0        0        0  

Current bank loans and borrowings

     54,298        0        0        54,298  

Non-current bank loans and borrowings

     386        363        2        751  

Bonds

     276,018        0        0        276,018  

Loans and borrowings with other financial backers

     2,310        5,248        0        7,558  

Lease liabilities as per IFRS 16

     3,265        3,997        555        7,817  
  

 

 

    

 

 

    

 

 

    

 

 

 

TOTAL

     336,659        9,607        557        346,824  
  

 

 

    

 

 

    

 

 

    

 

 

 

[4.4] Significant non-recurring transactions

None.

[4.5] Guarantees

Reference should be made to section [3.15] of the notes to the consolidated financial statements as at 31 December 2022.

 

64


[4.6] Related party transactions

The group carries out transactions with the ultimate parent recognised in line with the provisions of IAS 24. They are all financial in nature and are performed with full transparency and on an arm’s length basis. They do not include typical and/or unusual transactions.

Details of related party transactions carried out in 2022 and 2021 are as follows:

 

(€‘000)

 
     Liabilities      Assets      2021
Other non-
current
liabilities
     Other current
liabilities
     Sundry
recharges
    Services      Personnel
expenses
 

EMIL HOLDING II S.à.r.l.

     350        —            —         (1     350        —   

Senior management

     —         —         4,812        82        —        741        (806

Short-term

              82          275     

Post-employment

                   

Other long-term

                   

Shared-based benefits

           4,812             466        (806
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Total

     350        —         4,812        82        (1     1,091        (806
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

 

(€‘000)

 
     Liabilities      Assets      2022
Other non-
current
liabilities
     Other current
liabilities
     Sundry
recharges
    Services      Personnel
expenses
 

EMIL HOLDING II S.à.r.l.

     350        21        —         —         (24     350        —   

Senior management

     —         —         72        302        —        2,704        3,928  

Short-term

              302          586     

Post-employment

                   1,176     

Other long-term

                   —      

Share-based benefits

           72             941        3,928  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

Total

     350        21        72        302        (24     3,054        3,928  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

   

 

 

    

 

 

 

No other significant related party transactions took place during the year.

The group operates in a market dominated by entities directly or indirectly controlled by the Italian government through state bodies, agencies, related parties and other organisations (entities related to government bodies). The parent does not carry out transactions with other entities related to government bodies, such as, for example, the sale and purchase of goods and materials, the supply or receipt of services, leasing of assets or use of public services.

Transactions with Emil Holding II S.à.r.l.

Financial transactions with the ultimate parent are part of the parent’s normal business operations and take place at conditions similar to those applied to transactions with unrelated parties.

[4.7] Fees of directors, statutory auditors and key management personnel

The fees paid to directors and statutory auditors were as follows:

 

     2022      2021      Variation  

Statutory auditors’ fees

     57        57        0  

Directors’ fees

     2,704        741        1,963  
  

 

 

    

 

 

    

 

 

 

TOTAL

     2,760        798        1,962  
  

 

 

    

 

 

    

 

 

 

The fees of the independent auditors and entities belonging to its network for the statutory audit of the parent’s separate financial statements and the group’s consolidated financial statements as at 31 December 2022 and related activities amount to €237 thousand.

 

65


[4.8] Incentive plans

In accordance with IFRS 2, the parent identified cash-settled share-based payment and equity-settled share-based payment incentive plans for some managers.

Assumptions about the fair value of the share-based payment plans are based on the Monte Carlo method (by simulating the group’s gross operating profit and equity value).

In previous years, the parent had defined two types of plan:

 

   

Virtual share plan (“VSP”)

On 23 November 2016, the parent’s shareholders approved the 2016-2030 virtual share plan for one of its managers. This includes the free award of options to subscribe the parent’s ordinary shares. The manager has the right to receive a number of options each year calculated using a pre-set formula.

The plan vests on 31 December 2030 although this date may be brought forward in the case of i) an IPO, ii) a change of control, or iii) leaver events that lead to the beneficiary leaving the parent.

The manager’s right to exercise the options vests in line with their continued employment relationship with the events i), ii) and iii) being early exercise events.

This plan qualifies as a cash-settled plan under IFRS 2. Its fair value was calculated using market models and the market data at the reporting dates (such as interest rate curves, historical price curves of listed comparable companies’ shares, price volatility of listed comparable companies’ shares) as well as non-market conditions (the probability that the above events will take place). The parent updates the calculation each year. After the sole beneficiary of the VSP stepped down in the first half of 2022, the amount due under the VSP was defined and paid during the year.

 

   

MPP plan

In September 2016, the parent introduced an incentive plan for some group employees who signed agreements with Emil Holding I (Emil Holding II’s controlling shareholder) providing for i) the award of shares of Emil Holding II (the company that manages and coordinates the parent) to the plan beneficiaries, ii) the granting of call options by the beneficiaries to Emil Holding I whereby Emil Holding I can acquire the shares held by the beneficiaries if certain events occur, iii) the granting of put options by Emil Holding I to the beneficiaries whereby the latter can sell their shares in Emil Holding II at the same conditions set for the call option, generating an amount equal to the difference between the amount paid by the beneficiaries (on the subscription date or deferred) and the carrying amount of the shares at the option exercise date. The options can be exercised if one of the events occurs.

This plan qualifies as a cash-settled plan under IFRS 2. Its fair value was calculated using market models and the market data at the reporting dates (such as interest rate curve) as well as non-market conditions (the probability that the above leaver events will take place). The plan liability represents the plan’s future value less the cost incurred by each beneficiary as its initial investment to enter the plan. The parent updates the calculation each year.

These plans led to recognition of a non-current liability of €0 million at 31 December 2022 and costs of services and personnel expenses for the year of €346 thousand (€5.1 million and €340 thousand for 2021, respectively).

 

   

The Bonus Payments

Starting from June 2022 the Controlling Entity and the Entity agreed with certain employees some compensation plans which provide that upon occurrence of certain events (the “Bonus Payment Trigger Events”) a payment of a certain amount based on the enterprise value of the Entity at the trigger event date (the “Trigger Event Enterprise Value”).

 

66


The Bonus Payment Trigger Events occur at the first of the following events:

 

   

the listing of Emil NewCo S.a.r.l. or any entity of the Lima Group of companies which holds, directly and indirectly, all or substantially all of the assets of the Lima Group, on a regulated stock exchange;

 

   

in case no listing pursuant to paragraph a) has taken place, (i) any sale or transfer by Emil Holding I to a third party purchaser (not related to any EQT Funds) of more than 50% of the ordinary shares held by Emil Holding I in Emil NewCo S.a.r.l. or (ii) any sale to a third party purchaser (not related to any EQT Funds) of more than 50% of the shares in any other entity which holds, directly or indirectly, all or substantially all of the business or assets of the Lima Group; or

 

   

an asset sale of all or substantially all of the assets of the Lima Group which results in the EQT Funds no longer holding any interest (except for unsubstantial assets) in the Lima Group.

Considering that the amount to be paid to the employees is based on the Trigger Event Enterprise Value of the Entity and is therefore based on the value of the Entity’s equity instrument, the Bonus Payment falls within the scope of the “IFRS 2 – Share Based Payments”.

In particular, the management accounted for the Bonus Payment as follows:

 

  (i)

the agreements in which the Entity has the obligation to settle the payment as cash-settled share-based payments (the “Cash-settled Bonus Payments”);

 

  (ii)

the agreements in which the obligation is settled by Emil Holding I as equity-settled share-based payments (the “Equity-settled Bonus Payments”).

In accordance with IFRS 2, the Equity-settled Bonus Payments are measured at the fair value of grant date. Instead, the Cash-settled Bonus Payments are measured at the fair value of grant date and then re-measured at each reporting date until settlement.

The fair value of the Bonus Payments is recognized as an expense during the vesting period.

In order to evaluate the fair value of the Bonus Payments, the management used a Monte Carlo valuation model.

 

   

The Grant Dates considered for the valuation are: June 6, 2022, June 18, 2022, June 28, 2022, and August 9, 2022, which are the grant dates of the major part of the agreements.

 

   

The management of the company has assumed that the exercise of the plan will occur following an Exit Event on June 30, 2024 with a probability of 100%.

 

   

The riskfree interest rate is retrieved from public Information Provider and range from a minimun of 1.3% and maximum of 1.8% over the grant dates.

 

   

The volatility was estimated based on historical series of Equity Value from comparable companies. An adjustment was then applied in order to obtain the volatility relative to Enterprise Value, considering the framework derived from the Merton model.

 

   

Expected dividends rate is 0% for all the Bonus Payments.

 

   

Employee exit rate is 0% for all the Bonus Payments.

The fair value of the Cash-settled Bonus Payments at grant date amounted to € 464.3 thousand.

The fair value of the Equity-settled Bonus Payments at grant date amounted to € 17,752.0 thousand.

As of 31 December 2022, this plan involves 11 employees and led to a recognition of personnel expenses of €4,523 thousand in 2022.

 

67


[4.9] Information pursuant to article 1.125 of Law no. 124/2017

Pursuant to article 1 of Law no. 124 of 4 August 2017, in compliance with the transparency obligation, it is noted that the group received the following grants in 2022.

 

Granting body

 

Grant received

  

Reason

EUROPEAN COMMISSION

  33    H2020 MSCA ITN 2017 mCBEEs - 764977: Advanced integrative solutions to corrosion problems beyond micro-scale: towards long-term durability of miniaturized Biomedical, Electronic and Energy systems

MINISTRY FOR ECONOMIC DEVELOPMENT

  6    Project IAREPAM Artificial Intelligence for the Efficient Development of an Implant in Additive Manufacturing – subsidised loan

MINISTRY FOR ECONOMIC DEVELOPMENT

  11    Project IAREPAM Artificial Intelligence for the Efficient Development of an Implant in Additive Manufacturing – advance on the 1st progress report
 

 

  

TOTAL

  50   
 

 

  

The loan taken out to carry out the SICAT research and development project (commented on in note [3.15] Current and non-current financial liabilities in the notes to the consolidated financial statements as at 31 December 2022) bears interest at a subsidised rate of 0.80%.

The loan taken out to carry out the IAREPAM research and development project (commented on in note [3.15] Current and non-current financial liabilities in the notes to the consolidated financial statements as at 31 December 2022) bears interest at a subsidised rate of 0.13%.

For the purposes of the above disclosure requirements, in relation to any other relevant grants received, reference should also be made to the national register which is available for public consultation.

[4.10] Going concern

Though some parts of the world still felt the effects of the Covid-19 pandemic in early 2022, the current global situation means this is not a tangible or imminent significant factor in the group’s ability to continue as a going concern.

Due to the completion of the refinancing of the group described earlier and the economic and financial forecasts for the current year, supported by the group’s performance in early 2023, , the directors believe that going concern is comfortably ensured.

[4.11] Events after the reporting date

As described in more detail in the paragraph [3.15] Current and non-current financial liabilities, the group completed the restructuring of its credit facilities and bonds at the beginning of 2023, deferring maturity to early 2028. This was partly financed by a capital injection by the shareholder.

On 16 March 2023, the parent Limacorporate S.p.A. signed a mutually-agreed assessment settlement procedure with the tax authorities following the tax assessment carried out on 2016.

In summer 2023 the management of Limacorporate took the strategic decision to stop the Smart Space project (referred to TechMah CGU), all digital activities and resources have been refocused on other projects. The event has been considered as non-adjusting event under IAS 10 as the decision has been fully taken in 2023.

There were no other significant events after the reporting date.

 

68

EX-99.2

Exhibit 99.2

 

LOGO

KPMG S.p.A.

Revisione e organizzazione contabile

Piazza Salvemini, 20

35131 PADOVA PD

Telefono +39 049 8249101

Email it-fmauditaly@kpmg.it

PEC kpmgspa@pec.kpmg.it

Independent Auditors’ report on review of condensed consolidated interim financial statements

To the board of directors of

Limacorporate S.p.A.

Introduction

We have reviewed the accompanying condensed consolidated interim financial statements of Limacorporate Group, comprising the income statement and the statement of comprehensive income, statement of financial position, statement of changes in equity and statement of cash flow and notes thereto.

The directors of Limacorporate S.p.A. are responsible for the preparation and presentation of these condensed consolidated interim financial statements in accordance with International Accounting Standards 34 issued by International Accounting Standards Board, Interim Financial Reporting. Our responsibility is to express a conclusion on the condensed consolidated interim financial statements based on our review.

Scope of review

We conducted our review in accordance with International Standard on Review Engagements 2410, ‘‘Review of Interim Financial Information Performed by the Independent Auditor of the Entity’’. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion on the condensed consolidated interim financial statements.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying condensed consolidated interim financial statements of Limacorporate Group as at and for the six-month period ended 30 June 2023 have not been prepared, in all material respects, in accordance with International Accounting Standards 34 issued by International Accounting Standards Board, Interim Financial Reporting.

 

 

 

KPMG S.p.A. è una società per azioni di diritto italiano e fa parte del

network KPMG di entità indipendenti affiliate a KPMG International

Limited, società di diritto inglese.

  

Ancona Bari Bergamo Bologna Bolzano Brescia

Catania Como Firenze Genova

Lecce Milano Napoli Novara Padova Palermo Parma Perugia  

Pescara Roma Torino Treviso

Trieste Varese Verona

  

Società per azioni

Capitale sociale

Euro 10.415.500,00 i.v.

Registro Imprese Milano Monza Brianza Lodi    

e Codice Fiscale N. 00709600159

R.E.A. Milano N. 512867

Partita IVA 00709600159

VAT number IT00709600159

Sede legale: Via Vittor Pisani, 25

20124 Milano MI ITALIA


LOGO

Limacorporate Group

Auditors’ report on review of condensed consolidated interim financial statements

30 June 2023

 

Emphasis of Matter – IFRS issued by the IASB adoption and error correction

We draw attention to Note 2.2 “Format and content of the condensed consolidated interim financial statements“ to the condensed interim financial statements, which indicates the Limacorporate Group has corrected an error related to the payback mechanism accounted in compliance with IFRS 15 that was reported prior to the group’s adoption of the IFRS issued by IASB. Our conclusion is not qualified in respect of this matter.

Other matters

The condensed consolidated interim financial statements of Limacorporate Group as at and for the six-month period ended 30 June 2023 has been prepared for its inclusion in the offering memorandum drawn up by Enovis Corporation as part of its potential issue of notes.

Padua, 5 October 2023

KPMG S.p.A.

 

LOGO

Silvia Di Francesco

Director of Audit

 

2


LOGO

Condensed consolidated interim financial statements as of and for the six-months ended 30 June 2023

. LOGO


Contents

 

Condensed consolidated statement of financial position

     5  

Condensed consolidated income statement

     6  

Condensed consolidated statement of comprehensive income

     7  

Condensed consolidated statement of changes in equity

     8  

Condensed consolidated statement of cash flows

     9  

Notes to the condensed consolidated interim financial statements

     10  

 

4


Condensed consolidated statement of financial position

 

ASSETS

   Note     30/06/2023     31/12/2022  
                    

Non-current assets

  

Other intangible assets

     [3.1     21,204       58,234  

Goodwill

     [3.2     384,286       384,216  

Property, plant and equipment

     [3.3     78,292       79,837  

Equity investments

     [3.4     2       2  

Deferred tax assets

     [3.5     32,377       31,709  

Other non-current financial assets

     [3.6     906       —   

Other non-current assets

     [3.7     967       861  
    

 

 

   

 

 

 

Total non-current assets

       518,034       554,859  
    

 

 

   

 

 

 

Current assets

      

Inventories

     [3.8     89,205       86,728  

Trade receivables

     [3.9     79,106       70,161  

Current tax assets

     [3.10     2,225       2,087  

Other current assets

     [3.11     12,371       14,192  

Cash and cash equivalents

     [3.12     23,681       25,920  
    

 

 

   

 

 

 

Total current assets

       206,588       199,088  
    

 

 

   

 

 

 

TOTAL ASSETS

       724,622       753,947  
    

 

 

   

 

 

 

EQUITY AND LIABILITIES

                  

Equity

      

Share capital

     [3.13     9,868       9,868  

Share premium reserve

     [3.13     14,425       14,425  

Other reserves

     [3.13     375,584       323,510  

Retained earnings (accumulated deficit)

     [3.13     (41,239     (21,966

Profit (loss) for the year

     [3.13     (33,217     (19,273
    

 

 

   

 

 

 

Total equity attributable to the owners of the parent

       325,421       306,564  
    

 

 

   

 

 

 

Total equity

       325,421       306,564  
    

 

 

   

 

 

 

Non-current liabilities

      

Non-current financial liabilities

     [3.16     290,184       10,165  

Employee benefits

     [3.15     1,192       1,296  

Deferred tax liabilities

     [3.5     10,176       19,275  

Provisions for risks and charges

     [3.14     20,006       17,156  

Other non-current liabilities

     [3.18     766       649  
    

 

 

   

 

 

 

Total non-current liabilities

       322,324       48,541  
    

 

 

   

 

 

 

Current liabilities

      

Current financial liabilities

     [3.16     17,708       336,659  

Trade payables

     [3.19     34,272       36,564  

Current tax liabilities

     [3.20     1,234       877  

Other current liabilities

     [3.21     23,663       24,742  
    

 

 

   

 

 

 

Total current liabilities

       76,878       398,842  
    

 

 

   

 

 

 

TOTAL EQUITY AND LIABILITIES

       724,622       753,947  
    

 

 

   

 

 

 

The notes commenting on the individual items are an integral part of these condensed consolidated interim financial statements.

 

5


Condensed consolidated income statement

 

(€‘000)                     
     Note      30/06/2023      30/06/2022  

Revenue

     [3.22      140,687        121,251  

Other revenues and income

     [3.22      2,739        2,447  
     

 

 

    

 

 

 

Total revenue and income

        143,426        123,698  
     

 

 

    

 

 

 

Raw materials, consumables, supplies and goods

     [3.24      (35,447      (29,282

Services

     [3.25      (42,959      (38,815

Change in w.i.p., semi-finished products and finished goods

     [3.26      2,392        329  

Personnel expenses

     [3.27      (43,969      (37,150

Amortisation and Depreciation

     [3.28      (14,967      (17,186

Impairment losses on trade receivables

     [3.28      61        (154

Impairment losses on fixed assets

     [3.28      (37,331      (0

Other operating costs

     [3.29      (980      (699

Internal work capitalised

     [3.23      6,281        7,886  
     

 

 

    

 

 

 

Operating costs

        (166,920      (115,072
     

 

 

    

 

 

 

Operating profit

        (23,494      8,626  
     

 

 

    

 

 

 

Financial income

     [3.30      4,094        12,527  

Financial expense

     [3.30      (22,745      (11,817
     

 

 

    

 

 

 

Net financial expense

        (18,651      709  
     

 

 

    

 

 

 

Pre-tax income (loss)

        (42,144      9,335  
     

 

 

    

 

 

 

Income tax benefit (expense)

     [3.31      8,928        (882
     

 

 

    

 

 

 

Profit (loss) for the year

        (33,217      8,453  
     

 

 

    

 

 

 

of which attributable to the owners of the parent

        (33,217      8,453  
     

 

 

    

 

 

 

The notes commenting on the individual items are an integral part of these condensed consolidated interim financial statements.

 

6


Condensed consolidated statement of comprehensive income

Statement of comprehensive income

 

(€‘000)                     
     Note      30/06/2023      30/06/2022  

Profit (loss) for the year

        (33,217      8,453  
     

 

 

    

 

 

 

Other comprehensive income (expense)

        

Items that will never be reclassified to profit or loss (A)

        

Remeasurements of the net defined benefit liability (asset)

     [3.15]        —         —   

Related tax

     [3.15]        —         —   
     

 

 

    

 

 

 
        —         —   
     

 

 

    

 

 

 

Items that are or may be reclassified to profit or loss (B)

        

Exchange differences on translation of foreign operations

     [3.13]        1,042        797  

Net gains on the effective portion of cash flow hedges

     [3.17]        —         —   

Related tax

     [3.17]        
     

 

 

    

 

 

 
        1,042        797  
     

 

 

    

 

 

 

Other comprehensive income (expense), net of tax (A+B)

        1,042        797  
     

 

 

    

 

 

 

Comprehensive income (expense) for the year

        (32,175      9,250  
     

 

 

    

 

 

 

Comprehensive income (expense) attributable to:

        

Owners of the parent

        (32,175      9,250  
     

 

 

    

 

 

 

The notes commenting on the individual items are an integral part of these condensed consolidated interim financial statements. 

 

7


Condensed consolidated statement of changes in equity

 

(€‘000)                                                                               
     Note     Share
capital
     Share
premium
reserve
     Legal
reserve
     Negative
goodwill
     Capital
Injections
     Translation
reserve
     Actuarial
reserve
    Other
reserve
    Losses carried
forward
including the
profit (loss) for
the year
    Total equity
attributable to
the owners of
the parent
    Total equity  

At 1 January 2022

       9,868        14,425        2,101        288,261        28,051        1,508        (23     (2,329     (21,401     320,464       320,464  
    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Statement of comprehensive income

                              

Profit for the year

     [3.13     —         —         —         —         —         —         —        —        8,453       8,453       8,453  

Other comprehensive income

     [3.13     —         —         —         —         —         797        —        —        —        797       797  

Comprehensive income

       —         —         —         —         —         797        —        —        8,453       9,250       9,250  

Owner transactions

                              

Allocation of the loss for the previous year

     [3.13     —         —         —         —         —         —         —        565       (565     —        —   

Other owner transactions

     [3.13     —         —         —         —         —         —         —          —        —        —   

Total owner transactions

       —         —         —         —         —         —         —        565       (565     —        —   

Other changes

     [3.13     —         —         —         —         —         —         —        115       —        115       115  
    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

At 30 June 2022

       9,868        14,425        2,101        288,261        28,051        2,305        (23     (1,649     (13,513     329,829       329,829  
    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

At 1 January 2023

       9,868        14,425        2,101        288,261        28,051        2,379        31       2,687       (41,239     306,564       306,564  
    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Statement of comprehensive income

                              

Profit (Loss) for the period

     [3.13]       —         —         —         —         —         —         —        —        (33,217     (33,217     (33,217

Other comprehensive income (expense)

     [3.13]       —         —         —         —         —         1,042        —        —        —        1,042       1,042  

Comprehensive income (expense)

       —         —         —         —         —         1,042        —        —        (33,217     (32,175     (32,175

Owner transactions

                              

Allocation of the loss for the previous year

     [3.13]       —         —         —         —         —         —         —        —        —        —        —   

Other owner transactions

     [3.13]       —         —         —         —         46,296        —         —          —        46,296       46,296  

Total owner transactions

       —         —         —         —         46,296        —         —        —        —        46,296       46,296  

Other changes

     [3.13]       —         —         —         —         —         —         0       4,735       —        4,736       4,736  
    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

At 30 June 2023

       9,868        14,425        2,101        288,261        74,347        3,421        31       7,422       (74,456     325,422       325,421  
    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

The notes commenting on the individual items are an integral part of these condensed consolidated interim financial statements.

 

8


Condensed consolidated statement of cash flows

 

(€‘000)       
     Note   30/06/2023      30/06/2022  

Operating activities

       

Profit (loss) for the year

   [3.13]     (33.217      8.453  

Income tax (benefit)/expense

   [3.31]     (8.928      882  

Net financial (income)/expense

   [3.30]     18.506        222  

Amortisation, depreciation and impairment losses

   [3.28]     52.237        17.186  

Accruals/(Release) to provisions

   [3.28]     2.850        133  

Net (gains)/loss on disposals

   [3.21] [3.28]     (553      (305

FX on contingent consideration

       1.328        965  

Cash flows from operating activities before changes in working capital

       32.224        27.537  

Change in inventories

   [3.8]     (2.477      (756

Change in trade receivables

   [3.9]     (8.945      (4.166

Change in trade payables

   [3.19]     (2.291      4.060  

Change in other assets/liabilities

   [3.20] [3.21]     2.241        2.597  

Change in non-current assets

   [3.7]     (106      (190

Income taxes paid

       (942      (718
    

 

 

    

 

 

 

Cash flows from operating activities A)

       19.704        28.364  
    

 

 

    

 

 

 

Investing activities

       

Acquisitions of property, plant and equipment

   [3.3]     (12.083      (12.885

Disposal of property, plant and equipment

   [3.3]     450        564  

Acquisitions of intangible assets

   [3.1]     (2.888      (5.521

Disposal of intangible assets

   [3.1]     —         2  
    

 

 

    

 

 

 

Cash flows used in investing activities B)

       (14.520      (17.839
    

 

 

    

 

 

 

Financing activities

       

Third party funds

       

Bonds repayment

   [3.16]     (274.039      —   

Bank loans repayment

   [3.16]     (47.000      —   

Bonds issuance

   [3.16]     279.613        —   

Payment of lease liability

   [3.16]     (2.134      (3.518

Gross interest received

   [3.29]     45        92  

Gross interest paid

   [3.29]     (12.659      (6.519

Capital injection

   [3.13]     46.296        —   

Other financial liabilities

       2.455        7.605  
    

 

 

    

 

 

 

Cash flows from (used in) in financing activities C)

       (7.424      (2.341
    

 

 

    

 

 

 

Increase (decrease) in cash and cash equivalents (A ± B ± C)

       (2.240      8.184  
    

 

 

    

 

 

 

Opening cash and cash equivalent

       25.920        21.503  

Closing cash and cash equivalent

       23.681        29.687  
    

 

 

    

 

 

 

Increase (decrease) in cash and cash equivalents

       (2.240      8.184  
    

 

 

    

 

 

 

 

9


Notes to the condensed consolidated interim financial statements

[2.1] General information

The Limacorporate Group (the “group”) creates, designs and sells joint implants and orthopaedic solutions in the medical sector.

The parent, Limacorporate S.p.A. (“Limacorporate” or the “parent”), was set up and is domiciled in Italy. Its registered office is at Via Nazionale 52, San Daniele del Friuli (Udine) and its company registration number is 173824.

The group carries out most of its business at its registered office while some activities are also performed by the subsidiaries.

The condensed consolidated interim financial statements as of and for the six-months ended 30 June 2023 include the financial statements of the parent and the subsidiaries (together the “group”).

This condensed consolidated interim financial statement has been prepared for its inclusion in the offering memorandum drawn up by Enovis Corporation as part of its potential issue of notes.

The parent is managed and coordinated by Emil Holding II S.à.r.l., whose details are provided below:

 

   

Registered office: 26A, Boulevard Royal, L-2449 Luxembourg.

 

   

Legal form: limited liability company.

 

   

Description of its business activities and main operations: holding company

 

   

Parent’s name: Emil NewCo S.à.r.l.

 

   

Name of the ultimate indirect parent: EQT Luxembourg Management S.à r.l.

[2.2] Format and content of the condensed consolidated interim financial statements

The condensed consolidated income statement and consolidated statement of comprehensive income for the six-month period ended 30 June 2023 and the six-month period ended 30 June 2022 have been prepared in accordance with IAS 34 issued by International Accounting Standards Board (IASB). They do not include all the information that would be required for the annual consolidated financial statements and should be read in conjunction with the consolidated financial statements for the year ended as of 31 December 2022 which was prepared in accordance with the International Financial Reporting Standards (“IFRS”) issued by the International Accounting Standards Board (“IASB”).

The term “IFRS” is also used to refer to all revised international accounting standards (“IAS”), all interpretations of the International Financial Reporting Interpretations Committee (“IFRIC”), formerly known as the Standing Interpretations Committee (“SIC”).

These condensed consolidated interim financial statements comprise the statement of financial position, profit or loss, .statement of changes in equity, statement of cash flows and these notes. They comply with the provisions of IAS 1 Presentation of financial statements and the general principle of historical cost, except for those items that, pursuant to the IFRS, are measured at fair value. The statement of financial position has been prepared by separating assets and liabilities into current and non-current, whereas costs are classified in the income statements on the basis of their nature. The statement of cash flows has been prepared using the indirect method.

The notes to the condensed consolidated interim financial statements include the information generally required by ruling legislation and the IFRS, suitably presented with reference to the financial statements schedules used.

The condensed consolidated interim financial statements have been prepared on a going concern basis, as the related assumptions are deemed to be met.

All figures are in Euros, unless indicated otherwise. The Euro is the parent’s functional and presentation currency. For each financial statements caption, the corresponding amount of the previous year is provided for comparative purposes.

 

10


As already reported in the consolidated financial statements as of 31 December 2022 prepared in accordance with the IFRS issued by IASB, the Group restated the Group’s equity and profit for the year previously determined under the IFRS endorsed by the European Union. Accordingly, the Group also restated the comparative information of this condensed consolidated interim financial statements as of and for the six-months ended 30 June 2023. For all the considerations related to the first-time adoption (on 1 January 2021) to the IFRS issued by IASB, please refer to the consolidated financial statements as of 31 December 2022.

In the consolidated financial statements as of 31 December 2022 prepared in accordance with IFRS issued by IASB the Group corrected the payback treatment in compliance with IFRS 15 considering it as a variable consideration instead of applying IAS 37. The effect of the correction of error as of 1 January 2021 is a lower Group’s net equity of €6.9 million. For the correction reflected in the opening equity please refer to the previous mentioned consolidated financial statements as of 31 December 2022 issued by IASB. Instead, as provide for IAS 8, in the table below are reflected the effects affecting the profit and loss of the consolidated interim financial statements as of and for the six-months ended 30 June 2022 that led to a decrease of the net result of the period of €1.1 million.

Reconciliations of the statement of profit or loss

 

(€‘000)       
     Note      30/06/2022 EU      Errors      30/06/2022 IASB  

Revenue

     [3.20      122,378        (1,127      121,251  

Other revenues and income

     [3.20      2,447           2,447  
     

 

 

    

 

 

    

 

 

 

Total revenue and income

        124,825        (1,127      123,698  
     

 

 

    

 

 

    

 

 

 

Raw materials, consumables, supplies and goods

     [3.21      (29,282         (29,282

Services

     [3.22      (38,815         (38,815

Change in w.i.p., semi-finished products and finished goods

     [3.23      329           329  

Personnel expenses

     [3.24      (37,151         (37,151

Amortisation and Depreciation

     [3.25      (17,186         (17,186

Impairment losses on trade receivables

     [3.25      (154         (154

Impairment losses on fixed assets

     [3.25      —            —   

Other operating costs

     [3.26      (699         (699

Internal work capitalised

     [3.27      7,886           7,886  
     

 

 

    

 

 

    

 

 

 

Operating costs

        (115,072      —         (115,072
     

 

 

    

 

 

    

 

 

 

Operating profit

        9,753        (1,127      8,626  
     

 

 

    

 

 

    

 

 

 

Financial income

     [3.28      12,527           12,527  

Financial expense

     [3.28      (11,818         (11,818
     

 

 

    

 

 

    

 

 

 

Net financial expense

        709        —         709  
     

 

 

    

 

 

    

 

 

 

Pre-tax income (loss)

        10,462        (1,127      9,335  
     

 

 

    

 

 

    

 

 

 

Income tax benefit (expense)

     [3.29      (882         (882
     

 

 

    

 

 

    

 

 

 

Profit (loss) for the year

        9,580        (1,127      8,453  
     

 

 

    

 

 

    

 

 

 

of which attributable to the owners of the parent

        9,580        (1,127      8,453  
     

 

 

    

 

 

    

 

 

 

 

(€‘000)       
     Note      30/06/2022 EU      Errors      30/06/2022 IASB  

Profit (loss) for the year

        9,580        (1,127      8,453  
     

 

 

    

 

 

    

 

 

 

Other comprehensive income (expense)

           

Items that will never be reclassified to profit or loss (A)

        —         —         —   

Remeasurements of the net defined benefit liability (asset)

     [3.14      —         —         —   

Related tax

     [3.14      —         —         —   
     

 

 

    

 

 

    

 

 

 
        —         —         —   
     

 

 

    

 

 

    

 

 

 

Items that are or may be reclassified to profit or loss (B)

           

Exchange differences on translation of foreign operations

     [3.12      797        —         797  
     

 

 

    

 

 

    

 

 

 
        797        —         797  
     

 

 

    

 

 

    

 

 

 

Other comprehensive income (epense), net of tax (A+B)

        797        —         797  
     

 

 

    

 

 

    

 

 

 

Comprehensive income (expense) for the year

        10,377        (1,127      9,250  
     

 

 

    

 

 

    

 

 

 

Comprehensive income (expense) attributable to:

        —         

Owners of the parent

        10,377        (1,127      9,250  
     

 

 

    

 

 

    

 

 

 

 

11


[2.3] Consolidation scope

The condensed consolidated interim financial statements of the Limacorporate Group include the financial statements of the parent and the Italian and foreign subsidiaries as at 30 June 2023 and detailed in the following table:

 

Description

  

Location

  

Currency

   %
subsidiaries               
LIMA AUSTRIA GmbH    Seestadtstrasse 27 Top 6-7, 1220 Wien (Osterreich)    (EUR)    100%
LIMA BELGIUM SRL    Chaussée de Wavre 504, boîte 5A - 1390 Grez Doiceau (Belgium)    (EUR)    100%
LIMA CZ s.r.o.    Do Zahràdek I., 157/5 - 155 21 Praha 5 - Třebonice - (Czech Republic)    (CZK)    100%
LIMA DENMARK ApS    Lyngebaekgards Alle 2, 2990 Niva (Denmark)    (DKK)    100%

LIMA DEUTSCHLAND

GmbH

   Gasstraße 18 | Haus 1 - 22761 Hamburg - Germany    (EUR)    100%
LIMA DO BRASIL LTDA   

Al. Campinas, 728 – 2° andar salas 201, 202, 203 e 204.- Jardim Paulista - Sao Paulo - SP -

CEP:01404-001 (Brasil)

   (BRL)    100%
LIMA FRANCE Sas    1, Allée des Alisiers - Immeuble “Le Galilée” - 69500 Bron - (France)    (EUR)    100%

LIMA IMPLANTES

PORTUGAL S.U. LDA

   Rua Pêro Vaz de Caminha 8 E 2660-441 Stº António Cavaleiros - (Portugal)    (EUR)    100%
LIMA IMPLANTES Slu    Francisco Sancha, 4 3ª planta | 28034 Madrid | España    (EUR)    100%
LIMA JAPAN K.K.    Tokyo Front Terrace 13F 2-3-14 Higashi Shinagaw a,Shinagaw a, Tokyo, 140-0002, (Japan)    (JPY)    100%
LIMA KOREA Co., Ltd   

2Fl., EunSung Bldg., 741 Yeongdong-daero, Gangnam Gu,

Seoul, 06071, Korea

   (KRW)    100%

LIMA NETHERLANDS

B.V.

   Bergw eg 153A, 3707AC Zeist - (Netherlands)    (EUR)    100%

LIMA O.I. d.o.o. - ORTOPEDIJA I

IMPLANTATI

   Ante Kovačića, 3 - 10000 Zagreb - (Croatia)    (HRK)    100%

LIMA ORTHOPAEDICS

AUSTRALIA Pty Ltd

   Unit 1, 40 Ricketts Road - Mt Waverley, 3149 Victoria - (Australia)    (AUD)    100%

LIMA ORTHOPAEDICS

NEW ZEALAND Pty Ltd

   20 Crummer Rd Grey Lynn 1021 Auckland 1021 - New Zealand    (NZD)    100%

LIMA ORTHOPAEDICS SOUTH AFRICA (PTY)

LTD

   Northlands Deco Park, Stand 326, 10 New market Street, Design Boulevard, Northriding, 2186 (South Africa)    (ZAR)    100%

LIMA ORTHOPAEDICS

UK Ltd

  

4 Office Village Forder Way Cygnet Park Hampton Peterborough Peterborough PE7 8GX

(United Kingdom)

   (GBP)    100%

LIMA POLSKA SP.

z.o.o.

   ul. Ul Lopuszanska 95 - 02-457 Warsaw (Poland)    (PLN)    100%
LIMA SK S.r.o.    Cesta na Stadiòn 7 - 97404 Banska Banska Bystrica - (Slovakia)    (EUR)    100%
LIMA SWEDEN AB    Box 180 - SE-184 22 Akersberga - (Sweden)    (SEK)    100%

LIMA SWITZERLAND

SA

   Birkenstrasse, 49 - 6343 Rotkreuz - Zug - (Switzerland)    (CHF)    100%
TASFIYE HALINDE LIMA TURKEY ORTOPEDI AS    Serifali Mah. Hendem Cad.No: 54 Canan Residence OFIS A-2,34775 - UMRANIYE - Istanbul - (Turkiye)    (TRY)    100%
LIMA USA Inc.    2001 NE Green Oaks Blvd, Suite 100 - Arlington, TX 76006 - (United States)    (USD)    100%

LIMA SM S.p.A. in

liquidazione

   Strada Borrana, 38 - Serravalle 47899 - (Repubblica di San Marino)    (EUR)    100%

LIMA (BEIJING) MEDICAL DEVICES CO.,

LTD.

   Room 616, 6/F, Building 1, No.1, Lize Zhong 2 Road, Chaoyang District, Beijing, China    (CNY)    100%

LIMA ORTHOPAEDICS

CANADA INC.

   3715 Laird Road Suite Unit 9, Mississauga, ON, Canada    (CAD)    100%

Subsidiaries are those companies over which the group has control, as defined by IFRS 10 Consolidated financial statements. Control exists when the group has the power to, directly or indirectly, govern the financial and operating policies of an entity so as to obtain benefits from its activities. The financial statements of subsidiaries are included in the consolidated financial statements starting from when control is assumed and until such control ceases to exist.

 

12


Subsidiaries are included in the consolidation scope from when the group acquires control, as defined above, and are excluded from when the group no longer has control.

On 1 January 2023, the subsidiary TechMah Medical LLC was merged by incorporation into the subsidiary Lima USA Inc.

The interim reporting date of all of the consolidated companies is 30 June.

The basis of consolidation is set out below:

 

   

The line-by-line method, showing the portions of equity and profit or loss for the year attributable to non-controlling interests and recognising assets, liabilities, revenue and costs regardless of the percentage held in the subsidiaries.

 

   

Eliminating items deriving from intragroup transactions involving consolidated companies, including any unrealised gains and losses arising from intragroup transactions and recognising the resulting deferred tax effects.

 

   

Eliminating intragroup dividends and reallocating them to opening equity reserves.

 

   

Eliminating the carrying amount of investments in consolidated companies and the relevant portion of equity, allocating the resulting positive and negative differences to the relevant captions (assets, liabilities and equity), as defined at the time of acquisition of the investment and considering any subsequent variations. After control is acquired, any acquisitions of non-controlling interests or sales of shares to non-controlling interests that do not entail loss of control are recognised as owner transactions and the relevant effects are taken directly to equity. Any differences between the change in equity attributable to non-controlling interests and cash and cash equivalents exchanged are recognised under changes in equity attributable to the owners of the parent.

 

   

The financial statements of foreign operations are translated into Euros using the annual average rate for income statement items and the closing rate for statement of financial position items. The difference between the two rates along with the translation differences deriving from changes in opening and closing exchange rates are recognised as changes in equity.

The following rates were applied in translating the financial statements of foreign operations:

 

Currency

   Average rate
2023
     Closing rate:
30/06/2023
     Average rate
2022
     Closing rate:
30/06/2022
 

AUD - Australian dollar

     1.5989        1.6398        1.5204        1.5099  

BRL - Brazilian real

     5.4827        5.2788        5.5565        5.4229  

CAD - Canadian Dollar

     1.4565        1.4415        1.3900        1.3425  

CHF - Swiss franc

     0.9856        0.9788        1.0319        0.9960  

CNY - Yuan Renminbi

     7.4894        7.8983        7.0823        6.9624  

CZK - Czech koruna

     23.6873        23.7420        24.6485        24.7390  

DKK - Danish krone

     7.4462        7.4474        7.4402        7.4392  

GBP - Pound sterling

     0.8764        0.8583        0.8424        0.8582  

HRK - Croatian kuna

     n.a.        n.a.        7.5415        7.5307  

JPY - Japanese yen

     145.7604        157.16        134.3071        141.5400  

KRW - South Korean won

     1400.43        1435.88        1,347.8        1351.6000  

NZD - New Zealand dollar

     1.7318        1.7858        1.6491        1.6705  

PLN - Polish zloty

     4.6244        4.4388        4.6354        4.6904  

SEK - Swedish krona

     11.3329        11.8055        10.4796        10.7300  

TRY - Turkish lira

     21.5662        28.3193        16.2579        17.3220  

USD - US dollar

     1.0807        1.0866        1.0934        1.0387  

ZAR - South African rand

     19.6792        20.5785        16.8485        17.0143  

 

13


[2.4] Basis of presentation

[2.4.1] Business combinations and goodwill

Business combinations are recognised using the acquisition method under IFRS 3. To this end, the acquired identifiable assets and the assumed liabilities are recognised at their respective acquisition-date fair value. The consideration transferred in a business combination is the aggregate of the fair value, at the date of exchange, of assets acquired, assumed liabilities and equity instruments issued by the acquirer, in exchange for control of the acquiree.

Goodwill is the positive difference between the consideration transferred, increased by both the fair value at the acquisition date of any non-controlling interests already held in the acquiree and the amount of non-controlling interests held in the acquiree by third parties (measured at fair value or based on the present value of the acquiree’s identifiable net assets), and the fair value of such assets and liabilities.

At the acquisition date, goodwill is allocated to the single cash-generating unit that is expected to benefit from the synergies of the business combination.

If the difference between the consideration transferred (increased by the above components) and the fair value of the net assets acquired is negative, this is recognised as a gain from a bargain purchase in the income statement in the year of acquisition.

Any goodwill related to non-controlling interests is included in the carrying amount of the relevant equity investments.

After initial recognition, goodwill is not amortised and is recognised net of any cumulative impairment losses, calculated using the methods set out in section [2.4.6] Impairment losses on assets.

As set out in section [3.2] Goodwill of this report, the market multiples method is used to determine the fair value of goodwill, using listed comparable companies (these multiples are compared with the implicit multiple calculated using the group’s actual figures), except for CGU TechMah for which the value in use is defined using estimated future cashflows by applying a discount rate.

IFRS 3 is not applied retrospectively to business combinations that took place prior to 1 January 2018, i.e., the date of the parent’s transition to the IFRS. Accordingly, the amount of goodwill determined under the previous reporting standards, i.e., the carrying amount at such date, is maintained for such business combinations, subject to the recognition of any impairment losses.

[2.4.2] Intangible assets

An intangible asset is an identifiable asset without physical substance, controlled by the group and that generates future economic benefits, in addition to goodwill when acquired against consideration.

Identifiability is defined with reference to the possibility of distinguishing the intangible asset acquired from goodwill. An intangible asset is identifiable when it: (i) arises from a legal or contractual right or (ii) is separable, i.e., can be sold, transferred, licensed, rented, or exchanged, either individually or together with a related contract. An entity controls an asset if it has the power to obtain the future economic benefits flowing from the underlying resource and to restrict the access of others to such benefits.

Intangible assets are stated at cost, which is determined in same manner as for property, plant and equipment.

Intangible assets with finite useful lives are amortised over their estimated useful lives starting from when they are available for use.

The amortisation rates adopted in 2022 and 2023 are shown in the following table by asset category:

 

Description

  

2023 - 2022 (*)

Start-up and capital costs

   3 - 4 - 5 years

Development expenditure

   5 - 10 years

Patents and intellectual property rights

   10 - 20 years

Licences, trademarks and similar rights

   3 - 4 - 5 years

Other

   Contract term/Maximum 6 years

 

*

There were no changes to the amortisation rates

 

14


Development expenditure

Development expenditure is expensed when incurred.

Development expenditure incurred for a specific project is only capitalised when the group can demonstrate the technical feasibility of completing the intangible asset so that it will be available for use and for sale, its intention to complete such asset and use or sell it, how the intangible asset will generate probable future economic benefits, the availability of adequate technical, financial and other resources to complete the development and its ability to measure reliably the expenditure attributable to the intangible asset during its development.

Subsequent to initial recognition, development expenditure is measured at cost less any accumulated amortisation and any accumulated impairment losses. Amortisation of the asset starts from when the development phase has been completed and the asset is available for use. The asset is amortised over the period for which the underlying project is expected to generate revenue for the group.

Patents and intellectual property rights

Patents and intellectual property rights refer to costs for patents owned by Limacorporate S.p.A.

Licences, trademarks and similar rights

This caption refers to costs to file and register trademarks and costs incurred to acquire commercial licences. The acquisition costs are amortised over a period equal to the useful life of the acquired right.

Other intangible assets

This caption refers to leasehold improvements carried out in prior years. The capitalised costs are amortised on the basis of the residual term of the relevant lease contract.

[2.4.3] Property, plant and equipment

Property, plant and equipment are recognised at acquisition or production cost including directly attributable costs incurred to ready the asset for its intended use. Such cost includes costs to replace parts of equipment and plant when they are incurred if they meet the recognition requirements.

Assets acquired under business combinations before 1 January 2018 (the date of the parent’s e to the IFRS) are recognised at their pre-existing carrying amount, determined within such business combinations in accordance with the previous reporting standards, i.e., at deemed cost.

The carrying amount (cost less accumulated depreciation and cumulative impairment losses) of the replaced parts of equipment and plant is taken to profit or loss at the time of replacement.

Maintenance and repair costs, which do not add to the value of the assets and/or prolong their residual useful lives, are expensed when incurred. Otherwise they are capitalised.

Property, plant and equipment are stated net of any accumulated depreciation and any cumulative impairment losses determined using the methods set out below. Depreciation is calculated on a straight-line basis over the estimated useful life of the asset for the group.

 

15


The depreciation rates used are shown in the following table by asset category:

 

     2023      2022  

Buildings

     3%        3%  

Light constructions

     10%        10%  

Generic and specific plant

     10% - 15.5%        10% - 15.5%  

Machinery

     15.5%        16%  

Sundry and small equipment

     25%        25%  

Production equipment

     10%        10%  

Office furniture and machines

     12%        12%  

Electronic office machines

     20%        20%  

Transport vehicles

     20%        20%  

Cars

     25%        25%  

Right-of-use assets

     Lease term        Lease term  

The residual value of the assets, the useful life and the depreciation method applied are reviewed at each periods end and adjusted prospectively if necessary.

If significant parts of an item of property, plant and equipment have different useful lives, such parts are recognised separately. Land, free of construction or annexed to buildings, is recognised separately and is not depreciated since it has an unlimited useful life.

The carrying amount of an item of property, plant and equipment and every significant part initially recognised is eliminated on disposal or when no future economic benefits are expected from its use or disposal. The gain or loss arising from the derecognition of the item (calculated as the difference between the carrying amount of the asset and the net disposal proceeds) is included in profit or loss when the item is derecognised.

[2.4.4] Leases

If a contract contains a lease, at the commencement date, the lessee shall recognise an asset representing its right to use the underlying leased asset and a lease liability representing its obligation to make lease payments. The lessee shall recognise interest on the lease liability and depreciation of the right-of-use asset separately. At inception of a contract, the entity shall assess whether the contract is, or contains, a lease. The contract is, or contains, a lease if it conveys the right to control the use of an identified asset for a period of time in exchange for consideration.

[2.4.5] Equity investments

Investments in associates are measured using the equity method, recognising the group’s share of the profits or losses for the period in the income statement, with the exception of the effects related to other changes in the equity of the investee, other than owner transactions, that are directly recognised in other comprehensive income.

In the event of losses exceeding the carrying amount of the equity investment, the excess is recognised in a specific provision to the extent the parent is obliged to fulfil legal or constructive obligations to the investee or to cover its losses.

Investments in other companies are measured at fair value and the fair value gains and losses are taken to equity. If fair value cannot be reliably determined, they are measured at cost, adjusted for any impairment losses.

[2.4.6] Impairment losses

At the reporting date, the carrying amount of property, plant and equipment, intangible assets, financial assets and equity investments is tested for indicators of impairment. Should such indicators exist, the group estimates the recoverable amount of the asset to check the recoverability of the carrying amount and determine any impairment loss to be recognised. Intangible assets with indefinite useful lives or not yet available for use are tested for impairment at least annually, irrespective of whether any indication of impairment exists, or more frequently if an indication of impairment exists.

In order to identify impairment losses, assets are grouped into the smallest identifiable group of assets that generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets (the cash-generating unit, CGU). Reference should be made to section [3.2] Goodwill for details of the group’s CGU. The recoverable amount of an asset or a CGU is the higher of its value in use and its fair value less costs to sell.

 

16


The market multiples method is used to determine the value in use using listed comparable companies. These multiples are compared with the implicit multiple calculated using the group’s actual figures. When the carrying amount of an asset or a CGU exceeds its recoverable amount, the group recognises an impairment loss in profit or loss. Impairment losses on the CGU are allocated first to reduce the carrying amount of any goodwill allocated to it and then to the other assets of the CGU pro rata on the basis of their carrying amounts. Impairment losses on goodwill cannot be reversed. Impairment losses on other assets are reversed to the carrying amount that would have been determined (net of amortisation and depreciation) had no impairment losses been recognised in prior periods.

[2.4.7] Financial instruments

The financial instruments held by the group are described below.

Financial assets

Financial assets include equity investments, loans and borrowings, as well as derivatives with a positive fair value, trade receivables and other assets, in addition to cash and cash equivalents.

Specifically, cash and cash equivalents include cash, bank deposits and highly marketable securities that are readily convertible to cash and are subject to an immaterial risk of changes in value.

Financial assets represented by debt instruments are classified in the consolidated financial statements and measured using the business model adopted by the group for managing financial assets and based on the cash flows related to each financial asset. Financial assets also include equity investments not held for trading. Such assets are strategic investments, and the group has opted to recognise fair value gains or losses thereon through profit or loss (fair value through profit or loss, FVTPL).

Financial assets are tested for impairment using a model based on expected credit losses.

Financial liabilities

Financial liabilities include loans and borrowings, as well as derivatives with a negative fair value, trade payables and other liabilities.

Financial liabilities are classified and measured at amortised cost, with the exception of those initially measured at fair value, e.g., financial liabilities related to considerations for business combinations and derivatives and financial liabilities for options on non-controlling interests.

Derecognition of financial assets and liabilities

A financial asset or liability (or, where applicable, part of a financial asset/liability or part of a group of similar financial assets/liabilities) is derecognised when the group unconditionally transfers the contractual rights to receive the cash flows of the financial asset or the obligation to make payments or fulfil other obligations related to the liability.

Derivatives and hedging transactions

To cover-interest-rate risks, interest-rate swap contracts are generally used. All derivatives are measured at fair value. If an economic hedge does not qualify for hedge accounting, then any derivative used is measured at fair value with all changes in fair value recognised in profit or loss. These changes will not be offset by gains or losses on the hedged item when the hedged item is not also measured at FVTPL.

[2.4.8] Inventories

Raw materials and packaging are measured at the lower of purchase cost and estimated replacement value based on market trends. The cost is calculated using the weighted average cost for the period.

Semi-finished products and finished goods are measured at purchase or production cost, considering their stage of completion, or their realisable value based on market trends, if lower. The production cost includes the reasonably attributable portion of direct and indirect manufacturing costs.

 

17


The resulting amount is written down through the allowance for inventory write-down to account for items whose expected realisable value is lower than their cost.

[2.4.9] Trade receivables and other assets and trade payables and other liabilities

Trade receivables and other assets that derive from the supply of credit facilities, goods or services to third parties are classified under current assets, except when they are due after one year of the reporting date with reference to loans and receivables. If they have a set due date, current and non-current loans and receivables, other current and non-current assets and trade receivables, with the exception of derivatives, are measured at amortised cost calculated using the effective interest method. If they do not have a set due date, financial assets are measured at cost. Loans and receivables due after one year that are non-interest bearing or accruing interest lower than market rates are discounted using market rates.

The above financial assets are measured using the expected credit loss impairment model introduced by IFRS 9.

Trade payables and other liabilities that arise from the acquisition of credit facilities, goods or services from a third part supplier are classified under current liabilities, except when they are due after one year of the reporting date with reference to loans and borrowings.

On initial recognition, current and non-current loans and borrowings, other current and non-current liabilities and trade payables are stated at fair value, which normally coincides with the transaction price including transaction costs. Subsequently, with the exception of derivatives, all financial liabilities are measured at amortised cost calculated using the effective interest method. Hedged financial liabilities are measured in accordance with hedge accounting.

[2.4.10] Employee benefits

The liability related to short-term employee benefits paid during the employment relationship is recognised on an accruals basis at the amount accrued at the reporting date.

The liability related to employee benefits paid upon or after termination of the employment relationship via defined benefit plans, is recognised at the amount accrued at the reporting date.

The liability related to employee benefits paid upon or after termination of the employment relationship via defined benefit plans, net of any plan assets and advances granted, is calculated using actuarial assumptions and recognised on an accruals basis in line with the service needed to obtain the benefits. Such liability is calculated by independent actuaries. The gain or loss deriving from the actuarial calculation is fully recognised in the statement of comprehensive income.

Defined benefit plan liabilities are measured using the actuarial assumptions set out in section [3.15] Employee benefits.

[2.4.11] Provisions for risks and charges

The provisions for risks and charges are recognised when the group has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

The amount recognised as a provision is the best estimate of the expenditure required to settle the present obligation or transfer it to third parties at the reporting date. Where the effect of the discounting is material, the provisions are calculated by discounting the estimated future cash flows at a rate that reflects current market assessments of the time value of money. When discounting is used, the carrying amount of the provision increases to reflect the passage of time and this increase is recognised as borrowing cost.

[2.4.12] Share-based payments

The grant-date fair value of equity-settled share-based payment arrangements granted to employees is generally recognised as an expense, with a corresponding increase in equity, over the vesting period of the awards. The amount recognised as an expense is adjusted to reflect the number of awards for which the related service and non-market performance conditions are expected to be met, such that the amount ultimately recognised is based on the number of awards that meet the related service and non-market performance conditions at the vesting date. For share-based payment awards with non-vesting conditions, the grant-date fair value of the share-based payment is measured to reflect such conditions. With regard to non-vesting conditions, any differences between expected and actual outcomes do not have an impact on the consolidated financial statements.

 

18


The fair value of the amount payable to employees in respect of cash-settled share-based payments is recognised as an expense with a corresponding increase in liabilities, over the period during which the employees become unconditionally entitled to payment. The liability is remeasured at each reporting date and at the settlement date based on the fair value of the share-based payments. Any fair value gains or losses are recognised in profit or loss.

The parent has agreements with some managers for the award of options and/or shares (see section [4.7] Management Incentive plans).

[2.4.13] Revenue and expense

Based on the five-step model introduced by IFRS 15, the group recognises revenue after identifying the contract(s) with a customer and the performance obligations in the contract (transfer of goods and/or services), determining the transaction price to which it expects to be entitled in exchange for fulfilling performance obligations (at a point in time or over time). Revenue is measured on the basis of the transaction price excluding amounts collected on behalf of third parties. Based on the group’s internal analysis of contracts with customers, the group has not identified any performance obligations that are satisfied over time and, therefore, the group recognises revenue upon the transfer of control of the promised goods or services to the customer. Revenue is measured to the extent that it is probable that the economic benefits will flow to the group and the amount can be measured reliably.

Revenue is adjusted for any discounts and volume rebates allowed by the group in contracts with customers and for the payback (variable considerations).

Expense is recognised when the goods and services are sold or consumed during the period or by systematic allocation, or when it is not possible to identify their future use.

Expense items are classified by nature in accordance with the applicable IFRS.

[2.4.14] Government grants

Grants are recognized when there is reasonable assurance that the grant will be received.

Grants related to income are taken to profit or loss in the period in which the relevant expense is recognised.

Grants related to assets received for projects and development activities are recognised under liabilities and subsequently recognised under operating revenue in line with the amortisation and depreciation of the relevant assets.

Grants due for investments in research and development are recognised in line with the progress of the research, calculated on the basis of the progress reports issued to the relevant bodies and the stage of completion reported by those in charge of the research, if all requirements for their disbursement are met.

[2.4.15] Financial income and expense

Financial income and expense are recognised on the basis of interest accrued on the net amount of the relevant financial assets and liabilities, using the effective interest method.

[2.4.16] Dividends

Dividends are recognised when the shareholder’s right to receive payment is established.

[2.4.17] Income taxes

Income taxes recognised in profit or loss are the sum of current and deferred taxes.

 

19


Income taxes for the period are determined on the basis of ruling legislation. They are recognised in profit or loss, except for those related to items recognised directly in equity, for which the tax effect is accounted for directly in equity.

Income tax payables are recognised under current tax liabilities, net of advances paid. Any tax credits are recognised under current tax assets.

Deferred tax assets and liabilities are calculated on the temporary differences between the carrying amounts of assets and liabilities (resulting from the application of the accounting policies set out in note 4 “Basis of presentation”) and their tax bases (deriving from the application of the tax legislation ruling in the country of the subsidiaries). Current and deferred tax assets and liabilities are offset when the group has the legally enforceable right to offset.

Deferred taxes are calculated using the tax rates expected to be enacted in the periods in which the temporary differences will be recovered or settled. Deferred tax assets and liabilities are not discounted.

Deferred tax assets are recognised on temporary differences and to the extent that it is probable the group will have future taxable profits that will allow their recovery.

[2.4.18] Fair value

IFRS 13 is a common framework for fair value measurement and relevant disclosure when this measurement is required or allowed by other IFRS. Specifically, the standard sets out the definition of fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

IFRS 13 establishes a hierarchy that categorises the inputs used in the valuation techniques adopted to measure fair value into different levels, as follows:

 

   

level 1: quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity has the ability to access at the measurement date;

 

   

level 2: inputs other than quoted prices included in Level 1 that are observable for the assets or liabilities, either directly or indirectly;

 

   

level 3: inputs for the assets or liabilities that are not based on observable market data (unobservable inputs).

In some cases, the inputs used to measure the fair value of an asset or a liability might be categorised within different levels of the fair value hierarchy. In those cases, the fair value measurement is categorised in its entirety in the same level of the fair value hierarchy as the lowest level input that is significant to the entire measurement.

The group recognises transfers among the different levels of the fair value hierarchy at the end of the periods in which the transfer took place.

Reference should be made to the notes to the individual financial statements’ items for the definition of the fair value hierarchy level used to classify the individual instruments measured at fair value or whose fair value is disclosed.

The fair value of derivatives is calculated by discounting estimated cash flows using the market interest rates at the reporting date and the credit default swaps issued by the counterparty and group companies, to include the non-performance risk explicitly provided for under IFRS 13.

Where market prices are not available, the fair value of non-derivative medium/long-term financial instruments is calculated by discounting estimated cash flows using the market interest rates at the reporting date and considering counterparty risk for financial assets and credit risk for financial liabilities.

[2.4.19] Use of estimates

In preparing the condensed consolidated interim financial statements, the directors were required to apply accounting policies that are, at times, based on judgements or past experience or assumptions deemed reasonable and realistic at the time, depending on the relevant circumstances. The application of such estimates and assumptions impacts the carrying amounts recognised in the statement of financial position, income statement, statement of comprehensive income and statement of cash flows, in addition to the disclosure provided. The end results of the assessments in which such estimates and assumptions were used may differ from those recognised in the consolidated financial statements due to the inherent uncertainty of the assumptions and the conditions underlying the estimates.

 

20


Actual results may differ from those estimated. Estimates and assumptions are reviewed on an ongoing basis. The effect of a change in accounting estimates is recognised in profit or loss in the period of the change, if the change affects that period only, or the period of the change and future periods, if the change affects both.

Estimates mainly refer to the following captions:

 

   

impairment losses on non-current assets and goodwill;

 

   

loss allowance;

 

   

allowance for inventory write-down;

 

   

recoverability of deferred tax assets;

 

   

estimate of the provisions for risks and contingent liabilities;

 

   

financial liabilities;

 

   

employee incentive plans.

Impairment losses on non-current assets and goodwill

Non-current assets include property, plant and equipment, intangible assets including goodwill and other financial assets.

Management periodically revises the carrying amount of non-current assets held and used and assets held for sale when events and circumstances require such revision. This is performed using the estimates of cash flows the group expects to derive from using or selling the asset and suitable discount rates for calculating the present value.

When the carrying amount of a non-current asset has been impaired, the group recognises an impairment loss equal to the excess between the carrying amount and the amount to be recovered through use or sale of the asset, determined using the parent’s or group’s most recent plans. Reference should be made to note [3.28] Impairment losses.

Loss allowance

The loss allowance is management’s best estimate of the potential credit losses on trade receivables from end customers. Reference should be made to note [3.9] Trade receivables and other assets and [3.19] trade payables and other liabilities for a description of the criteria used in estimating the allowance.

Allowance for inventory write-down

Inventories of slow-moving raw materials and finished goods are periodically analysed on the basis of historical data and the possibility of selling them at prices lower than normal market transactions. If, as a result, the carrying amount of inventories needs to be written down, the group recognises a specific allowance for inventory write-down.

Recoverability of deferred tax assets

The group pays taxes in numerous countries and some estimates are required to calculate the taxes in each jurisdiction. It recognises deferred tax assets to the extent that it is probable that future taxable profits will be available and over a period of time compatible with the time horizon implicit in the management estimates.

Estimate of the provisions for risks and contingent liabilities

The group could be subject to legal and tax disputes regarding a vast range of issues that are subject to the jurisdiction of various countries. Disputes and litigation against the group are subject to a different degree of uncertainty, including the facts and circumstances inherent to each dispute, the jurisdiction and different applicable laws. In the ordinary course of business, management consults its legal consultants and legal and tax experts. The group recognises a liability for such disputes when it is deemed probable that they will result in an outflow of resources and when the amount of the resulting losses can be reasonably estimated. If an outflow of resources is possible but the amount cannot be determined, such fact is disclosed in the notes to the consolidated financial statements.

 

21


Employee incentive plans and financial liabilities

Reference is made to section [4.7] for a description of the calculation of the fair value of share-based payments as part of group management incentive plans.

Section [3.16] provides details of the calculation of fair value of the group’s financial liabilities.

[2.4.20] Translation of foreign currency items

The financial statements of each consolidated company are prepared using the functional currency related to the economy where each company operates. Transactions in currencies other than the functional currency are recognised at the exchange rate at the date of the transaction. Foreign currency monetary assets and liabilities are subsequently translated at the closing rate and any exchange differences are taken to profit or loss. Foreign currency non-monetary assets and liabilities recognised at historical cost are translated using the exchange rate at the date of the transaction.

For consolidation purposes, the foreign currency financial statements prepared for consolidation purposes of the consolidated companies are translated using the closing rates for asset and liability captions, including goodwill and consolidation adjustments, and the average rate for the period (if similar to the respective transaction-date rates) or the period under consolidation, if lower, for income statement captions. The relevant exchange differences are taken directly to the statement of comprehensive income and reclassified to profit or loss when control over the investee is lost and, thus, it is deconsolidated.

[2.4.21] Operating segments

An operating segment is a component of an entity:

 

   

that engages in business activities from which it may earn revenue and incur expenses (including revenue and expenses relating to transactions with other components of the same entity);

 

   

whose operating results are regularly reviewed by the entity’s chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance; and

 

   

for which discrete financial information is available.

Note [4.1] provides information about the single operating segment identified.

[2.4.22.1] New standards and interpretations applicable from 1 January 2023

The amendments to the IFRS adopted during the period included:

 

Document Title

  

Issued Date

  

Effective Date

IFRS 17, ‘Insurance contracts’    December 2021    Annual periods beginning on or after 1 January 2023.
Narrow scope amendments to IAS 1, Practice statement 2 and IAS 8    February 2021    Annual periods beginning on or after 1 January 2023
Amendment to IAS 12 – deferred tax related to assets and liabilities arising from a single transaction    May 2021    Annual periods beginning on or after 1 January 2023
Amendment to IAS 12 – International tax reform – pillar two model rules    May 2021    23 May 2023

 

22


There are not any material impact from the application of these amendments.

[2.4.22.2] Other Standards

 

Document Title

  

Issue date by IASB

  

Effective date of IASB document

Amendments      
Sale or Contribution of Assets between an Investor and its Associate or Joint Venture (Amendments to IFRS 10 and IAS 28)    September 2014    Deferred until the completion of the IASB project on the equity method
Amendment to IAS 1 – Non-current liabilities with covenants    October 2022    1 January 2024
Amendment to IFRS 16 – Leases on sale and leaseback    September 2022    1 January 2024

The group will adopt such new standards and amendments, on the basis of the relevant application date, and will assess the potential impacts on the consolidated financial statements. There are not any material impact from the application of these amendments.

[3] Notes to the condensed consolidated interim financial statements

Below are comments on the statement of financial position captions as at 30 June 2023. For details on statement of financial position captions deriving from related party transactions, reference should be made to note [4.5] Related party transactions.

[3.1] Other intangible assets

The carrying amount of other intangible assets at each period is as follows:

 

   

€21,204 thousand at 30 June 2023;

 

   

€58,234 thousand at 31 December 2022;

Changes in other intangible assets between 30 June 2023 and 31 December 2022 and a breakdown of historical cost, accumulated amortisation and any cumulative impairment losses are summarised in the following tables.

 

(€‘000)  
     31/12/2022      Exchange
difference
    Increases      Reclassifications     Decreases     Amortisation     30/06/2023  

Development expenditure

     37,118        (472     21        —        (35,574     (172     922  

Industrial patents and intellectual property rights

     2,208        (0     130        —        (0     (180     2,158  

Concessions, licences, trademarks and similar rights

     5,900        40       501        27       (150     (1,599     4,719  

Assets under development and payments on account

     12,507        (9     1,512        86       (1,012     —        13,084  

Other

     500        (12     —         (113     —        (55     321  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

Total

     58,234        (452     2,164        0       (36,735     (2,006     21,204  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

 

 

23


(€‘000)  
     Historical cost      30/06/2023
Accumulated amortisation
     Carrying amount  

Development expenditure

     1,726        804        922  

Industrial patents and intellectual property rights

     3,671        1,513        2,158  

Concessions, licences, trademarks and similar rights

     19,951        15,232        4,719  

Assets under development and payments on account

     13,084        —         13,084  

Other

     1,583        1,262        321  
  

 

 

    

 

 

    

 

 

 

Total

     40,015        18,811        21,204  
  

 

 

    

 

 

    

 

 

 

Intangible assets with an indefinite useful life only comprise goodwill, while the other assets (development expenditure, industrial patents and intellectual property, concessions, licences, trademarks and similar rights, other intangible assets and assets under development and payments on account) all have a finite life. More information on each item is provided below.

Capitalized development expenditure amounts to €922 thousand at 30 June 2023 compared to €37,118 thousand at 31 December 2022. The significant decrease is mainly due to the write-off, made in the first half of 2023, of developments costs related to TechMah business, as consequence of the interruption of the project and the subscription of a new partnership with a software supplier on shoulder preoperative planning.

The decision to interrupt the project was formalized by an internal communication issued on 7 July 2023 by the new CEO, who was appointed on 12 September 2022, after investing several months in reviewing the pre-existing technologies strategy and consequently re-defining the strategy for 2023 and further years. See also [4.8] Events after the reporting date.

Industrial patents and intellectual property rights, amounting to € 2,158 thousand and €2,208 thousand at 30 June 2023 and 31 December 2022, respectively, are comprised of costs incurred by Limacorporate S.p.A. to acquire patents in half of 2023 and previous period.

Concessions, licences, trademarks and similar rights amounting to €4,719 thousand and €5,900 thousand at 30 June 2023 and 31 December 2022, respectively. The amount is mainly referred to the parent cost to register Lima products on the European, US, Chinese, Korean and Japanese markets.

Assets under development and payments on accounts, amounting to €13,084 thousand and €12,507 thousand at 30 June 2023 and 31 December 2022, respectively.

[3.2] Goodwill

Goodwill amounts to €384,286 thousand and €384,216 thousand at 30 June 2023 and 31 December 2022, respectively.

Pursuant to IAS 36, goodwill is not subject to amortisation, but is tested for impairment at least annually or more frequently if events or circumstances indicate that it might be impaired. With regard to testing goodwill for impairment, the group identified a two operating CGUs for its operations, one for the Group except TechMah (“Group CGU”) and one related to TechMah.It considered the sources of information set out by IAS 36 such as the fact that management monitors the group’s performance and takes strategic decisions about its product offering and investments at group level.

The goodwill recognised in Limacorporate condensed consolidated interim financial statements in relation to the above-mentioned merger, together with other items of goodwill, was tested for impairment as at 31 December 2022. Specifically, the recoverable amount of the group’s assets was calculated by estimating their fair value and comparing it with the carrying amount of consolidated net invested capital at 31 December 2022 in order to examine whether recognised amounts had to be impaired.

At 30 June 2023 management evaluated that there are no indicators of triggering events which required to update the impairment test of Group CGU performed at 31 December 2022. In the context of the acquisition of Limacorporate Group by Enovis, the enterprise value shows the full recoverability of goodwill (25 September 2023 public information are available on Enovis Corporation website: “€800 million transaction includes a cash payment of €700 million at closing, and €100 million in shares of Enovis common stock expected to be issued within 18 months after closing…”).

 

24


Given the decision taken in early July by the management to interrupt the Smart Space project, an impairment test of TechMah CGU has been performed and led to the full write-off of the capitalized cost of Techmah CGU at 30 June 2023. See also [4.8] Events after the reporting date.

[3.3] Property, plant and equipment

The carrying amount of property, plant and equipment and other assets at each period end is as follows:

 

   

€78,292 thousand at 30 June 2023;

 

   

€79,837 thousand at 31 December 2022.

Changes in property, plant and equipment assets between 30 June 2023 and 31 December 2022 and a breakdown of historical cost, accumulated amortisation and any cumulative impairment losses are summarised in the following tables:

 

(€‘000)  
     31/12/2022      Exchange
difference
    Increases      Reclassifications     Decreases     Depreciation     Other
changes
    30/06/2023  

Land and buildings

     15,496        —        11        —        —        (341     —        15,165  

Leased land and buildings

     6,755        (91     822        —        —        (1,637     390       6,239  

Plant and equipment

     16,416        (19     764        83       —        (2,028     —        15,216  

Leased plant and equipment

     79        —        —         —        —        (8     —        71  

Industrial and commercial equipment

     34,674        (252     6,942        45       (449     (7,902     —        33,056  

Leased industrial and commercial equipment

     19        (0     45        —        —        (10     —        54  

Other assets

     1,787        (23     361        —        (1     (316     —        1,807  

Other leased assets

     2,299        (22     886        —        —        (717     (9     2,438  

Assets under construction and payments on account

     2,311        (1     2,252        (128     (190     —        —        4,245  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

Total

     79,837        (408     12,083        0       (640     (12,961     381       78,292  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

   

 

 

   

 

 

   

 

 

 

 

(€‘000)  
     30/06/2023  
     Historical
cost
     Accumulated
depreciation
     Accumulated
impairment
losses
     Carrying
amount
 

Land and buildings

     23,881        8,716        —         15,165  

Leased land and buildings

     19,624        13,385        —         6,239  

Plant and equipment

     59,959        44,743        —         15,216  

Leased plant and equipment

     202        130        —         71  

Industrial and commercial equipment

     142,399        109,087        256        33,056  

Leased industrial and commercial equipment

     74        20        —         54  

Other assets

     8,207        6,400        —         1,807  

Other leased assets

     5,392        2,954        —         2,438  

Assets under construction and payments on account

     4,435        —         190        4,245  
  

 

 

    

 

 

    

 

 

    

 

 

 

Total

     264,173        185,435        446        78,292  
  

 

 

    

 

 

    

 

 

    

 

 

 

Land and building, amounting to €15,165 thousand at 30 June 2023 and €15,496 thousand at 31 December 2022. The decrease occurred during the first half of 2023 is mainly due to the amortization effect.

Plant and equipment, amounting to €15,216 thousand at 30 June 2023 and €16,416 thousand at 31 December 2022. The decrease in plant and equipment during the first half of 2023 mainly refers to the amortization effect. The investments of €764 thousand refer to the acquisition of production machines.

Industrial and commercial equipment amounting to €33,056 thousand and €34,674 thousand at 30 June 2023 and 31 December 2022, respectively and is chiefly comprised of equipment capitalised during the current and previous years. The decrease of €449 thousand is mainly due to write-off of obsoleted instrument sets.

Other assets amounting to €1,807 thousand and €1,787 thousand at 30 June 2023 and 31 December 2022, respectively. This category includes office furniture and machines, electronic office machines, transport vehicles and cars. Investments, during the first half of 2023 amounting to €361 thousand refer to purchases of electronic office machines and furniture.

 

25


Asset under construction amounting to €4,245 thousand and €2,311 thousand at 30 June 2023 and 31 December 2022, respectively. The increase in assets under construction and payments on account during 2023 is mainly due to costs incurred to expand the Villanova production facility and for the purchase of production equipment and machinery.

Some plant and equipment are subject to a special lien at the reporting dates. Additional information is provided in note [3.16] Current and non-current financial liabilities.

Changes in right-of-use assets deriving from the application of IFRS 16 are set out in the following tables, where such changes are shown for each asset category along with details on the historical cost and accumulated depreciation:

 

(€‘000)  
     31/12/2022      Exchange
difference
    Increases      Decreases      Depreciation     Other
changes
    30/06/2023  

Right-of-use assets

                 

Leased land and buildings

     6,755        (91     822        —         (1,637     390       6,239  

Leased plant and equipment

     79        —        —         —         (8     —        71  

Leased industrial and commercial equipment

     19        (0     45        —         (10     —        54  

Other leased assets

     2,299        (22     886        —         (717     (9     2,438  
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Total

     9,153        (113     1,753        —         (2,373     381       8,802  
  

 

 

    

 

 

   

 

 

    

 

 

    

 

 

   

 

 

   

 

 

 

Lease liabilities deriving from the application of IFRS 16 are included under current and non-current financial liabilities (analysed in note [3.16] Current and non-current financial liabilities). Changes in current and non-current lease liabilities between 30 June 2023 and 31 December 2022 are set out below:

 

(€‘000)  
     31/12/2022      Exchange
difference
    Increases      Decreases     Other
changes
     Reclassifications     30/06/2023  

Lease liabilities as per IFRS 16 - non-current portion

     4,552        (43     1,753        —        381        (1,340     5,303  

Lease liabilities as per IFRS 16 - current portion

     3,265        (43     1        (1,995     —         1,340       2,568  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Total

     7,817        (86     1,753        (1,995     381        —        7,871  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

The decrease in lease liabilities of €1,995 thousand refers to the payments of the period.

The increase of €1,753 thousand refers for about €700 thousand to new offices in Germany and for about €880 to other assets.

[3.4] Equity investments

Equity investments amount to €2 thousand as at 30 June 2023 and no changes in the caption occurred compared to 31 December 2022.

The following information is provided on direct and indirect equity investments in subsidiaries, associates and other companies.

Subsidiaries

On 1 January 2023, the subsidiary TechMah Medical LLC was merged by incorporation into the subsidiary Lima USA Inc.

Other companies

Equity investments in other companies amount to €2 thousand and refer to CAAF Interregionale dipendenti S.r.l., Consorzio Friuli Energia, Terra degli Elimi and CE.R.ME.T..at 30 June 2023.

 

26


[3.5] Deferred tax assets and liabilities

Deferred tax assets and liabilities are only offset when there is a legal provision within the same tax jurisdiction. The group recognised deferred tax assets and liabilities on the temporary differences between carrying amounts and tax bases. The latter were calculated using the rates ruling when the temporary differences will reverse in the different countries where the group operates.

Deferred tax assets and liabilities are broken down as follows on 30 June 2023 and 31 December 2022:

 

(€‘000)  
     30/06/2023      31/12/2022      Variation
2023 vs 2022
 

Deferred tax assets

     11,948        11,558        391  

Deferred tax assets arising on consolidation

     20,429        20,151        278  
  

 

 

    

 

 

    

 

 

 

Total

     32,377        31,709        668  
  

 

 

    

 

 

    

 

 

 

 

(€‘000)  
     30/06/2023      31/12/2022      Variation
2023 vs 2022
 

Deferred tax liabilities

     9,576        9,414        162  

Deferred tax liabilities arising on consolidation

     600        9,861        (9,261
  

 

 

    

 

 

    

 

 

 

Total

     10,176        19,275        (9,099
  

 

 

    

 

 

    

 

 

 

[3.6] Other non-current financial assets

Other non-current financial assets amounting to €906 thousand at 30 June 2023. The amount refers to fair value of Interest Rate Swap at 30 June 2023 subscribed in first half of 2023 as described in note [3.17] Derivatives.

[3.7] Other non-current assets

Other non-current assets, amounting to:

 

   

€967 thousand at 30 June 2023;

 

   

€861 thousand at 31 December 2022.

Refer to guarantee deposits, mainly for rental contracts taken out by the group.

[3.8] Inventories

A breakdown of inventories at 30 June 2023 and 31 December 2022 is provided below:

 

(€‘000)  
     30/06/2023      31/12/2022      Variation  

Raw materials and supplies

     6,489        6,272        216  

Work in progress and semi-finished products

     12,195        11,533        661  

Contract work in progress

     —         —         —   

Finished goods

     81,207        79,583        1,624  

Payments on account

     —         —         —   

Goods in transit

     1,077        831        246  

Allowance for inventory write-down

     (11,762      (11,492      (270
  

 

 

    

 

 

    

 

 

 

Total

     89,205        86,728        2,478  
  

 

 

    

 

 

    

 

 

 

Inventories were measured using the cost of the production company for the consolidated companies.

 

27


The allowance for inventory write-downs, amounting to €11,762 thousand at 30 June 2023 and €11,492 thousand at 31 December 2022, changed as follows during the period:

 

(€‘000)  

Balance at 31/12/2022

     11,492  

Exchange difference

     15  

Utilisations

     (825

Accruals

     1,081  
  

 

 

 

Balance at 30/06/2023

     11,762  
  

 

 

 

Utilisations of the allowance during the first half of 2023 is mainly referred to the scrapping of obsolete goods by Limacorporate S.p.A. and the accruals done by the subsidiaries and Limacorporate S.p.A..

[3.9] Trade receivables

Trade receivables at 30 June 2023 amount to €79,106 thousand, compared to €70,161 thousand at 31 December 2022, and are broken down as follows:

 

(€‘000)  
     Gross amount      Loss allowance      Carrying amount
31/12/2022
 

Trade receivables - third parties

     72,527        2,387        70,140  

Trade receivables - related parties

     21        —         21  
  

 

 

    

 

 

    

 

 

 

Total

     72,548        2,387        70,161  
  

 

 

    

 

 

    

 

 

 

 

(€‘000)  
     Gross amount      Loss allowance      Carrying amount
30/06/2023
 

Trade receivables - third parties

     81,356        2,250        79,106  

Trade receivables - related parties

     —         —         —   
  

 

 

    

 

 

    

 

 

 

Total

     81,356        2,250        79,106  
  

 

 

    

 

 

    

 

 

 

The loss allowance amounts to €2,250 thousand and €2,387 thousand at 30 June 2023 and 31 December 2022, respectively.

The loss allowance is management’s estimate of the expected credit losses on trade receivables from customers. The estimate is based on the group’s expected credit losses, determined using past experience with similar receivables, current and historical overdue amounts, losses and collections, a careful monitoring of credit quality and forecasts of economic and market conditions.

Changes in the loss allowance in 2023 and 2022 are as follows:

 

(€‘000)  
     Amount  

Balance at 31/12/2022

     2,387  

Exchange difference

     8  

Accruals

     —   

Utilisations

     (144
  

 

 

 

Balance at 30/06/2023

     2,250  
  

 

 

 

The utilisations mainly refer to losses related to various positions against small different clients.

[3.10] Current tax assets

Tax assets amounting to €2,225 thousand and €2,087 thousand at 30 June 2023 and 31 December 2022, respectively and include direct taxes, particularly in relation to the parent’s IRES for €1,061 thousand at 30 June 2023 and 31 December 2022.

 

28


[3.11] Other current assets

Other current assets amounting to €12,371 thousand and €14,192 thousand at 30 June 2023 and 31 December 2022, respectively, and are broken down as follows:

 

(€‘000)  
     30/06/2023      31/12/2022      Variation  

Grants

     5,023        5,281        (258

Other tax assets

     859        827        32  

Advances to agents

     669        776        (107

VAT

     997        1,317        (320

Advances to suppliers

     807        1,327        (520

Hire and maintenance

     1,441        873        568  

Other sundry

     726        1,354        (628

VAT to be offset

     146        325        (179

Insurance premiums and sureties

     311        574        (263

Other

     1,391        1,538        (147
  

 

 

    

 

 

    

 

 

 

Total

     12,371        14,192        (1,821
  

 

 

    

 

 

    

 

 

 

Assets for research grants refer mainly to:

 

   

PON-SIB grant (€4,630 thousand at 30 June 2023 and €4,630 at 31 December 2022);

 

   

MCBEES grant (€0 at 30 June 2023 and €258 thousand at 31 December 2022);

 

   

AIM grant (€40 thousand at 30 June 2023 and €40 thousand at 31 December 2022);

 

   

IAREPAM grant (€158 thousand at 30 June 2023 and €158 thousand at 31 December 2022);

 

   

PROST3SIS grant (€195 thousand at 30 June 2023 and €195 thousand at 31 December 2022).

Other assets also include guarantee deposits on gas and electricity consumption (€472 thousand at 30 June 2023 and 31 December 2022).

Hire and maintenance amounting to €1,441 thousand and €873 thousand at 30 June 2023 and 31 December 2022, respectively. The increase is mainly due to prepayments of the new maintenance agreement.

[3.12] Cash and cash equivalents

Cash and cash equivalents amounting to €23,681 thousand and €25,920 thousand at 30 June 2023 and 31 December 2022, respectively.

This caption shows the group’s liquidity at the reporting date.

Reference should be made to the statement of cash flows for an analysis of changes in cash and cash equivalents.

 

(€‘000)  
     30/06/2023      31/12/2022      Variation
2023 vs 2022
 

Bank and postal accounts

     23,681        25,903        (2,222

Cash-in-hand and cash equivalents

     —         17        (17
  

 

 

    

 

 

    

 

 

 

Total

     23,681        25,920        (2,239
  

 

 

    

 

 

    

 

 

 

 

29


[3.13] Equity

Equity attributable to the owners of the parent amounts to €325,421 thousand and €306,564 thousand at 30 June 2023 and 31 December 2022, respectively and is broken down as follows:

 

(€‘000)  
     30/06/2023      31/12/2022      Variation
2023 vs 2022
 

Share capital

     9,868        9,868        —   

Share premium reserve

     14,425        14,425        —   

Legal reserve

     2,101        2,101        —   

Merger reserve

     288,261        288,261        —   

Capital contributions

     74,347        28,051        46,296  

Actuarial reserve

     31        31        —   

Translation reserve

     3,421        2,379        1,042  

Other reserves

     7,421        2,687        4,734  

Retained earnings (losses carried forward)

     (41,239      (21,966      (19,273

Profit (loss) for the year

     (33,217      (19,273      (13,944
  

 

 

    

 

 

    

 

 

 

Equity

     325,421        306,564        18,855  
  

 

 

    

 

 

    

 

 

 

Parent’s share capital at 30 June 2023 and 31 December 2022 is €9,868 thousand and is fully subscribed and paid up. It comprises of €9,868 thousand ordinary shares without a nominal amount.

The share premium reserve amounts to €14,425 thousand and it is unchanged during the period.

Legal reserve amount to €2,101 thousand at 31 June 2023 and €2,101 thousand at 31 December 2022. This reserve is not distributable. Merger reserve, amounting to €288,261 thousand at 30 June 2023 and 31 December 2022 and no changes during the period under analysis, comprises the effects of the reverse merger between the parent and Emil Holding III S.p.A. in October 2016 on equity.

Capital contribution for capital amounting to € 74,347 thousand at 30 June 2023 and € 28,051 thousand at 31 December 2022.

The transactions that affected this caption are summarised below:

 

  a.

€4,963 thousand for the contribution in kind made in 2021 by the shareholder for the acquisition of TechMah Medical.

The contribution in kind is directly related to the shared-based payment of certain milestones regarding the acquisition of TechMah Medical. Under the agreement signed in 2018, the subsidiary Lima USA allocated the founding shareholders of TechMah Medical a set number of new EmilNewCo Sarl (indirect parent of Limacorporate S.p.A. with a 100% interest) shares upon reaching set targets regarding the development of new products benefiting the group.

The above-mentioned allocation of shares in October 2021 led to a share capital increase for EmilNewCo and the recognition of an amount due from the founding shareholders of TechMah Medical equal to the liability recognised by Lima USA for the contractual milestones to be settled. The two transactions between the founding shareholders of Techmah Medical and Lima Group (EmilNewCo Sarl, Limacorporate S.p.A. and Lima USA) have been offset using claim notes, which generated the capital injection referred to above.

 

  b.

capital injection by the shareholder of €20,000 thousand in June 2020.

 

  c.

€3,088 thousand for the agreement with HSS (Hospital for Special Surgery). On 4 January 2019, Lima USA and HSS (the operator of the most prestigious US orthopaedic surgery hospital in New York) signed a collaboration agreement for the production of implants on hospital grounds, via the following agreements:

 

  I.

a six-year lease for the premises where Lima USA will produce the implants for HSS, of which payment for the first three years have been made by awarding HSS a fixed number of new Emil NewCo shares and the second three years will be paid by monthly instalments;

 

  II.

a supply contract which establishes that HSS will bear the cost of any leasehold improvements made by Lima USA and will receive a set number of new Emil NewCo shares in return.

The accounting effects of the above transaction with HSS are as follows:

 

   

recognition of other right-of-use assets for €1,793 thousand, lease liabilities of €875 thousand and other reserves of €918 thousand.

 

30


   

recognition of greater leasehold improvement costs of €2,170 thousand with a balancing increase of €2,170 thousand in other reserves.

 

  d.

Capital injection by the shareholder of €46,296 thousand in February 2023.

Actuarial reserve was set up as a result of application of IAS 19 for post-employment benefits and has a positive balance of €31 thousand at 30 June 2023 and 31 December 2022, respectively.

Translation reserve, with a positive balance of €3,421 thousand at 30 June 2023 and €2,379 thousand at 31 December 2022, reflects the changes in the group’s share of the equity of consolidated companies due to changes in exchange rates of such companies’ functional currencies compared to the presentation currency of the condensed consolidated interim financial statements.

The main items making up the other reserves are as follows:

 

   

the revaluation reserve, which arose from the merger of Lima S.p.A., amounts to €111 thousand and is recognised in compliance with Law no. 413 of 30 December 1991 in relation to deferred tax on the revalued amount of land and industrial buildings. There were no changes in the reserve during the three-year period.

 

   

the IFRS 2 reserve amounting to €9,383 thousand and €4,650 at 30 June 2023 and 31 December 2022, respectively, deriving from the accounting treatment of cash-settled share-based payment and equity-settled share-based payment arrangements, due to a new incentive plan signed by the company during the third part of 2022;

 

   

other sundry reserves of €1,764 thousand and €1,987 thousand at 30 June 2023 and 31 December 2022, respectively.

Retained earnings (losses carried forward) amount to a negative net balance of €34,294 thousand at 30 June 2023 and €15,021 thousand at 31 December 2022.

The following supplementary information is provided on the parent’s reserves:

1) Reserves or other provisions that do not contribute to the taxable profit of shareholders in the event of distribution regardless of when they are formed.

 

(€‘000)  
     30/06/2023      31/12/2022  

Emil Holding III merger reserve

     288,261        288,288  

Capital injections for capital increase

     74,347        28,051  

Share premium reserve

     14,425        14,425  
  

 

 

    

 

 

 

Total

     377,033        330,764  
  

 

 

    

 

 

 

2) Reserves or other provisions that do contribute to the taxable profit of the parent in the event of distribution regardless of when they are formed.

 

(€‘000)  
     30/06/2023      31/12/2022  

Revaluation reserve as per Law no. 413/1991

     111        111  

Reserve as per article 55 of Presidential decree no. 917/86

     —         —   
  

 

 

    

 

 

 

Total

     111        111  
  

 

 

    

 

 

 

3) Reserves included in share capital.

Reserves or other provisions that do contribute to the taxable profit of shareholders in the event of distribution, irrespective of when they were set up, for a free share capital increase by using the reserve as per the shareholders’ resolution of 15 October 1999.

 

31


(€‘000)  
     30/06/2023      31/12/2022  

Extraordinary reserve

     540        540  
  

 

 

    

 

 

 

Total

     540        540  
  

 

 

    

 

 

 

[3.14] Provisions for risks and charges

Details of this caption and changing between 30 June 2023 and 31 December 2022 are set out below.

 

(€‘000)  
     31/12/2022      Exchange
differences
    Increases      Decreases     Reclassification      30/06/2023  

Pension and similar provisions

     584        —        134        —        —         719  

Other provisions

     16,572        (6     2,834        (113     —         19,287  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Total

     17,156        (6     2,968        (113     —         20,006  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

 

Agents’ termination indemnity (€719 thousand and €584 thousand at 30 June 2023 and 31 December 2022, respectively) is the estimated liability deriving from the application of ruling legislation and the contractual clauses in relation to the termination of agency contracts. Unlike accruals to the provision for risks, warranties and other provisions, accruals to agents’ termination indemnity are classified by nature among costs for services.

Other provisions, amounting to €19,287 thousand and €16,572 thousand at 30 June 2023 and 31 December 2022 respectively, are comprised as follows:

 

   

the provision for charges of €1,978 thousand and €1,859 thousand at 30 June 2023 and 31 December 2022, respectively, of which €1,579 thousand and €1,460 thousand related to commission expense on revenue yet to be invoiced, €0 thousand and €0 thousand related to highly probable consultancy success fees the payment date of which is not yet known, both respectively at 30 June 2023 and 31 December 2022 and €399 thousand at 30 June 2023 and 31 December 2022 related to highly probable non-competition agreements the payment date of which is not yet known;

 

   

The provision related to the payback system €16,622 thousand that increases from the prior period for an amount equal to €2,305 thousand.

 

   

compensation for damage caused by products of €480 thousand and €300 thousand at 30 June 2023 and 31 December 2022, respectively.

 

   

other disputes/contingent liabilities of €95 thousand at 30 June 2023 and 31 December 2022.

The accruals of the year mainly refer to the best estimate of the amounts due under the payback system.

The market in which the Group operates is strictly controlled by laws and regulations such as, e.g., the EU Medical Devices Regulation (‘MDR’) in Europe and the Federal Food, Drug and Cosmetic Act (‘FDCA’) in USA. In order to demonstrate adherence to regulatory requirements and to maintain the ability to sell its products, the Group must obtain and maintain authorisations and certifications from the relevant authorities. Discussions are currently underway with the Australian authority, the Therapeutic Goods Administration (the ‘TGA’), which has been provided with clarification regarding an observation made by the TGA on the high revision rate of certain elements of the ‘SMR’ shoulder solution.

[3.15] Employee benefits

Employee benefits amounts to €1,192 thousand and €1,296 thousand at 30 June 2023 and 31 December 2022, respectively

At 30 June 2023 this item mainly consists of post-employment benefits due upon termination of employment pursuant to current legislation in Italy. The actuarial model used to measure Italian post-employment benefits (“TFR”) is based on the same assumptions previously used for measurement at 31 December 2022, illustrated in the notes to the consolidated financial statements at 31 December 2022, to which reference should be made, as there were no significant changes in the demographic or economic assumptions underlying the actuarial calculation in the half of 2023 and 2022, respectively.

 

32


(€‘000)  
     30/06/2023      31/12/2022      Variation
2023 vs 2022
 

Balance at 1 January

     1,296        1,442        (146

Exchange difference

     (32      (13   

Benefits settled/advances paid

     (123      (189      66  

Accruals

     908        1,716        (808

Cometa Fund, other pension funds

     (821      (1,599      778  

Post-employment benefits - Substitute tax on revaluation

     (36      —         (36

Interest

     —         10        (10

Actuarial (gain) loss

     —         (71      71  
  

 

 

    

 

 

    

 

 

 

Total

     1,192        1,296        (85
  

 

 

    

 

 

    

 

 

 

[3.16] Current and non-current financial liabilities

Non-current financial liabilities, amounting to €290,184 thousand at 30 June 2023 and €10,165 at 31 December 2022, comprise the portion of loans and borrowings due after one year and are broken down as follows:

 

(€‘000)  
     30/06/2023      31/12/2022      Variation
2023 vs 2022
 

Bonds

     279,613        —         279,613  

Lease liabilities as per IFRS 16

     5,303        5,248        55  

Other financial liabilities

     4,970        4,552        418  

Non-current bank loans and borrowings

     191        363        (172

Derivatives

     106        —         106  

Non-current bank loans and borrowings (due after five years)

     2        2        0  
  

 

 

    

 

 

    

 

 

 

Total

     290,184        10,165        280,019  
  

 

 

    

 

 

    

 

 

 

Derivatives, amounting to €106 thousand at 30 June 2023, refer to fair value of Interest Rate Cap subscribed in first half of 2023 as described in note [3.17] Derivatives.

Current financial liabilities, amounting to €17,708 thousand at 30 June 2023 and €336,659 at 31 December 2022, comprise the current portion of loans and borrowings and are broken down as follows:

 

(€‘000)  
     30/06/2023      31/12/2022      Variation
2023 vs 2022
 

Credit cards

     380        383        (3

Advances on exports

     —         —         —   

Current bank loans and borrowings

     7,000        54,000        (47,000

Non-current bank loans and borrowings

     365        386        (21

Bonds - current portion

     —         274,039        (274,039

Accrued expenses on bonds - due within one year

     4,728        1,979        2,749  

Accrued financial expense - due within one year

     215        298        (83

Loans and borrowings with other financial backers

     2,452        2,310        142  

Lease liabilities as per IFRS 16

     2,568        3,265        (697
  

 

 

    

 

 

    

 

 

 

Total

     17,708        336,659        (318,951
  

 

 

    

 

 

    

 

 

 

Current financial liabilities chiefly include the bond issued by Limacorporate S.p.A. in 2017 equal to €0 thousand and €274,039 thousand at 30 June 2023 and 31 December 2022, respectively, related to senior secured bonds redeemable in 2023 for a total nominal amount of €275 million. The bonds were initially recognised at fair value, net of directly related costs, and measured at amortised cost applying the effective interest rate method.

 

33


The bonds have coupons based on the 3-month Euribor plus a 3.75% spread, with a Euribor floor threshold of 0.00%. They are listed on the Euro MTF market of the Luxembourg Stock Exchange and the professional section of the ExtraMOT market of the Italian Stock Exchange.

The coupons mature every three months on 15 February, 15 May, 15 August and 15 November each year starting from 15 November 2017.

The following guarantees were issued in relation to the bonds:

 

   

pledge on the shares of Limacorporate S.p.A.;

 

   

pledge on the shares of some subsidiaries;

 

   

pledge on some of the current accounts of the parent and some subsidiaries;

 

   

special lien on plant, equipment and other items of property, plant and equipment of the parent;

 

   

lien on certain categories of assets of some subsidiaries;

 

   

guarantees on some categories of assets of the parent and some subsidiaries.

In relation to the refinancing put in place in 2017, as well as the issue of bonds, Limacorporate also finalised an agreement for a new super senior revolving credit facility for a maximum of €60 million. It may also be used partially, in several instalments with set repayment terms. If the financial covenants are complied with, the interest rate is the same as the bond, i.e., 3-month Euribor plus a 3.75% spread, with a Euribor floor threshold of 0.00%.

The same guarantees provided for the issue of the bonds were granted for this revolving credit facility; specifically:

 

   

pledge on the shares of Limacorporate S.p.A.;

 

   

pledge on the shares of some subsidiaries;

 

   

pledge on some of the current accounts of the parent and some subsidiaries;

 

   

special lien on plant, equipment and other items of property, plant and equipment of the parent;

 

   

lien on certain categories of assets of some subsidiaries;

 

   

guarantees on some categories of assets of the parent and some subsidiaries.

€54 million was used at 31 December 2022.

If more than 35% (as explained in financing agreement) of the available amount of the revolving facility is used (i.e., draw-downs exceeding €21 million), a covenant related to the ratio of “Super Senior Net Debt” (represented by the utilization of the revolving facility less cash and cash equivalents) and consolidated EBITDA which cannot exceed 1.83, is activated under the terms of the contract. Such covenant was complied with at 31 December 2022.

On 3 February 2023, the parent issued new senior secured bonds redeemable in February 2028 for a total nominal amount of €295 million. In addition to the bond issue, the parent also signed a new super senior revolving facility for a maximum of €65 million expiring in November 2027 (used for €7 million at 30 June 2023).

On 9 March 2023, the parent privately placed additional notes with the same terms and conditions as the bonds, for an amount of €15 million.

The pre-existing bonds and super senior revolving facility were fully redeemed and repaid.

The bonds have coupons based on the 3-month Euribor plus a 5.75% spread, with a Euribor floor threshold of 0.00%. They are listed on the Euro MTF market of the Luxembourg Stock Exchange.

The completion of the refinancing also saw a significant capital injection of €46,295 thousand by the parent’s shareholder.

Non-current financial liabilities (“Other current financial liabilities”) and current financial liabilities (“Other loan and borrowing”) also include liabilities for the purchase of business units related to the amount due in 2024 for the acquisition of a business unit from the group’s Sicilian distributor. The non-current amount is €nil at 30 June 2023 and €185 thousand at 31 December 2022. The current amount is €185 thousand at 30 June 2023 and €nil at 31 December 2022.

 

34


The caption also includes the non-current portion of the medium/long-term loans taken out by the parent for the SICAT and IAREPAM projects and by some branches in relation to the relief available for the Covid-19 pandemic, detailed as follows (residual amount includes current and no current portion of medium/long-term loans):

(€‘000)

Description

   Company      Original
amount
     Rate   Expiry date      Residual
amount at

30/06/2023
     Guarantee

SICAT sustainable growth fund 1st progress report

     Limacorporate S.p.A.        274      Fixed     30/06/2026        105      None

SICAT sustainable growth fund 2nd progress report

     Limacorporate S.p.A.        339      Fixed     30/06/2026        138      None

Sustainable growth fund “Project IAREPAM - Artificial Intelligence for the Efficient Development of an Implant in Additive Manufacturing” 1st progress report

     Limacorporate S.p.A.        6      Fixed     30/06/2031        6      None

Covid-19 subsidised loan

     Lima France        500      Fixed     31/05/2024        235      Government

guarantee

Covid-19 subsidised loan

     Lima Austria        200      0% until August

2022, then a
floating loan

    31/12/2024        75      None
     

 

 

         

 

 

    

Total

        1,319             559     
     

 

 

         

 

 

    

Current and non current bank loan and borrowing include the group medium-long term loans that are explained in part also in the table above and are the follows:

 

   

subsidised loan of €500 thousand granted by BNP Paribas to Lima France in May 2020 to be used to offset the negative economic effects of the Covid-19 pandemic. The interest subsidised rate was 0.45%; The residual amount at 30 June 2023 is €235.

 

   

subsidised loan of €200 thousand granted by Unicredit Bank of Austria to Lima Austria in August 2020. Like the above loans, the Austrian group company applied for this loan to offset the negative economic effects of the Covid-19 pandemic. The subsidised interest rate applied is 0.00% until August 2022 after which it will be the 3M Euribor + 0.75%; The residual amount at 30 June 2023 is €75 thousand.

Accrued financial expense and accrued expenses on bonds due within one year include interest accrued at each reporting date and not yet paid.

Other financial liabilities (non-current) and Other loans and borrowings (current) - include mainly the amounts yet to be paid in relation to the acquisition of TechMah Medical LLC (contingent consideration).

Finally, financial liabilities include lease liabilities deriving from the application of IFRS 16. The discount rate applied at 30 June 2023 and 31 December 2022 was revised and modified to take into consideration the higher interest rates compared to previous years.

Changing in the caption between 30 June 2023 and 31 December 2022 are set out below:

(€‘000)

     31/12/2022      Exchange
difference
    Increases      Decreases     Other
changes
     Reclassifications     30/06/2023  

Lease liabilities as per IFRS 16 - non-current portion

     4,552        (43     1,753        —        381        (1,340     5,303  

Lease liabilities as per IFRS 16 - current portion

     3,265        (43     1        (1,995     —         1,340       2,568  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Total

     7,817        (86     1,753        (1,995     381        —        7,871  
  

 

 

    

 

 

   

 

 

    

 

 

   

 

 

    

 

 

   

 

 

 

Lease liabilities are detailed by due dates as follows:

 

(€‘000)              
     30/06/2023      31/12/2022  

Current liabilities - due within one year

     2,568        3,265  

Non-current liabilities - due from one to five years

     4,216        3,997  

Non-current liabilities - due after five years

     1,087        555  
  

 

 

    

 

 

 

Total

     7,871        7,817  
  

 

 

    

 

 

 

[3.17] Derivatives

The derivatives refer to the interest rate swap and to the interest rate cap signed to hedge the bond issued in the first half of 2023.

 

35


The fair value of interest rate cap at 30 June 2023 is negative for €106 thousand and is included in non-current financial liabilities. The fair value of interest rate swap at 30 June 2023 is positive for €906 thousand and is included in non-current financial assets.

The derivatives are not listed. Therefore, their fair value is measured using financial techniques and compared to the counterpart’s measurement.

Although the derivatives were subscribed for hedging purposes, the Company decided not to apply hedge accounting, therefore fair value gains or losses on the derivative are recognized in profit or loss.

[3.18] Other non-current liabilities

Other non-current liabilities, amounting to €766 thousand and €649 thousand at 30 June 2023 and 31 December 2022 respectively and include incentive plans for some managers (€202 thousand and €73 thousand at 30 June 2023 and 31 December 2022, respectively) and the non-current portion of deferred income (€215 thousand and €221 thousand at 30 June 2023 and 31 December 2022, respectively), chiefly related to insurance costs.

The significant decrease during the half of 2022 is referred to the step down from the role of CEO which led to the partial liquidation of the VSP, and the remained part was reclassified on other liabilities (see paragraph [3.21]).

Reference should be made to note [4.7] Management Incentive plans under section [4] Other information for further information about such plans.

[3.19] Trade payables

Trade payables amount to €34,272 thousand and €36,564 thousand at 30 June 2023 and 31 December 2022 respectively and refer to short-term obligations to suppliers of goods and services. They refer to positions payable in the short term and there are no amounts due after one year.

There are no differences between the carrying amount and fair value of such payables.

Trade payables do not accrue interest. The terms and conditions for related parties do not differ from those applied for third party suppliers.

 

(€‘000)              
     30/06/2023      31/12/2022  

Trade payables

     34,097        36,214  

Payable to subsidiaries

     —         —   

Payables to parents

     175        350  
  

 

 

    

 

 

 

Total

     34,272        36,564  
  

 

 

    

 

 

 

[3.20] Current tax liabilities

Tax liabilities amount to €1,234 thousand and €877 thousand at 30 June 2023 and 31 December 2022, respectively. Specifically, the caption is comprised of the parent’s IRAP payable (€450 thousand at 30 June 2023) while the remainder refers to current taxes payable by all of the foreign branches (€784 thousand at 30 June 2023).

[3.21] Other current liabilities

Other current liabilities are broken down in the following table. The main liabilities refer to payments on account, tax liabilities, social security charges payable and amounts due to employees:

 

36


(€‘000)                     
     30/06/2023      31/12/2022      Variations  

Wages and salaries

     2,848        1,848        1,001  

Employee and performance bonus

     8,031        8,911        (880

Directors’ fees

     345        302        43  

Statutory auditors’ fees

     —         34        (34

Liabilities for the purchase of business units

     194        194        0  

Payables to factors for collections received

     100        7        93  

Foreign commissions

     —         4        (4

Sundry other liabilities

     964        1,034        (71

Payments on account

     4,367        4,380        (13

IRPEF withholdings

     781        1,241        (460

Other tax liabilities

     1,564        1,852        (288

VAT

     1,341        1,280        61  

INPS - Inpdai - Previndai

     2,180        2,390        (210

INAIL

     38        19        19  

Cometa Fund, other pension funds

     278        292        (14

Enasarco for agents

     126        181        (55

Other social security charges payable

     421        612        (191

Accrued expenses:

        

Insurance premiums

     —         5        (5

Interest on non-current loans

     —         —         —   

Other

     54        80        (26

Deferred income:

        

Grants related to assets

     28        72        (44

Rent

     —         1        (1

Other

     4        3        1  
  

 

 

    

 

 

    

 

 

 

Total

     23,663        24,742        (1,079
  

 

 

    

 

 

    

 

 

 

Payments on account amount to €4,367 thousand and €4,380 thousand at 30 June 2023 and 31 December 2022, respectively include the following:

 

   

PON SIB grant advance of €3,773 thousand, unchanged on the previous period;

 

   

MC BEES grant advance of €nil thousand at 30 June 2023 and €249 thousand at 31 December 2022;

 

   

PROST3SIS grant advance of €196 thousand at 30 June 2023 and €nil thousand at 31 December 2022;

 

   

IAREPAM grant advance of €11 thousand at 30 June 2023 and 31 December 2022;

 

   

advances received from customers of €191 thousand and €231 thousand at 30 June 2023 and 31 December 2022 respectively;

 

   

other payments on account of €196 thousand and €116 thousand at 30 June 2023 and 31 December 2022 respectively.

Liabilities for the purchase of business units of €194 thousand (unchanged from the previous period) refers to the acquisition of the Lima Brazil business unit. This liability dates back to 2011 when the Brazilian business unit was set up.

Other tax liabilities include taxes, fines and interest which arose from the parent signing a mutually-agreed assessment settlement procedure with the tax authorities (Friuli-Venezia Giulia regional tax authorities)for about €1,476 thousand, under which the first instalment was paid on 3 April 2023 (the parent opted for settlement in four quarterly instalments).

[3.22] Revenue and other revenue and income

Revenue amounts to €140,687 thousand on 30 June 2023, compared to €121,251 thousand on 30 June 2022.

Revenue derives from sales and distribution contracts with group customers essentially related to the sale of orthopaedic implants, mostly shoulders, hips and knees.

In accordance with IFRS 15, revenues are stated net of discounts and allowances and are constrained in order to only represent the ones that are highly probable to be collected. The constraints related to variable consideration refer to payback, amounting to € 2.3 million, established in connection with the activation of the Italian government payback provision as a retroactive rebate (i.e. variable consideration). Such variable consideration was estimated based on the publicly available information. The Italian payback law is a mechanism to obtain from suppliers a contribution to offset variances occurring when Italian government expenditures exceed their ceiling for the purchase of medical devices.

 

37


It is broken down by geographical segment as follows:

 

(€‘000)                     
     30/06/2023      30/06/2022      Variation
30/06/2023 - 30/06/2022
 

Europe (excluding Italy)

     59,443        46,651        12,792  

Italy

     29,431        24,524        4,906  

APAC

     19,448        18,427        1,022  

United States

     22,747        20,500        2,246  

Rest of world

     9,619        11,148        (1,530
  

 

 

    

 

 

    

 

 

 

Total

     140,687        121,251        19,436  
  

 

 

    

 

 

    

 

 

 

Under Italian healthcare regulations, each region is allocated an annual budget for purchasing medical devices. Upon exceeding the assigned budget, the region can ask suppliers of medical devices to reimburse a portion of the excess amount in proportion to the annual market share of each supplier in the region involved (the payback system). Specifically, pursuant to Decree law no. 115 of 9 August 2022 (converted into Law no. 142/2022), the Ministry for Health, with Ministerial decree published on 15 September 2022 (“Decree 216/2022”), set the amounts exceeding the regional budgets for each year from 2015 to 2018 and, with Ministerial decree published on 6 October 2022 (“Decree 251/2022”), set out guidelines for the Italian regions to follow in requesting reimbursements under the payback system.

Under the payback system, each region issues payment orders to suppliers of medical devices. At the date of these consolidated financial statements, Limacorporate S.p.A. and Lima SM in liquidation received payment orders for reimbursements under the payback system for amounts totalling €8.8 million for 2015, 2016, 2017 and 2018 which were recognised as variable consideration under IFRS 15.

Should a supplier not pay the requested amounts within 30 days, Decree 216/2022 provides that such amounts be offset against any amounts due to such suppliers from each region and/or body partnered with regional healthcare authorities. In addition, under Decree law no. 4 of 11 January 2023, the due date for the payment of such amounts was deferred to 30 April 2023. Decree law no. 34 of 31 March 2023 as modified by Law Decree n 98 of 28 July 2023, then further deferred the payment to 30 October 2023.

In line with the approach adopted by other suppliers of medical devices, Limacorporate contested Decree 216/2022 and Decree 251/2022 before the Lazio regional administrative court, contesting, inter alia, whether the decrees comply with the constitution. The parent also contested the individual deeds through which the regions involved individually settled and requested the amounts deemed due to it.

Furthermore, as it cannot be excluded that the Italian Ministry for Health may deem that the regional budgets for each year from 2019 to 2022 have been exceeded and, thus, that the Italian regions may issue further payment orders for each of those years, the group has calculated its best estimate of amounts probably due, based on:

 

   

publicly available data on spending by the regions over the relevant budgets

 

   

Limacorporate’s turnover in the various regions;

 

   

Limacorporate’s market share in the various regions.

 

38


Other revenue and income are broken down as follows:

 

(€‘000)  
     30/06/2023      30/06/2022      Variation
30.06.2023 - 30.06.2022
 

Service recharges

     1,667        1,246        421  

Lease income

     207        234        (27

Recharges to subsidiaries/associates

     9        —         9  

Gains

     583        418        165  

Release of the provision for risks

     —         —         —   

Other income

     137        455        (318

Grants

     58        81        (23

Other revenue

     79        13        66  
  

 

 

    

 

 

    

 

 

 

Total

     2,739        2,447        292  
  

 

 

    

 

 

    

 

 

 

The increase in revenue from recharges for services is linked to the rise in turnover and sales.

[3.23] Internal work capitalised

This caption amounts to €6,281 thousand on 30 June 2023 and €7,886 thousand on 30 June 2022. It may be broken down as follows:

 

(€‘000)  
     30/06/2023      30/06/2022      Variation
30/06/2023 - 30/06/2022
 

Increases in property, plant and equipment for capitalisation of equipment

     5,417        5,890        (473

Increases in intangible assets for capitalisation of sundry costs

     76        401        (325

Increases in property, plant and equipment for internal work

     788        1,595        (807
  

 

 

    

 

 

    

 

 

 

Total

     6,281        7,886        (1,605
  

 

 

    

 

 

    

 

 

 

Increases in property, plant and equipment for capitalisation of equipment and internal work both refer to the capitalisation of equipment built internally. This equipment is provided to hospitals on a free loan basis to be used to implant the group’s products.

Increases in intangible assets for capitalisation of sundry costs (€76 thousand) refer to the capitalisation of internal and external costs incurred for product development projects.

[3.24] Raw materials, consumables, supplies and goods

This caption amounts to €35,447 thousand on 30 June 2023, compared to €29,282 thousand on 30 June 2022. It is broken down as follows:

 

(€‘000)  
     30/06/2023      30/06/2022      Variation
30/06/2023 - 30/06/2022
 

Purchase of raw materials

     6,463        4,711        1,751  

Purchase of semi-finished products

     13,069        10,900        2,169  

Purchase of finished goods

     7,118        4,553        2,565  

Individual equipment components

     7,529        8,452        (923

Opening balance of raw materials, consumables, supplies and goods

     6,272        6,094        178  

Closing balance of raw materials, consumables, supplies and goods

     (6,488      (6,503      15  

Other

     1,484        1,074        410  
  

 

 

    

 

 

    

 

 

 

Total

     35,447        29,282        6,165  
  

 

 

    

 

 

    

 

 

 

[3.25] Services

Services amount to €42,959 thousand on 30 June 2023, compared to €38,815 thousand on 30 June 2022.

 

39


The caption is broken down as follows:

 

(€‘000)  
     30/06/2023      30/06/2022      Variation
30/06/2023 - 30/06/2022
 

Enasarco (agent social security charges)

     15,632        13,050        2,582  

Technical and commercial consultancy

     3,235        2,716        519  

Transport costs for sales

     3,299        2,712        587  

Outsourced processing and analyses

     1,644        1,694        (50

Insurance costs

     2,029        1,778        251  

Travel costs

     2,461        2,077        384  

Non-recurring consultancy

     295        273        22  

Maintenance of HW/SW/office machines

     1,513        1,237        276  

Administrative services

     929        788        141  

Maintenance and repair

     1,110        906        204  

Energy, power supply (industrial costs)

     1,216        1,339        (123

Workshops

     1,037        1,241        (204

Royalties

     348        673        (325

Transport costs for purchases

     462        400        62  

Management remuneration

     377        2,487        (2,110

Other

     7,373        5,444        1,929  
  

 

 

    

 

 

    

 

 

 

Total

     42,959        38,815        4,144  
  

 

 

    

 

 

    

 

 

 

The increase in this caption is chiefly due to fees directly related to the growth in turnover and higher processing, transport costs and commissions also tied to the rise in sales.

Management remuneration at 30 June 2022 include € 941 thousand for management incentive plans (30 June 2023: € nil thousand). Reference should be made to section [4.7] Management Incentive plans for a description of such plans.

[3.26] Change in work in progress, semi-finished products and finished goods

This caption shows a positive balance of €2,392 thousand on 30 June 2023 (30 June 2022: €329 thousand).

[3.27] Personnel expenses

Personnel expenses amount to €43,969 thousand on 30 June 2023, compared to €37,150 thousand on 30 June 2022, and are broken down as follows:

 

(€‘000)  
     30/06/2023      30/06/2022      Variation
30/06/2023 - 30/06/2022
 

Wages and salaries

     36,373        30,063        6,310  

Social security contributions

     6,620        6,159        461  

Employees’ leaving entitlement

     927        889        38  

Other costs

     49        39        10  
  

 

 

    

 

 

    

 

 

 

Total

     43,969        37,150        6,819  
  

 

 

    

 

 

    

 

 

 

[3.28] Amortisation, depreciation and impairment losses

Amortisation amount to €14,967 thousand on 30 June 2023, compared to €17,186 thousand on 30 June 2022, and include depreciation of right-of-use assets of €2,373 thousand on 30 June 2023 (30 June 2022: €2,632 thousand). Reference should be made to note [3.3] Property, plant and equipment for details on the individual categories.

 

40


The caption is broken down as follows:

 

(€‘000)  
     30/06/2023      30/06/2022      Variation
30/06/2023 - 30/06/2022
 

Amortisation of intangible assets

     2,006        3,989        (1,983

Amortisation of tangible assets

     10,588        10,565        23  

Depreciation of right-of-use assets as per IFRS 16

     2,373        2,632        (260
  

 

 

    

 

 

    

 

 

 

Total

     14,967        17,186        (2,220
  

 

 

    

 

 

    

 

 

 

The impairment losses on trade receivables of €61 thousand positive (2022: €154 thousand negative) include the accrual for net impairment losses on trade receivables recognised pursuant to IFRS 9.

During the first half of 2023 the group impaired developments costs related to TechMah business, as consequence of the interruption of the project and the subscription of a new partnership with a software supplier on shoulder preoperative planning for an amount of €35,574 thousand.

As of the date of preparation of these condensed consolidated interim financial statements, the relevant losses are not expected to be reversed.

[3.29] Other operating costs

Other operating costs amount to €980 thousand on 30 June 2023, compared to €699 thousand in on 30 June 2022, and are broken down as follows:

 

(€‘000)  
     30/06/2023      30/06/2022      Variation
30/06/2023 - 30/06/2022
 

Taxes and duties

     359        419        (60

Other costs

     180        8        172  

Losses on assets

     30        10        20  

Gifts and donations

     64        147        (84

Sundry costs - previous years

     1        113        (113

Tax expense - previous years

     2        1        1  

Provision for risks

     345        —         345  
  

 

 

    

 

 

    

 

 

 

Total

     980        699        281  
  

 

 

    

 

 

    

 

 

 

[3.30] Financial income and expense

Net financial (income) expense amounts to €18,651 thousand on 30 June 2023, compared to €(709) thousand on 30 June 2022, and is broken down as follows:

 

(€‘000)  
     30/06/2023      30/06/2022      Variation
30/06/2023 - 30/06/2022
 

Exchange losses

     5,202        4,495        706  

Interest on bonds

     12,168        5,185        6,983  

Other interest and financial expenses

     5,269        2,137        3,132  

Financial expense for adjusting liabilities to fair value

     106        —         106  

Financial expenses

     22,745        11,817        10,928  

Exchange gains

     (3,122      (7,707      4,585  

Other interest income

     (66      (92      25  

Financial income for adjusting liabilities to fair value

     (906      (4,728      3,822  

Financial income

     (4,094      (12,527      8,432  
  

 

 

    

 

 

    

 

 

 

Total

     18,651        (709      19,360  
  

 

 

    

 

 

    

 

 

 

The increase in financial expenses during the period is chiefly due to higher interests on bond.

 

41


Financial income include an amount for adjusting the derivatives’ fair value (€906 thousand at 30 June 2023 and €nil at 30 June 2022) and for adjusting to fair value the liability of Techmah’s acquisition (€137 thousand at 30 June 2023 and €4,728 thousand at 30 June 2022).

Exchange losses amount to €5,202 consist in €911 related to realised exchange losses and €4,291 refers to unrealised exchange losses.

Exchange gains amount to €3,122 consist in €766 related to realised exchange gains and €2,356 refers to unrealised exchange gains.

[3.31] Income tax (benefit) expense

Income tax (benefit) expense amounts to €(8,928) thousand on 30 June 2023 compared to an Income tax expense of € 882 thousand on 30 June 2022.

The decrease in deferred tax liabilities is mainly related to the write off of Techmah’s development costs.

[4.1] Operating segments

The disclosure about operating segments was prepared in accordance with IFRS 8 Operating segments which provides for the presentation of information in line with the measures adopted by the chief operating decision maker to make operating decisions.

At operating level, the group has a matrix organisational structure split by product line, distribution channel and geographical segment providing a coherent strategic vision of the business. This structure can be seen in the way management monitors and directs the group’s activities. Specifically, senior management reviews the group’s results as a whole as it does not have identifiable operating segments. Therefore, the group’s operations are presented as a single segment for IFRS 8 reporting purposes.

A breakdown of revenue earned in 2023 and 2022 by product line, distribution channel and geographical segment is shown below:

 

(€‘000)  

Revenue by PRODUCT LINE

   30/06/2023      30/06/2022      Variation
30/06/2023 - 30/06/2022
 

Hip

     47,755        44,143        3,612  

Extremities

     57,189        48,472        8,717  

Knee

     30,596        24,220        6,376  

Fixation & Other

     5,148        4,416        732  
  

 

 

    

 

 

    

 

 

 

Total sales revenue

     140,687        121,251        19,436  
  

 

 

    

 

 

    

 

 

 

 

(€‘000)  

Revenue by DISTRIBUTION CHANNEL

   30/06/2023      30/06/2022      Variation
30/06/2023 - 30/06/2022
 

Direct customers

     115,889        95,653        20,236  

Indirect channel

     24,797        25,597        (800
  

 

 

    

 

 

    

 

 

 

Total sales revenue

     140,687        121,251        19,435  
  

 

 

    

 

 

    

 

 

 

 

(€‘000)  

Revenue by GEOGRAPHICAL SEGMENT

   30/06/2023      30/06/2022      Variation
30/06/2023 - 30/06/2022
 

Europe

     88,874        71,176        17,698  

APAC

     19,448        18,427        1,022  

United States

     22,747        20,500        2,246  

Rest of world

     9,619        11,148        (1,530
  

 

 

    

 

 

    

 

 

 

Total sales revenue

     140,687        121,251        19,436  
  

 

 

    

 

 

    

 

 

 

 

42


As required by IFRS 8, it is noted that the group does not have individual customers that generate revenue of 10% or more of its total revenue in 2023 and 2022.

[4.2] Financial instruments - Fair value and risk management

 

  A.

Accounting classification and fair value

The next table shows the carrying amount and fair value of each financial asset and liability, including their fair value hierarchy level. Information about the fair value of financial assets and liabilities not measured at fair value is not provided as their carrying amount reasonably approximates their fair value.

Trade receivables and other assets and trade payables and other liabilities classified as held for sale are not included in the table. Their carrying amount reasonably approximates their fair value.

 

(€‘000)         Carrying Amount      Fair value  

30 June 2022

   Notes    Fair value
– Hedging
instruments
     Mandatorily at
FVTPL - other
     FVOCI - debt
instruments
     FVOCI -
equity
instruments
     Financial Assets
measured at
amortised cost
     Other
liabilities
     Total      Level 1      Level 2      Level 3      Total  

Financial assets measured at fair value

                                   

Hedging Interest rate swap

   [3.17]      —                        —            —            —   
        —                        —         —         —         —         —   

Financial assets not measured at fair value

                                   

Trade receivables and other assets

   [3.9] [3.11]                  84,618           84,618           84,618           84,618  

Cash and cash equivalents

   [3.12]                  29,687           29,687           29,687           29,687  
        —         —         —         —         114,305        —         114,305        —         114,305        —         114,305  

Financial liabilities measured at fair value

                                   

Hedging Interest rate swap

   [3.17]      —                        —            —            —   

Liabilities for acquisitions - MT Ortho

   [3.16]                     185        185              185        185  

Liabilities for acquisitions - Techmah

   [3.16]                     9,671        9,671              9,671        9,671  
        —         —         —         —         —         9,856        9,856        —         —         9,856        9,856  

Financial liabilities not measured at fair value

                                   

Bank credit facilities

   [3.16]                     1,170        1,170           1,170           1,170  

Secured bank loans

   [3.16]                     54,000        54,000           54,000           54,000  

Undecured bank loans

   [3.16]                     938        938           938           938  

Secured bonds - listed bonds

   [3.16]                     273,297        273,297           261,608           261,608  

Lease liabilities - IFRS 16

   [3.16]                     8,527        8,527           8,527           8,527  

Trade payables and other liabilities

   [3.19] [3.21]                     63,101        63,101           63,101           63,101  
        —         —         —         —         —         401,033        401,033           389,344           389,344  
     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

TOTALE

        —         —         —         —         114,305        410,889        525,194        —         503,649        9,856        513,505  
     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

(€‘000)           Carrying Amount      Fair value  

30 June 2023

   Notes      Fair value
– Hedging
instruments
     Mandatorily at
FVTPL - other
     FVOCI - debt
instruments
     FVOCI -
equity
instruments
     Financial Assets
measured at
amortised cost
     Other
liabilities
     Total      Level 1      Level 2      Level 3      Total  

Financial assets measured at fair value

                                   

Hedging Interest rate swap

     [3.17]        906                       906           906           906  
        906                       906        —         906        —         906  

Financial assets not measured at fair value

                                   

Trade receivables and other assets

     [3.9] [3.11]                    79,106           79,106           79,106           79,106  

Cash and cash equivalents

     [3.12]                    5,023           5,023           5,023           5,023  
        —         —         —         —         84,128        —         84,128        —         84,128        —         84,128  

Financial liabilities measured at fair value

                                   

Hedging Interest rate swap

     [3.17]        106                       106           106           106  

Liabilities for acquisitions - MT Ortho

     [3.16]                       185        185              185        185  

Liabilities for acquisitions - Techmah

     [3.16]                       7,237        7,237              7,237        7,237  
        106        —         —         —         —         7,422        7,528        —         106        7,422        7,528  

Financial liabilities not measured at fair value

                                   

Bank credit facilities

     [3.16]                       380        380           380           380  

Secured bank loans

     [3.16]                       7,000        7,000           7,000           7,000  

Undecured bank loans

     [3.16]                       559        559           559           559  

Secured bonds - listed bonds

     [3.16]                       279,613        279,613           308,146           308,146  

Lease liabilities - IFRS 16

     [3.16]                       7,871        7,871           7,871           7,871  

Trade payables and other liabilities

     [3.19] [3.21]                       66,735        66,735           66,735           66,735  
        —         —         —         —         —         362,157        362,157           390,691           390,691  
     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

TOTALE

        1,012        —         —         —         84,128        369,579        454,720        —         475,831        7,422        483,253  
     

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

 

43


  B.

Fair value measurement

i. Measurement techniques and significant unobservable inputs

The following tables present the measurement techniques and significant unobservable inputs used to determine the fair value of level 2 and 3 financial instruments in the statement of financial position.

Financial instruments measured at fair value

Movements of TechMah liabilities over the periods are mainly related to fair value impact and payments. At 30 June 2023 the Management updated the evaluation and changed the assumptions to determine the value of the liability compared to 31 December 2022, in particular taking in consideration the milestone achieved, the decision to interrupt the Smart Space project, the contract with the TechMah Founder and the Complaint filed by the founding shareholders of TechMah (see also subsequent events). The valuation resulted in no further major adjustment compared to the balance at 31 December 2022, except for the foreign exchange impact.

Financial instruments not measured at fair value

 

Type    Measurement technique
Secured bonds    Discounted cash flows:
Lease liabilities    This measurement technique
Secured bank loans    considers the present value of
Unsecured bank loans    estimated payments, discounted
   using a discount rate that reflects
   the risk.

Reconciliation of Level 3

 

(€‘000)

   Liabilities  

Balance at 31 December 2021

     13,434  

Gain (losses) included in “finance income”

  

- Net change in fair value (unrealised)

     (4,728

- Foreing exchange (gain) losses

     965  

Payments

  

Balance at 30 June 2022

     9,671  

Gain (losses) included in “finance income”

  

- Net change in fair value (unrealised)

     (2,253

- Foreing exchange (gain) losses

     (44

Payments

  

Balance at 31 December 2022

     7,374  

Gain (losses) included in “finance income”

  

- Foreing exchange (gain) losses

     (137

Payments

  

Balance at 30 June 2023

     7,237  

 

  C.

Financial risk management

The group is exposed to the following risks deriving from its use of financial instruments:

 

   

credit risk;

 

   

liquidity risk;

 

   

market risk.

Risk management system

Overall responsibility for the design and oversight of the group’s risk management system lies with the parent’s board of directors. This committee is in charge of developing and monitoring the group’s risk management policies.

The group’s risk management policies are designed to identify and analyse any risks it is exposed to, establish appropriate limits and controls and monitor the risks and compliance with such limits. The committee regularly revisits the policies and related systems to align them with market developments and the group’s business. The group aims to create a disciplined and constructive control environment through training programmes, standards and management procedures so that its employees are familiar with their roles and responsibilities.

The board of directors ensures compliance with the risk polices and management procedures and checks that the risk management system is appropriate to deal with risks that could affect the group.

 

44


The group’s financial instruments comprise cash and cash equivalents, loans, trade receivables and payables, current and non-current assets and liabilities as well as derivatives.

In its normal business operations, the group is exposed to:

 

   

market risk, mainly currency and interest rate risks;

 

   

commercial or counterparty credit risks, related to the risk of default on commercial or financial obligations by various counterparties as part of normal business operations or lending, investment and hedging transactions;

 

   

liquidity risk, related to the availability of financial resources and access to the credit market and refers to the need to meet the group’s financial needs in the short term.

Financial risk management is carried out centrally and essentially ensures that there are enough financial resources to meet business development needs and that resources are suitably invested in profitable activities.

Market risk

Market risk can be broken down into the following components:

 

   

interest rate risk,

 

   

currency risk.

Interest rate risk

The group’s exposure to interest rate risk is chiefly related to cash and cash equivalents, bonds and bank loans and borrowings, especially the revolving credit facility that is managed centrally. The derivatives are referred of the interest rate swap and a cap contract put in place by the parent to hedge fluctuations in payments of interest on the bond issued in 2023. At 31 December 2022, 30 June 2022 and 31 December 2021 there weren’t derivatives. A 100bps increase in the interest rate applied to the first six months of 2023 would have led to an increase in financial expense of roughly €0.5 million.

Currency risk

As the group sells its products in various countries, it is exposed to currency risk. This risk mainly derives from sales in currencies other than the Euro, like the US dollar, British pound, Japanese yen and Australian dollar.

The group regularly assesses its exposure to market financial risks. It does not manage such risks by using derivatives.

Credit risk

Credit risk is the risk that a customer or counterparty to a financial instrument may default on a contractual obligation generating a loss for the group. It mainly arises on trade receivables and debt instruments.

The group’s maximum exposure to this type of risk is the assets’ carrying amount.

Some of the markets on which the group operates have a higher level of risk, such as southern Italy, where the health system is deeply in debt, southern European countries, like Spain and Portugal, and eastern European countries, such as Croatia, the Czech Republic and Slovakia, where collection times are very long.

Most of the group’s receivables are due from public institutions, thus solely linked to the country risk. Moreover, payments from public administration have improved notably in some cases in recent years thanks to measures taken to cut public entity debt with private companies.

Credit risk is also mitigated by the fact that the group is increasing its sales in countries with shorter average collection times. Therefore, the weight of markets with higher credit risk will be reduced.

At 30 June 2023 and 2022, the group does not have exposures with individual customers for more than 10% of its total trade receivables.

The amount of financial assets for which recovery is doubtful is immaterial in terms of the total amount of receivables and is, in any case, covered by adequate accruals to the relevant allowances.

 

45


Liquidity risk

Liquidity risk derives from the ability to obtain financial resources at a sustainable cost to carry out the group’s normal business operations.

The group uses the usual tools to manage current trade receivables, as well as partially using the facilities available.

Moreover:

 

   

the group has debt instruments and credit lines to deal with liquidity requirements;

there are no significant concentrations of liquidity risk with regard to financial assets.

[4.3] Significant non-recurring transactions

The condensed consolidated interim financial statements were not affected by significant non-recurring transactions.

[4.4] Guarantees

Reference should be made to section [3.16] of the notes to the condensed consolidated interim financial statements.

[4.5] Related party transactions

The group carries out transactions with the ultimate parent recognised in line with the provisions of IAS 24. They are all financial in nature and are performed with full transparency and on an arm’s length basis. They do not include typical and/or unusual transactions.

Details of related party transactions carried out during 30 June 2023 and 30 June 2022 are as follows:

 

(€‘000)                                                 
30.06.2023  
     Payables      Receivables      Other non-
current
liabilities
     Other
current
liabilities
     Sundry
recharges
     Services      Personnel
expenses
 

EMIL HOLDING II S.à.r.l.

     175        —         —         —         9        175        —   

Senior Management

     —         —         202        284        —         373        4,862  

Short-term

              284           373        —   

Post-empoyment

              —            —         —   

Other long - term

                    —         —   

Share based benefits

           202        —            —         4,862  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

Total

     175        —         202        284        9        548        4,862  
  

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

    

 

 

 

No other significant related party transactions took place during the period.

The group operates in a market dominated by entities directly or indirectly controlled by the Italian government through state bodies, agencies, related parties and other organisations (entities related to government bodies). The parent does not carry out transactions with other entities related to government bodies, such as, for example, the sale and purchase of goods and materials, the supply or receipt of services, leasing of assets or use of public services.

Transactions with Emil Holding II S.à.r.l.

Financial transactions with the ultimate parent are part of the parent’s normal business operations and take place at conditions similar to those applied to transactions with non-related parties.

 

46


[4.6] Fees of directors, statutory auditors and key management personnel

The remuneration of managers and the fees paid to statutory auditors were as follows:

 

(€‘000)                     
     30/06/2023      30/06/2022      Variation
30/06/2023 - 30/06/2022
 

Management remuneration

     377        2,487        (2,110
  

 

 

    

 

 

    

 

 

 

Total

     377        2,487        (2,110
  

 

 

    

 

 

    

 

 

 

[4.7] Management Incentive plans

In accordance with IFRS 2, the parent identified cash-settled share-based payment incentive plans for some managers.

 

   

The Bonus Payments

Starting from June 2022 the Controlling Entity and the Entity agreed with certain employees some compensation plans which provide that upon occurrence of certain events (the “Bonus Payment Trigger Events”) a payment of a certain amount based on the enterprise value of the Entity at the trigger event date (the “Trigger Event Enterprise Value”).

The Bonus Payment Trigger Events occur at the first of the following events:

 

   

the listing of Emil NewCo S.a.r.l. or any entity of the Lima Group of companies which holds, directly and indirectly, all or substantially all of the assets of the Lima Group, on a regulated stock exchange;

 

   

in case no listing pursuant to paragraph a) has taken place, (i) any sale or transfer by Emil Holding I to a third party purchaser (not related to any EQT Funds) of more than 50% of the ordinary shares held by Emil Holding I in Emil NewCo S.a.r.l. or (ii) any sale to a third party purchaser (not related to any EQT Funds) of more than 50% of the shares in any other entity which holds, directly or indirectly, all or substantially all of the business or assets of the Lima Group; or

 

   

an asset sale of all or substantially all of the assets of the Lima Group which results in the EQT Funds no longer holding any interest (except for unsubstantial assets) in the Lima Group.

Considering that the amount to be paid to the employees is based on the Trigger Event Enterprise Value of the Entity and is therefore based on the value of the Entity’s equity instrument, the Bonus Payment falls within the scope of the “IFRS 2 – Share Based Payments”.

In particular, the management accounted for the Bonus Payment as follows:

 

  (i)

the agreements in which the Entity has the obligation to settle the payment as cash-settled share-based payments (the “Cash-settled Bonus Payments”);

 

  (ii)

the agreements in which the obligation is settled by Emil Holding I as equity-settled share-based payments (the “Equity-settled Bonus Payments”).

In accordance with IFRS 2, the Equity-settled Bonus Payments are measured at the fair value of grant date. Instead, the Cash-settled Bonus Payments are measured at the fair value of grant date and then re-measured at each reporting date until settlement.

The fair value of the Bonus Payments is recognized as an expense during the vesting period.

In order to evaluate the fair value of the Bonus Payments, the management used a Monte Carlo valuation model.

 

   

The Grant Dates considered for the valuation are: June 6, 2022, June 18, 2022, June 28, 2022, and August 9, 2022, which are the grant dates of the major part of the agreements.

 

   

The management of the company has assumed that the exercise of the plan will occur following an Exit Event on June 30, 2024 with a probability of 100%.

 

   

The riskfree interest rate is retrieved from public Information Provider and range from a minimun of 1.3% and maximum of 1.8% over the grant dates.

 

   

The volatility was estimated based on historical series of Equity Value from comparable companies. An adjustment was then applied in order to obtain the volatility relative to Enterprise Value, considering the framework derived from the Merton model.

 

   

Expected dividends rate is 0% for all the Bonus Payments.

 

   

Employee exit rate is 0% for all the Bonus Payments.

The fair value of the Cash-settled Bonus Payments at grant date amounted to € 464.3 thousand.

 

47


The fair value of the Equity-settled Bonus Payments at grant date amounted to € 17,752.0 thousand.

The movement of the interest rate curve and volatility is not expected to result in a significant change in the cash-settled bonus payment.

This plan led to a recognition of personnel expenses of €4,862 thousand and €115 thousand at 30 June 2023.

[4.8] Events after the reporting date

In early July 2023 the management of Limacorporate announced the strategic decision, substantially taken over the weeks before the reporting date, to stop the Smart Space project (referred to TechMah CGU), all digital activities and resources have been refocused on other projects.. The event has been considered as adjusting event under IAS 10 as at 30 June 2023 already existed the elements on the basis of the decision.

On 18th September 2023 the company was served a Complaint filed by the founding shareholders of TechMah Medical (“TechMah Founders”) versus Lima USA Inc. and Limacorporate S.p.A. for alleged breach contract based on the milestones set out in the Investor and Founders Agreement entered into by TechMah Medical LLC, TechMah Founders, Lima USA Inc., and Limacorporate S.p.A. on 8th October 2021.

The Complaint contains high level allegations that Lima USA, Inc. and Limacorporate S.p.A. breached the Investor and Founders Agreement by not using their “reasonable best efforts” to achieve some Regulatory Milestones and by failing to pay out certain Commercial Milestones the Founders assume have been met. The Founders have claimed an amount in a range of USD 5.5 – 11.5 million.

The company is convinced that no breach occurred and shall prove this in the appropriate venues. As at the date of approval of these Condensed consolidated interim financial statements no estimate is possible of any potential financial effect arising from the complaint.

 

48

EX-99.3

Exhibit 99.3

UNAUDITED PRO FORMA CONDENSED COMBINED FINANCIAL INFORMATION

On September 22, 2023, the Company entered into the Lima Acquisition Agreement for a purchase price of approximately $850,000,000 (consisting of €700 million in cash consideration plus up to 1,942,686 Enovis common shares), subject to certain adjustments. The Enovis shares are expected to be issued within 18 months following the closing of the Acquisition, subject to certain adjustments and conditions as provided for in the Lima Acquisition Agreement.

Lima is a global orthopedics company providing a broad range of innovative and technology-driven joint replacement solutions used by surgeons to restore motion for patients. Their offering includes extremities (comprising shoulder and elbow), knee and hip implants as well as ancillary fixation products. The Company is targeting a closing of the Lima Acquisition in early 2024, subject to regulatory approvals and customary closing conditions.

The Company and certain of its subsidiaries intend to enter into an Amendment of its Existing Credit Agreement to provide for the Term Loan Facility. Solely for purposes of these pro forma financial statements, the Company has assumed that it will issue $400,000,000 of 3.50% Convertible Senior Notes due 2028 as part of the offering herein (the “Convertible Notes”) (collectively, the “Debt Financing”).

A portion of the proceeds from this offering of Convertible Notes, together with approximately $400 million of borrowings from the Term Loan Facility and cash on hand, are intended to fund the cash purchase price for the Lima Acquisition. In addition, in connection with the pricing of the Convertible Notes, the Company expects to enter into privately negotiated capped call transactions with the option counterparties. The funding transactions, including the Convertible Notes and the capped call transactions, along with the Lima Acquisition are collectively referred to herein as the “Transactions.”

This unaudited pro forma condensed combined financial information and explanatory notes present how the consolidated financial statements of Enovis Corporation may have appeared had the Transactions occurred at earlier dates. The unaudited pro forma condensed combined statement of operations for six months ended June 30, 2023 and for the year ended December 31, 2022 combines the historical consolidated statements of operations of Enovis and the historical consolidated income statement of Lima, giving effect to the Transactions as if closing had occurred on January 1, 2022. The unaudited pro forma condensed combined balance sheet combines the historical consolidated balance sheets of Enovis and Lima as of June 30, 2023, giving effect to the Transactions as if closing had occurred on June 30, 2023. See “Summary—Pending Acquisition of Limacorporate S.p.A.” herein for additional information on the Transactions.

The following unaudited pro forma condensed combined financial information gives effect to the acquisition and financing, which includes adjustments for the following:

 

   

Certain adjustments to reflect Lima’s historical financial statements prepared in accordance with IFRS to U.S. GAAP

 

   

Certain reclassifications to conform Lima’s historical financial statement presentation to Enovis’ presentation;

 

   

Application of the acquisition method of accounting under the provisions of ASC 805;

 

   

Proceeds and uses of the financing entered into in connection with the acquisition; and

 

   

Certain adjustments to reflect non-recurring transaction costs in connection with the acquisition.

The unaudited pro forma condensed combined financial information is presented for informational purposes only and does not purport to represent what the results of operations or financial condition would have been had the Transactions actually occurred on the dates indicated, nor do they purport to project the results of operations or financial condition for any future period or as of any future date.

The combination is considered a business combination and therefore will be accounted for under the acquisition method of accounting in accordance with ASC 805.

Under the acquisition method of accounting for purposes of these unaudited pro forma condensed combined financial statements, management of Enovis has determined a preliminary estimated purchase price, calculated as described in “Note 3. Estimated Purchase Price and Preliminary Purchase Price Allocation” to these unaudited pro forma condensed combined financial statements. The Lima assets acquired and liabilities assumed in connection with the combination are recorded at their estimated acquisition date fair values. A final determination of these estimated fair values will be based on the actual net assets of Lima that exist as of the date of closing. Differences between these preliminary estimates and the final acquisition accounting may occur and these differences could be material.

The unaudited pro forma condensed combined financial information should be read in conjunction with:

 

   

The accompanying notes to the unaudited pro forma condensed combined financial information;

 

   

The separate historical financial statements of Enovis as of and for the year ended December 31, 2022 and the related notes included in Enovis’ Annual Report on Form 10-K for the year ended December 31, 2022;

 

1


   

The separate historical financial statements of Enovis as of and for the six months ended June 30, 2023 and the related notes included in Enovis’ Quarterly Report on Form 10-Q for the quarterly period ended June 30, 2023;

 

   

The separate historical financial statements of Lima as of and for the year ended December 31, 2022 and the related notes included in Lima’s Annual Report for the year ended December 31, 2022, filed as an exhibit to our Current Report on Form 8-K filed with the SEC on October 19, 2023; and;

 

   

The separate historical financial statements of Lima as of and for the six months ended June 30, 2023 and the related notes included in Lima’s Interim Financial Report for the six months ended June 30, 2023, filed as an exhibit to our Current Report on Form 8-K filed with the SEC on October 19, 2023.

The unaudited pro forma condensed combined financial statements do not reflect the costs of any integration activities or benefits that may result from realization of future cost savings from operating efficiencies or revenue synergies that may result from the Transactions.

 

2


UNAUDITED PRO FORMA CONDENSED COMBINED BALANCE SHEET

As of June 30, 2023

($ in thousands)

 

     Enovis Historical
As of June 30, 2023
    Lima Historical
As of June 30, 2023 (Note 2)
    Transaction
Accounting
Adjustments
    Note 4     Financing
Adjustments
    Note 4     Pro Forma
Combined
 
ASSETS               

Current assets:

              

Cash and cash equivalents

   $ 32,491     $ 25,737     $ (780,636     (a   $ 725,800       (a   $ 3,392  

Trade receivables, less allowance for credit losses

     298,976       85,975       —          —          384,951  

Inventories, net

     453,897       96,951       39,033       (b     —          589,881  
              

Prepaid expenses

     26,758       2,788       —          —          29,546  
              

Other current assets

     75,117       13,076       —          —          88,193  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Total current assets

     887,239       224,527       (741,603     $ 725,800         1,095,963  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Property, plant and equipment, net

     260,754       75,524       100,162       (m     —          436,440  
              

Goodwill

     2,034,087       417,657       (161,217     (c     —          2,290,527  

Intangible assets, net

     1,110,950       23,045       317,472       (d     —          1,451,467  

Lease asset - right of use

     61,739       9,566       —          —          71,305  

Other assets

     88,784       37,226       —          —          126,010  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Total assets

   $ 4,443,553     $ 787,545     $ (485,186     $ 725,800       $ 5,471,712  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

LIABILITIES AND EQUITY

              

Current liabilities:

              

Current portion of long-term debt

   $ —      $ 16,452     $ (16,452     (e   $ 20,000       (j   $ 20,000  

Accounts payable

     147,180       37,248       —          —          184,428  

Accrued liabilities

     206,493       29,850       80,000       (f     —          316,343  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Total current liabilities

     353,673       83,550       63,548         20,000         520,771  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Long-term debt, less current portion

     400,000       309,620       (309,620     (e     761,800       (j     1,161,800  

Non-current lease liability

     47,567       5,764       —          —          53,331  

Other liabilities

     191,553       34,931       125,607       (k     —          352,091  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Total liabilities

     992,793       433,865       (120,465       781,800         2,087,993  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Equity:

              

Common stock

     55       10,725       (10,725     (g     —          55  

Additional paid-in capital

     2,944,094       423,877       (423,877     (h     (56,000     (l     2,888,094  

Retained earnings

     542,387       (80,922     69,881       (i     —          531,346  

Accumulated other comprehensive loss

     (37,898     —        —          —          (37,898
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Total shareholders’ equity

     3,448,638       353,680       (364,721       (56,000       3,381,597  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Noncontrolling interest

     2,122       —        —          —          2,122  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Total equity

     3,450,760       353,680       (364,721       (56,000       3,383,719  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Total liabilities and equity

   $ 4,443,553     $ 787,545     $ (485,186     $ 725,800       $ 5,471,712  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

See the accompanying notes to the Unaudited Pro Forma Condensed Combined Financial Information

 

3


UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

For The Six Months Ended June 30, 2023

($ in thousands)

 

     Enovis Historical
Six Months Ended
June 30, 2023
    Lima Historical
Six Months Ended
June 30, 2023 (Note 2)
    Transaction
Accounting
Adjustments
    Note 5     Financing
Adjustments
    Note 5     Pro Forma
Combined
 
Net sales    $ 834,653     $ 153,915     $ —     

 

 

 

  $ —     

 

 

 

  $ 988,568  

Cost of sales

     351,229       48,428       11,503       (a ) (f)      —          411,160  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Gross profit (loss)

     483,424       105,487       (11,503       —          577,408  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Selling, general and administrative expense      415,046       83,890       3,748       (f)       —     

 

 

 

    502,684  
Research and development expense      37,111       9,055       —     

 

 

 

    —     

 

 

 

    46,166  
Amortization of acquired intangibles      64,289       2,168       8,832       (c)       —     

 

 

 

    75,289  
Insurance settlement gain      —        —        —     

 

 

 

    —     

 

 

 

    —   
Restructuring and other charges      6,440       40,354       —     

 

 

 

    —     

 

 

 

    46,794  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Total operating expenses

     522,886       135,467       12,580         —          670,933  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Income (loss) from operations      (39,462     (29,980     (24,083  

 

 

 

    —     

 

 

 

    (93,525
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Interest expense, net      9,728       17,896       (17,942     (d)       26,607       (d)       36,289  
Debt extinguishment charges      —        —        —     

 

 

 

    —     

 

 

 

    —   
Unrealized gain on investment in ESAB Corporation      —        —        —     

 

 

 

    —     

 

 

 

    —   
Other expense, net      92       977       —     

 

 

 

    —     

 

 

 

    1,069  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Income (loss) from continuing operations before taxes      (49,282     (48,853     (6,141  

 

 

 

    (26,607  

 

 

 

    (130,883
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Income tax expense (benefit)      (11,826     (9,651     (1,678     (e)       (7,272     (e)       (30,427
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Net income (loss) from continuing operations      (37,456     (39,202     (4,463  

 

 

 

    (19,335  

 

 

 

    (100,456
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Income (loss) from discontinued operations, net of taxes      4,485       —        —     

 

 

 

    —     

 

 

 

    4,485  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Net income (loss)      (32,971     (39,202     (4,463  

 

 

 

    (19,335  

 

 

 

    (95,971
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Less: Net income attributable to noncontrolling interest from continued operations – net of taxes      374       —        —     

 

 

 

    —     

 

 

 

    374  
Less: Net income attributable to noncontrolling interest from discontinued operations – net of taxes      —        —        —     

 

 

 

    —     

 

 

 

    —   
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Net income (loss) attributable to Enovis Corporation    $ (33,345   $ (39,202   $ (4,463  

 

 

 

  $ (19,335  

 

 

 

  $ (96,345
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Net income (loss) per share - basic   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations      (0.70  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    (1.84
Discontinued operations      0.08    

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    0.08  
Consolidated operations      (0.61  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net income (loss) per share - diluted   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations      (0.70  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    (1.84
Discontinued operations      0.08    

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    0.08  

Consolidated operations

     (0.61            

See the accompanying notes to the Unaudited Pro Forma Condensed Combined Financial Information

 

4


UNAUDITED PRO FORMA CONDENSED COMBINED STATEMENT OF OPERATIONS

For the Year Ended December 31, 2022

($ in thousands)

 

     Envois Historical
Year Ended December
31, 2022
    Lima Historical
Year Ended
December 31,
2022 (Note 2)
    Transaction
Accounting
Adjustments
    Note 5     Financing
Adjustments
    Note 5     Pro Forma
Combined
 

 

Net sales

   $ 1,563,101     $ 261,255     $ —     

 

 

 

  $ —     

 

 

 

  $ 1,824,356  
Cost of sales      693,718       84,559       31,418       (a) (f)       —     

 

 

 

    809,695  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Gross profit (loss)

     869,383       176,696       (31,418       —          1,014,661  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Selling, general and administrative expense      772,913       147,325       18,405      
(b)
(f)
 
 
    —     

 

 

 

    938,643  
Research and development expense      60,827       17,988       —     

 

 

 

    —     

 

 

 

    78,815  
Amortization of acquired intangibles      126,301       9,101       12,899       (c)       —     

 

 

 

    148,301  
Insurance settlement gain      (36,705     —        —     

 

 

 

    —     

 

 

 

    (36,705
Restructuring and other charges      17,225       16,981       —     

 

 

 

    —     

 

 

 

    34,206  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 

Total operating expenses

     940,561       191,395       31,304         —          1,163,260  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Income (loss) from operations      (71,178     (14,699     (62,722  

 

 

 

    —     

 

 

 

    (148,599
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Interest expense, net      24,052       15,795       (15,927     (d)       54,791       (d)       78,711  
              
Debt extinguishment charges      20,396       —        —     

 

 

 

    —     

 

 

 

    20,396  
              
Unrealized gain on investment in ESAB Corporation      (102,669     —        —     

 

 

 

    —     

 

 

 

    (102,669
Gain on cost basis investment      (8,800     —        —     

 

 

 

    —     

 

 

 

    (8,800
Other expense (income), net      (2,088     (10,678     —     

 

 

 

    —     

 

 

 

    (12,766
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Income (loss) from continuing operations before taxes      (2,069     (19,816     (46,795  

 

 

 

    (54,791  

 

 

 

    (123,471
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Income tax expense (benefit)      36,120       6,861       (12,790     (e)       (14,975     (e)       15,216  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Net income (loss) from continuing operations      (38,189     (26,677     (34,005  

 

 

 

    (39,816  

 

 

 

    (138,687
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Income (loss) from discontinued operations, net of taxes      26,430       —        —     

 

 

 

    —     

 

 

 

    26,430  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Net income (loss)      (11,759     (26,677     (34,005  

 

 

 

    (39,816  

 

 

 

    (112,257
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Less: Net income attributable to noncontrolling interest from continued operations – net of taxes      567       —        —     

 

 

 

    —     

 

 

 

    567  
Less: Net income attributable to noncontrolling interest from discontinued operations – net of taxes      966       —        —     

 

 

 

    —     

 

 

 

    966  
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Net income (loss) attributable to Enovis Corporation    $ (13,292   $ (26,677   $ (34,005  

 

 

 

  $ (39,816  

 

 

 

  $ (113,790
  

 

 

   

 

 

   

 

 

     

 

 

     

 

 

 
Net income (loss) per share - basic   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations      (0.72  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    (2.57
Discontinued operations      0.47    

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    0.47  
Consolidated operations      (0.25  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    (2.10
Net income (loss) per share - diluted   

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Continuing operations      (0.72  

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    (2.57
Discontinued operations      0.47    

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

    0.47  

Consolidated operations

     (0.25               (2.10

See the accompanying notes to the Unaudited Pro Forma Condensed Combined Financial Information

 

5


Note 1 – Basis of Presentation

The Acquisition is preliminarily being accounted for as a business combination using the acquisition method with Enovis as the accounting acquirer in accordance with Accounting Standards Codification (“ASC”) Topic 805, Business Combinations (“ASC 805”). Under this method of accounting, the aggregate transaction consideration will be allocated to Lima’s assets acquired and liabilities assumed based upon their estimated fair values at the date of completion of the Acquisition. The process of valuing the net assets of Lima immediately prior to the Acquisition is preliminary. Any differences between the estimated fair value of the consideration transferred and the estimated fair value of the assets acquired and liabilities assumed will be recorded as goodwill. Accordingly, the aggregate transaction consideration allocation and related adjustments reflected in this unaudited pro forma condensed combined financial information are preliminary and subject to revision based on a final determination of fair value.

The Company and certain of its subsidiaries intend to enter into an Amendment of its Existing Credit Agreement to provide for the Term Loan Facility. Solely for purposes of these pro forma financial statements, the Company has assumed that it will issue $400,000,000 of 3.50% Convertible Senior Notes due 2028 as part of the offering and that it will use a portion of the proceeds from this offering of Convertible Notes, together with approximately $400 million of borrowings from the Term Loan Facility and cash on hand to fund the cash purchase price for the Lima Acquisition.

The unaudited pro forma condensed combined financial information presented is for informational purposes only and is not necessarily indicative of the financial position or results of operations that would have been realized if the Acquisition and Debt Financing had been completed on the dates set forth above, nor is it indicative of the future results or financial position of the Business. In addition, the unaudited pro forma condensed combined financial information does not reflect any anticipated synergies or dissynergies, operating efficiencies or cost savings that may result from the Acquisition.

All amounts presented within the notes to the unaudited pro forma condensed combined financial statements are presented in thousands of U.S. Dollars and have been prepared by applying Envois’ historical accounting policies. The unaudited pro forma condensed combined balance sheet as of June 30, 2023 gives effect to the Acquisition and the Debt Financing as if those transactions had been completed on June 30, 2023, and are applied to the unaudited condensed combined balance sheet of Enovis as of June 30, 2023.

The unaudited pro forma condensed combined statement of operations for the year ended December 31, 2022 and the six months ended June 30, 2023 give effect to the Acquisition and the Debt Financing as if those transactions had occurred on January 1, 2022, the first day of fiscal year 2022 and are applied to the historical results of Enovis.

The assumptions and estimates underlying the adjustments to the pro forma financial statements are described in the accompanying notes.

The pro forma adjustments are preliminary, subject to further revision as additional information becomes available and additional analyses are performed. The pro forma adjustments have been made solely for the purpose of providing unaudited pro forma combined financial information and actual adjustments, when recorded, may differ materially.

The pro forma financial statements have been prepared for illustrative purposes only and may not be indicative of the operating results or financial condition that would have been achieved if the Transactions had been completed on the dates or for the periods presented, nor do they purport to project the results of operations or financial position for any future period or as of any future date. In addition to the pro forma adjustments, various other factors will have an effect on the financial condition and results of operations after the completion of the Transactions. The actual balance sheet and statements of operations may differ materially from the pro forma amounts reflected herein due to a variety of factors.

The historical financial statements of Enovis were prepared in accordance with U.S. GAAP and have been adjusted in the accompanying unaudited pro forma condensed combined financial information to give effect to pro forma adjustments which are necessary to account for the Acquisition and the Debt Financing. The unaudited pro forma adjustments are based upon available information and certain assumptions that management believes are reasonable.

 

6


Note 2 – Adjustments to the Historical Financial Information of Lima

The historical financial information of Lima was prepared in accordance with IFRS issued by the International Accounting Standards Board (IASB) and presented in EUR.

Reclassification adjustments have been made to Lima’s historical financial information to comply with Enovis’ presentation.

The historical financial information was translated from EUR to USD using the following historical exchange rates:

 

     EUR to USD  

Period end exchange rate as at June 30, 2023

   $ 1.09  

Average exchange rate for the 6 months ended June 30, 2023

     1.09  

Average exchange rate for the year ended December 31, 2022

     1.05  

 

7


UNAUDITED SCHEDULE OF ADJUSTED CONDENSED COMBINED STATEMENT OF FINANCIAL POSITION OF LIMA

As of June 30, 2023

(in thousands)

 

     IFRS                              U.S. GAAP  
     Lima historical
June 30, 2023

EUR
     IFRS to U.S.
GAAP differences

- EUR
    Note     Presentation
Reclassification
EUR
    Note     Lima adjusted
historical June

30, 2023
EUR
     Lima adjusted
historical June

30, 2023
USD
 
ASSETS                 

Current assets:

                

Cash and cash equivalents

   23,681      —        —        23,681      $ 25,737  

Trade receivables

     79,106        —          —          79,106        85,975  

Inventories

     89,205        —          —          89,205        96,951  

Prepaid expenses

     —         —          2,565       (aa     2,565        2,788  

Other current assets

     12,371        —          (340     (aa     12,031        13,076  

Current tax assets

     2,225        —          (2,225     (aa     —         —   
  

 

 

    

 

 

     

 

 

     

 

 

    

 

 

 

Total current assets

     206,588        —          —          206,588        224,527  
  

 

 

    

 

 

     

 

 

     

 

 

    

 

 

 

Property, plant and equipment

     78,292        (8,802     (b     —          69,490        75,524  

Goodwill

     384,286        —          —          384,286        417,657  

Intangible assets, net

     —         —          21,204       (bb     21,204        23,045  

Other intangible assets

     21,204        —        (a     (21,204     (bb     —         —   

Lease asset - right of use

     —         8,802       (b     —          8,802        9,566  

Other assets

     —         —          34,252       (cc     34,252        37,226  

Equity investments

     2        —          (2     (cc     —         —   

Deferred tax assets

     32,377        —          (32,377     (cc     —         —   

Other non-current financial assets

     906        —          (906     (cc     —         —   

Other Non-current assets

     967        —          (967     (cc     —         —   
  

 

 

    

 

 

     

 

 

     

 

 

    

 

 

 

Total assets

   724,622      —        —        724,622      $ 787,545  
  

 

 

    

 

 

     

 

 

     

 

 

    

 

 

 

 

8


UNAUDITED SCHEDULE OF ADJUSTED CONDENSED COMBINED STATEMENT OF FINANCIAL POSITION OF LIMA (continued)

As of June 30, 2023

(in thousands)

 

     IFRS                         U.S. GAAP  
     Lima historical
June 30, 2023

EUR
    IFRS to U.S.
GAAP differences

- EUR
    Note   Presentation
Reclassification

EUR
    Note   Lima adjusted
historical June
30, 2023

EUR
    Lima adjusted
historical June
30, 2023

USD
 

LIABILITIES AND EQUITY

              

Current liabilities:

              

Current portion of long-term debt

   —      —        15,140     (dd)   15,140     $ 16,452  

Trade payables

     34,272       —          —          34,272       37,248  

Accrued liabilities

     —        2,568     (b)     24,897     (ee)     27,465       29,850  

Current financial liabilities

     17,708       (2,568   (b)     (15,140   (dd)     —        —   

Current tax liabilities

     1,234       —          (1,234   (ee)     —        —   

Other current liabilities

     23,663       —          (23,663   (ee)     —        —   
  

 

 

   

 

 

     

 

 

     

 

 

   

 

 

 

Total current liabilities

     76,878       —          —          76,878       83,550  
  

 

 

   

 

 

     

 

 

     

 

 

   

 

 

 

Long-term debt, less current portion

     —        —          284,881     (ff)     284,881       309,620  

Non-current lease liability

     —        5,303     (b)     —          5,303       5,764  

Other liabilities

     —        —          32,140     (gg)     32,140       34,931  

Non-current financial liabilities

     290,184       (5,303   (b)     (284,881   (ff)     —        —   

Employee benefits

     1,192       —          (1,192   (gg)     —        —   

Deferred tax liabilities

     10,176       —          (10,176   (gg)     —        —   

Provisions for risks and charges

     20,006       —          (20,006   (gg)     —        —   

Other non-current liabilities

     766       —          (766   (gg)     —        —   
  

 

 

   

 

 

     

 

 

     

 

 

   

 

 

 

Total liabilities

   399,201     —        —        399,201     $ 433,865  
  

 

 

   

 

 

     

 

 

     

 

 

   

 

 

 

Equity

              

Common stock

     —        —          9,868     (hh)     9,868       10,725  

Share capital

     9,868       —          (9,868   (hh)     —        —   

Additional paid-in capital

     —        —          390,009     (ii)     390,009       423,877  

Share premium reserve

     14,425       —          (14,425   (ii)     —        —   

Other reserves

     375,584       —          (375,584   (ii)     —        —   

Retained earnings

     —        —      (a)     (74,456   (jj)     (74,456     (80,922

Retained earnings (accumulated deficit)

     (41,239     —          41,239     (jj)     —        —   

Profit (loss) for the year

     (33,217     —          33,217     (jj)     —        —   

Accumulated other comprehensive loss

     —        —          —          —        —   
  

 

 

   

 

 

     

 

 

     

 

 

   

 

 

 

Total shareholders’ equity

     325,421       —          —          325,421       353,680  
  

 

 

   

 

 

     

 

 

     

 

 

   

 

 

 

Noncontrolling interest

     —        —          —          —        —   
  

 

 

   

 

 

     

 

 

     

 

 

   

 

 

 

Total equity

     325,421       —          —          325,421       353,680  
  

 

 

   

 

 

     

 

 

     

 

 

   

 

 

 

Total liabilities and equity

   724,622     —        —        724,622     $ 787,545  
  

 

 

   

 

 

     

 

 

     

 

 

   

 

 

 

 

9


UNAUDITED SCHEDULE OF ADJUSTED CONDENSED COMBINED STATEMENT OF OPERATIONS OF LIMA

For The Six Months Ended June 30, 2023

(in thousands)

 

     IFRS                         U.S. GAAP  
     Lima six months
ended June 30,
2023
    IFRS to U.S.
GAAP
differences –
EUR
    Note   Presentation
Reclassification

EUR
    Note   Lima adjusted six
months ended June
30, 2023

EUR
    Lima adjusted six
months ended June
30, 2023

USD
 

Revenue

   140,687     —        (140,687   (aa)   —      $ —   

Other revenues and income

     2,739       —          (2,739   (aa, kk)     —        —   

Raw materials, consumables, supplies and goods

     35,447       —          (35,447   (bb, dd)     —        —   

Services

     42,959       5,571     (a, b)     (48,530   (bb, cc,
dd)
    —        —   

Change in W.I.P., semi-finished products and finished

     (2,392     —          2,392     (bb)     —        —   

Personnel expenses

     43,969       —          (43,969   (bb, cc)     —        —   

Amortisation and depreciation

     14,967       (2,373   (b)     (12,594   (ee)     —        —   

Impairment losses on trade receivables

     (61     —          61     (ff)     —        —   

Impairment losses on fixed assets

     37,331       —          (37,331   (gg)     —        —   

Other operating costs

     980       —          (980   (cc)     —        —   

Internal work capitalised

     (6,281     —          6,281     (bb, cc)     —        —   

Financial income

     (4,094     —          4,094     (hh, ii)     —        —   

Financial expense

     22,745       (148   (b)     (22,597   (hh, ii)     —        —   

Income taxes expense (benefit)

     (8,928     —          8,928     (jj)     —        —   

Net sales

     —        —          142,384     (aa)     142,383       153,915  

Cost of sales

     —        —          44,800     (bb, ee)     44,800       48,428  

Selling, general and administrative expense

     —        —          77,605     (cc, ee,
ff)
    77,605       83,890  

Research and development expense

     —        —          8,377     (dd)     8,377       9,055  

Amortization of acquired intangibles

     —        —          2,006     (ee)     2,006       2,168  

Restructuring and other charges

     —        —          37,331     (gg)     37,331       40,354  

Interest expense, net

     —        —          16,555     (hh)     16,555       17,896  

Other expense, net

     —        —          904     (ii, kk)     904       977  

Income tax expense (benefit)

   —      —        (8,928   (jj)   (8,928   $ (9,651

 

10


UNAUDITED SCHEDULE OF ADJUSTED CONDENSED COMBINED STATEMENT OF OPERATIONS OF LIMA

For The Year Ended December 31, 2022

(in thousands)

 

     IFRS                         U.S. GAAP  
     Lima Year Ended
December 31,
2022

EUR
    IFRS to U.S.
GAAP
differences –
EUR
    Note   Presentation
Reclassification
EUR
    Note   Lima adjusted Year
Ended December 31,
2022

EUR
    Lima adjusted Year
Ended December 31,
2022

USD
 

Revenue

   245,669     —        (245,669   (aa)   —      $ —   

Other revenues and income

     5,798       —          (5,798   (aa,
kk)
    —        —   

Raw materials, consumables, supplies and goods

     56,391       —          (56,391   (bb,
dd)
    —        —   

Services

     81,645       11,655     (a, b)     (93,300   (bb,
cc, dd)
    —        —   

Change in W.I.P., semi-finished products and finished

     887       —          (887   (bb)     —        —   

Personnel expenses

     76,858       —          (76,858   (bb,
cc)
    —        —   

Amortisation and depreciation

     35,408       (5,335   (b)     (30,073   (ee)     —        —   

Impairment losses on trade receivables

     502       —          (502   (ff)     —        —   

Impairment losses on fixed assets

     16,152       —          (16,152   (gg)     —        —   

Other operating costs

     1,857       —          (1,857   (cc)     —        —   

Internal work capitalised

     (13,532     —          13,532     (bb,
cc)
    —        —   

Financial income

     (14,561     —          14,561     (hh, ii)     —        —   

Financial expense

     22,609       (220   (b)     (22,389   (hh, ii)     —        —   

Income taxes expense (benefit)

     6,526       —          (6,526   (jj)     —        —   

Net sales

     —        —          248,506     (aa)     248,506       261,255  

Cost of sales

     —        —          80,433     (bb,ee)     80,433       84,559  

Selling, general and administrative expense

     —        —          140,136     (cc, ee,
ff)
    140,136       147,325  

Research and development expense

     —        —          17,110     (dd)     17,110       17,988  

Amortization of acquired intangibles

     —        —          8,657     (ee)     8,657       9,101  

Restructuring and other charges

     —        —          16,152     (gg)     16,152       16,981  

Interest expense, net

     —        —          15,024     (hh)     15,024       15,795  

Other expense, net

     —        —          (10,157   (ii, kk)     (10,157     (10,678

Income tax expense (benefit)

   —      —        6,526     (jj)   6,526     $ 6,861  

 

11


Statement of financial position IFRS to U.S. GAAP and Reclassification Adjustments

a – Under U.S. GAAP, only certain development costs that are proven to have alternative future use can be capitalized. As some of the costs incurred by Lima do not have alternative future use, such capitalized costs would be adjusted under U.S. GAAP, however, the balance will be valued in connection with purchase accounting and no adjustment is reflected herein for the IFRS to U.S. GAAP conversion.

b – As of January 1, 2019, Enovis and Lima adopted ASC 842, Leases and IFRS 16, Leases, respectively. U.S. GAAP follows finance lease and operating lease models for lessees, which impacts the pattern of expense recognition associated with the lease. Under IFRS, lessees account for all their leases under one accounting model, which is effectively equivalent to that of a finance lease under U.S. GAAP. To comply with U.S. GAAP, the unaudited Schedule of Adjusted Condensed Combined Statement of Financial Position as of June 30, 2023 includes a reclassification to Lease asset – right-of-use of €8.8 million, Accrued liabilities of €2.5 million, and Non-current lease liability of €5.3 million. The company is continuing to evaluate the classification of potential finance leases under US GAAP.

aa – Adjustment to reclassify a portion of Lima’s Other current assets to Prepaid expenses and Lima’s Current tax assets to Other current assets

bb – Adjustment to reclassify Lima’s Other intangible assets to Intangible assets, net

cc – Adjustment to reclassify Lima’s Equity investments, Deferred tax assets, Other non-current financial assets, and Other non-current assets to Other assets

dd – Adjustment to reclassify Lima’s Current financial liabilities to Current portion of long-term debt

ee – Adjustment to reclassify Lima’s Current tax liabilities, and Other liabilities to Accrued liabilities

ff – Adjustment to reclassify Lima’s Non-current financial liabilities to Long-term debt

gg – Adjustment to reclassify Lima’s Other non-current liabilities, Employee benefits, Deferred tax liabilities, and Provision for risks and charges to Other liabilities

hh – Adjustment to reclassify Lima’s Share capital to Common stock

ii – Adjustment to reclassify Lima’s Share premium reserve, and Other reserves to Additional paid-in capital

jj – Adjustment to reclassify Lima’s Retained earnings (accumulated deficit), and Profit (loss) for the year to Retained earnings

 

12


Statement of operations IFRS to U.S. GAAP and Reclassification Adjustments

a - To adjust for certain development costs capitalized by Lima into intangible assets, net. Lima capitalizes certain costs such as software licenses and research and development to intangible assets in accordance with IFRS. Under U.S. GAAP, only research and development costs that are proven to have alternative future use can be capitalized. As some of the costs incurred by Lima do not have alternative future use, such capitalized costs are adjusted. The impact of the adjustment on the unaudited Schedule of Adjusted Condensed Combined Statement of Operations for the six months ended June 30, 2023 and year ended December 31, 2022 is calculated as the incremental expense that would have been recorded in accordance with U.S. GAAP during the respective periods. The adjustments result in an increase to Services for the six months ended June 30, 2023 and year ended December 31, 2022 totaling €3.1 million and €6.1 million, respectively.

b - As of January 1, 2019, Enovis and Lima adopted ASC 842, Leases and IFRS 16, Leases, respectively. U.S. GAAP follows finance lease and operating lease models for lessees, which impacts the pattern of expense recognition associated with the lease. Under IFRS, lessees account for all their leases under one accounting model, which is effectively equivalent to that of a finance lease under U.S. GAAP. To comply with U.S. GAAP, the unaudited Schedule of Adjusted Condensed Combined Statement of Operations for the six months ended June 30, 2023 and year ended December 31, 2022 includes a reclassification from Depreciation and Amortisation and Financial Expense to Services of €2.5 million and €5.6 million, respectively. The company is continuing to evaluate the classification of potential finance leases under US GAAP.

aa – Adjustment to reclassify Lima’s Revenue and a portion of Other revenues and income to Net sales. Reclassification to Net sales consists of revenue related to sales activities

bb – Adjustment to reclassify Lima’s Raw materials, Change in W.I.P., semi-finished products and finished, Services, Personnel, and Internal work capitalised to Cost of sales. Reclassification to Cost of sales consists of raw material costs, Changes in W.I.P., semi-finished products and finished, personnel costs and services costs related to production

cc – Adjustment to reclassify Lima’s Services, Personnel, Internal work capitalised, and Other operating costs to Selling, general and administrative expense. Reclassification to Selling, general and administrative expense consist of service costs, salary and wages expense of employees

dd – Adjustment to reclassify Lima’s Raw materials and Services to Research and development expense. Reclassification to Research and development expense consist of raw material and services costs related to research and development activities

ee – Adjustment to reclassify Lima’s Amortisation and depreciation to Cost of Sales, Selling, general and administrative expense and Amortization of acquired intangibles

ff – Adjustment to reclassify Lima’s Impairment losses on trade receivables to Selling, general and administrative expense

gg – Adjustment to reclassify Lima’s Impairment losses on fixed assets to Restructuring and other charges

hh – Adjustment to reclassify a portion of Lima’s Financial income and Financial expense to Interest expense, net. Reclassification of Interest expenses consists of interest income and financial charges related to bonds and loans

ii – Adjustment to reclassify a portion of Lima’s Financial income and Financial expense to Other expense, net

jj – Adjustment to reclassify Lima’s Income tax expense (benefit) to Income tax expense (benefit)

kk – Adjustment to reclassify a portion of Lima’s Other revenues and income to Other expense, net

 

13


Note 3 – Preliminary Aggregate Transaction Consideration and Allocation

Estimated Aggregate Transaction Consideration

The following table summarizes the preliminary estimated aggregate transaction consideration for the Lima Business:

 

(in thousands)

   Amount  

Closing cash consideration

   $ 438,280  

Cash paid to settle Lima historical long-term debt

     331,315  

Estimated fair value of shares to be issued as contingent consideration (i)

     80,000  
  

 

 

 

Preliminary aggregate transaction consideration

   $ 849,595  
  

 

 

 

 

(i)

Reflects the preliminary fair value of the contingent consideration payable to Lima based on the historical share price of Enovis and will change through the closing date of the acquisition. As part of the purchase consideration, Enovis may issue up to 1,942,686 shares of Enovis common stock as a result of the arrangement within approximately 18 months after closing. The market price of the Enovis common stock may fluctuate between the timing of issuance, a 5% fluctuation in the market price of the common stock would have approximately a $3.5 million impact on the aggregate transaction consideration.

 

14


Preliminary Aggregate Transaction Consideration Allocation

The assumed accounting for the Acquisition, including the preliminary aggregate transaction consideration, is based on provisional amounts, and the associated purchase accounting is not final. The preliminary allocation of the purchase price to the acquired assets and assumed liabilities was based upon the preliminary estimate of fair values. For the preliminary estimate of fair value of assets acquired and liabilities assumed of Lima, management used publicly available benchmarking information, as well as a variety of other assumptions, including market participant assumptions. Management is expected to use widely accepted income-based, market-based, and cost-based valuation approaches in connection with the finalization of purchase accounting for the Acquisition. Actual results may differ materially from the assumptions within the accompanying unaudited pro forma condensed combined financial information. The unaudited pro forma adjustments are based upon available information and certain assumptions that management believes are reasonable under the circumstances. The purchase price adjustments applied to the historical financial information of Lima are preliminary and subject to change as additional information becomes available and as additional analyses are performed.

The following table summarizes the preliminary aggregate transaction consideration allocation, as if the Acquisition had been completed on June 30, 2023, with excess recorded to Goodwill:

 

(in thousands)

   Amount  

Preliminary aggregate transaction consideration

   $ 849,595  
  

 

 

 

Assets

  

Cash and cash equivalents

     25,737  

Trade receivables

     85,975  

Inventories

     135,984  

Prepaid expenses

     2,788  

Other current assets

     13,076  

Property, plant and equipment

     175,686  

Intangible assets

     340,517  

Lease asset - right of use

     9,566  

Other assets

     37,226  
  

 

 

 

Total assets

     826,555  

Liabilities

  

Accounts payable

     37,248  

Accrued liabilities

     29,850  

Non-current lease liability

     5,764  

Other liabilities

     160,538  
  

 

 

 

Total liabilities

     233,400  
  

 

 

 

Less: Estimated preliminary net assets acquired

     593,155  
  

 

 

 

Goodwill (see Footnote 4(c))

   $ 256,440  
  

 

 

 

 

15


Note 4 – Adjustments to the Unaudited Pro Forma Condensed Combined Balance Sheet

Adjustments included in the Transaction Accounting Adjustments column and Financing Adjustments column in the accompanying unaudited pro forma condensed combined balance sheet as of June 30, 2023 are as follows:

(a) Reflects adjustment to Cash and cash equivalents:

 

(in thousands)

   Amount  

Pro forma transaction accounting adjustments:

  

Estimated transaction costs (i)

   $ (11,041

Cash paid to settle Lima historical long-term debt

     (331,315

Cash paid for acquisition of Lima

     (438,280
  

 

 

 

Net pro forma transaction accounting adjustments to Cash and cash equivalents

   $ (780,636
  

 

 

 

Pro forma financing adjustments:

  

Cash from new Debt Financing, net of debt issuance costs and capped call fees (ii)

   $ 725,800  
  

 

 

 

Net pro forma adjustments to Cash and cash equivalents

   $ (54,836
  

 

 

 

 

(i)

These costs consist of legal advisory, financial advisory, accounting and consulting costs expected to be incurred by Enovis. This is a preliminary estimate of costs and is subject to change upon close of the Transactions.

(ii)

New Debt Financing is reduced for debt issuance costs and original issue discount of $18.2 million as referenced in Footnote 4(j) and adjustments for capped call transaction of $56.0 million as referenced in Footnote 4(l).

(b) Represents a $39.0 million adjustment to the inventory balance to account for the preliminary adjustment to fair value of the inventory acquired as of the Acquisition Date. The estimated range of calculated value for inventory is based on preliminary estimates and assumptions. The final value determination of the acquired inventory may differ from this preliminary determination. The related assumptions and inputs will be refined as more data becomes available to determine the fair value indication.

(c) Preliminary adjustment to Goodwill, which represents the excess of the estimated aggregate transaction consideration over the preliminary fair value of the underlying assets acquired and liabilities assumed and the elimination of Lima’s historical Goodwill.

 

(in thousands)

   Amount  

Pro forma transaction accounting adjustments:

  

Goodwill resulting from the Acquisition (Note 3)

   $ 256,440  

Elimination of the Lima historical Goodwill

     (417,657
  

 

 

 

Net pro forma adjustments to Goodwill

   $ (161,217
  

 

 

 

 

16


(d) Reflects the preliminary purchase accounting adjustment for estimated intangibles based on the acquisition method of accounting. Adjustments to preliminary identifiable intangible assets in the unaudited pro forma condensed combined financial information consists of the following:

 

(in thousands)

   Preliminary
Fair Value
     Estimated
Useful Life
(Years)
 

Pro forma transaction accounting adjustments:

     

Estimated fair value – Technology

   $ 182,000        15  

Estimated fair value – Customer Relationships

     115,000        15  

Estimated fair value – Trade Name

     44,000        20  

Less: Historical Lima Intangible assets, net of amortization

     (23,528   
  

 

 

    

Net pro forma adjustments to Intangible assets, net

   $ 317,472     
  

 

 

    

(e) Reflects the settlement of historical Lima existing debt.

(f) Record estimated fair value of shares to be issued as contingent consideration.

(g) Reflects the elimination of Lima’s historical Common stock.

(h) Reflects the elimination of Lima’s historical Additional paid-in capital.

(i) Reflects the preliminary adjustment to Retained earnings, which includes the elimination of Lima’s historical Retained earnings.

 

(in thousands)

   Amount  

Pro forma transaction accounting adjustments:

  

Estimated transaction costs (i)

   $ (11,041

Less: Historical Lima Retained earnings elimination

     80,922  
  

 

 

 

Net pro forma adjustments to Retained earnings

   $ 69,881  
  

 

 

 

(i) These costs consist of legal advisory, financial advisory, accounting and consulting costs expected to be incurred by Enovis. This is a preliminary estimate of costs and is subject to change upon close of the Transactions.

(j) Reflects the Debt Financing obtained from the Lenders, net of unamortized debt issuance costs. The adjustment to current and long-term debt is comprised of the following items:

 

(in thousands)

   Current portion
of long-term debt
     Long-term debt      Total  

Pro forma financing adjustments:

 

Convertible Notes

   $ —       $ 400,000      $ 400,000  

Term Loan

     20,000        380,000        400,000  

Less: Debt issuance costs and original issue discount

     —         (18,200      (18,200
  

 

 

    

 

 

    

 

 

 

Net pro forma financing adjustments

   $ 20,000      $ 761,800      $ 781,800  
  

 

 

    

 

 

    

 

 

 

 

17


(k) Reflects the adjustments to record a deferred tax liability of $125.6 million resulting from pro forma fair value adjustments for the assets acquired and liabilities assumed. The estimate of the deferred tax was determined based on the estimated book basis of the net assets acquired after the application of acquisition accounting as compared to the tax basis of the net assets acquired using an estimated blended statutory tax rate of 27.3% for Intangible assets, net and estimated statutory tax rate of 27.9% for Property, plant and equipment, net and Inventories, net. Adjustments to established deferred tax assets and liabilities due to refined determination of statutory rates, changes in tax elections, as well as the changes in the estimates of the fair value of assets acquired and liabilities assumed may occur in conjunction with the finalization of the acquisition accounting and these changes in estimates could be material.

(l) Reflects a $56.0 million adjustment to record the capped call transactions entered into in connection with the issuance of the Convertible Notes. As these transactions meet certain accounting criteria, the capped call transactions are recorded in Shareholders’ equity and are not accounted for as derivatives.

(m) Reflects the preliminary purchase accounting adjustment of $100.1 million for Property, plant and equipment, net based on the acquisition method of accounting.

 

18


Note 5 – Pro Forma Adjustments to the Unaudited Condensed Combined Statement of Operations

Adjustments included in the Transaction Accounting Adjustments column and Financing Adjustments in the accompanying unaudited pro forma condensed combined statement of operations for the six months ended June 30, 2023 and the fiscal year ended December 31, 2022 are as follows:

(a) Reflects $10.2 million for six months ended June 30, 2023 and $28.7 million for the year ended December 31, 2022 adjustments associated with the step-up in estimated fair value of Inventories, net recognized through Cost of sales during the 18 months after the acquisition.

A 10% change in the estimated fair value of Inventories, net would cause a corresponding increase or decrease in Cost of sales of approximately $1.0 million and $2.9 million for the six months ended June 30, 2023 and the year ended December 31, 2022, respectively. Pro forma Cost of sales is preliminary and based on assumption that the inventory will be sold within 18 months of the closing date after the Transaction. The amount of Cost of sales following the Transaction may differ significantly between periods based upon the final value assigned and actual inventory turnover for each period.

(b) Reflects a $11.0 million adjustments to Selling, general and administrative expense (“SG&A”) related to expected transaction expenses.

(c) The following table reflects adjustments to Amortization of acquired intangibles related to amortization expense for the newly identified intangible assets, less the amortization expense on Lima’s historical intangible assets. Management is still in the process of evaluating the fair value of the intangible assets. Any resulting change in the fair value would have a direct impact to amortization expense, which could be material.

 

(in thousands)

   For the Six Months
Ended
June 30, 2023
     For the Year
Ended

December 31, 2022
 

Pro forma transaction accounting adjustments:

     

Amortization expense of Technology

   $ 6,067      $ 12,133  

Amortization expense of Customer Relationships

     3,833        7,667  

Amortization expense of Trade Name

     1,100        2,200  

Less: Historical amortization

     (2,168      (9,101
  

 

 

    

 

 

 

Net pro forma adjustments to Amortization of acquired intangibles

   $ 8,832      $ 12,899  
  

 

 

    

 

 

 

A 10% change in the valuation of technology intangible assets, customer relationship intangible assets, and trade name intangible assets would cause a corresponding increase or decrease in the amortization expense of approximately $1.1 million and $2.2 million for the six months ended June 30, 2023 and the year ended December 31, 2022, respectively. Pro forma amortization is preliminary and based on the use of straight-line amortization. The amount of amortization following the Acquisition may differ significantly between periods based upon the final value assigned and amortization methodology used for each identifiable intangible asset.

(d) Reflects the expense related to the financing and amortization of issuance costs related to the Transactions:

 

(in thousands)

   For the Six Months
Ended June 30, 2023
     For the Year Ended
December 31, 2022
 

Pro forma transaction adjustments:

     

Remove historical Lima Interest expense

   $ (17,942    $ (15,927

Pro forma financing adjustments:

     

Interest expense from the financing transactions

   $ 26,607      $ 54,791  

The interest expense included in the unaudited pro forma condensed combined financial information was calculated using an effective interest rate, which considers transaction costs and issuance discounts, and reflects an approximate weighted-average interest rate of 7.0%. Actual interest rates may vary from those depicted in the pro forma amounts.

 

19


A sensitivity analysis on interest expense for the six months ended June 30, 2023 and the year ended December 31, 2022 has been performed to assess the effect of a 12.5 basis point change of the hypothetical interest on the Debt Financing. The following table shows the change in the Interest expense for the Debt Financing described above:

 

(in thousands)

   For the Six Months Ended
June 30, 2023
     For the Year Ended
December 31, 2022
 

Interest expense assuming:

     

Increase of 0.125%

   $ 486      $ 993  

Decrease of 0.125%

   $ (486    $ (993

(e) Adjustment to reflect the income tax impact of the pro forma adjustments related to the Transactions using the estimated blended statutory tax rate of 27.3%. Income tax rates do not take into account any possible future tax events or changes in planned structure for the combined company. The effective tax rate of the combined company could be significantly different than what is presented in the pro forma financial information.

(f) Adjustment to reflect the incremental depreciation expense associated with the fair value step up of Property, plant and equipment, net. The following table reflects adjustments to Cost of sales and Selling, general and administrative expense related to depreciation expense for the increase in fair value of Property, plant and equipment, net. Management is still in the process of evaluating the fair value of the property, plant and equipment assets. Any resulting change in the fair value would have a direct impact to depreciation expense, which could be material.

 

(in thousands)

   For the Six Months
Ended June 30, 2023
     For the Year
Ended December 31, 2022
 

Pro forma transaction adjustments – Cost of Sales:

     

Incremental depreciation expense associated with Property, plant and equipment, net

   $ 1,252      $ 2,636  

Net pro forma adjustments to Cost of sales

   $ 1,252      $ 2,636  

Pro forma transaction adjustments – Selling, general and administrative expense:

     

Incremental depreciation expense associated with Property, plant and equipment, net

   $ 3,748      $ 7,364  

Net pro forma adjustments to Selling, general and administrative expense

   $ 3,748      $ 7,364  

 

20


Note 6 – Pro Forma Earnings Per Share

The unaudited pro forma condensed combined basic and diluted earnings per share calculations are based on the condensed combined basic and diluted average shares of Enovis and Lima. 

 

(in thousands, except per share data)

   For the six months
ended June 30, 2023
     For the Year Ended
December 31, 2022
 

Pro Forma Weighted Average Shares

     

Basic and diluted weighted average number of common shares outstanding – historical

     54,510,688        54,065,420  

Pro Forma Earnings per Share

     

Pro forma Net income (loss) from continuing operations

     (100,456      (138,687

Basic – Pro Forma

   $ (1.84      (2.57

Diluted – Pro Forma

   $ (1.84      (2.57

 

21

EX-99.4

Exhibit 99.4

 

LOGO

 

 

News Release

 

ENOVIS CORPORATION ANNOUNCES PROPOSED PRIVATE OFFERING OF $400 MILLION

OF CONVERTIBLE SENIOR NOTES

WILMINGTON, DE, October 19, 2023 (GLOBE NEWSWIRE)—Enovis Corporation (NYSE: ENOV, “Enovis” or the “Company”) today announced its intention to offer, subject to market conditions and other factors, $400 million aggregate principal amount of Convertible Senior Notes due 2028 (the “Notes”) in a private offering (the “Offering”). In connection with the Offering, Enovis expects to grant the initial purchasers of the Notes an option to purchase, within a 13-day period beginning on, and including, the date on which the Notes are first issued, up to an additional $60 million aggregate principal amount of the Notes on the same terms and conditions.

In connection with the pricing of the Notes, the Company expects to enter into privately negotiated capped call transactions with one or more of the initial purchasers or their respective affiliates and/or other financial institutions (the “option counterparties”). The capped call transactions are expected generally to mitigate potential dilution to the Company’s common stock upon conversion of any Notes and/or offset any cash payments the Company is required to make in excess of the principal amount of converted Notes, as the case may be, with such reduction and/or offset subject to a cap. If the initial purchasers exercise their option to purchase additional Notes, the Company expects to enter into additional capped call transactions with the option counterparties.

In connection with the capped call transactions, concurrently with or shortly after the pricing of the Offering, the Company expects the option counterparties or their respective affiliates to purchase shares of the Company’s common stock and/or enter into various derivative transactions with respect to the Company’s common stock. This activity could increase or reduce the size of any decrease in the market price of the Company’s common stock and/or the Notes. Further, while the Notes are outstanding, these counterparties may modify any such hedge positions by entering into or unwinding such positions, or by purchasing or selling the Company’s common stock or other securities in secondary market transactions. These counterparties are likely to engage in such activities at any exercise date of or termination of any portion of the capped call transactions. This activity could cause or avoid an increase or decrease in the market price of the Company’s common stock and/or the Notes.

Enovis intends to use a portion of the net proceeds from the Offering to pay the cost of the capped call transactions. Enovis intends to use the remainder of the net proceeds from the Offering, together with approximately $400 million of borrowings under a new term loan facility, and cash on hand to fund the cash purchase price of the pending acquisition of LimaCorporate S.p.A. (“Lima”) (the “Lima Acquisition”), with any remaining proceeds being used for general corporate purposes. Until the Lima Acquisition is consummated, Enovis intends to hold the net proceeds from the Offering in cash and cash equivalents or use the net proceeds from the Offering to pay down borrowings under its existing credit facility pending the closing of the transaction. If the initial purchasers exercise their option to purchase additional Notes, the Company expects to use a portion of the net proceeds from the sale of the additional Notes to enter into additional capped call transactions with the option counterparties and the remainder to fund the purchase price of the Lima Acquisition, with any remaining proceeds being used for general corporate purposes.

If the Lima Acquisition is not consummated, and the Company does not elect to redeem the Notes in connection therewith pursuant to the option described below, the Company intends to use the proceeds the Company would have otherwise used to finance in part the Lima Acquisition for general corporate purposes.

The final terms of the Notes, including the initial conversion price, interest rate and certain other terms, will be determined at the time of pricing of the Offering. When and if issued, the Notes will be senior unsecured obligations of Enovis and will rank equal in right of payment to the Company’s unsecured and unsubordinated indebtedness. The Notes will mature on October 15, 2028, unless earlier repurchased, redeemed or converted in accordance with their terms prior to such date. Prior to the close of business on the business day immediately preceding April 15, 2028, the Notes will be convertible at the option of the holders of the Notes only upon the satisfaction of specified conditions and during certain periods. On or after April 15, 2028 until the close of business on the second scheduled trading day immediately preceding the maturity date, the Notes will be convertible, at the option of the holders of Notes, at any time regardless of such conditions. Upon conversion, Enovis will pay cash up to the aggregate principal amount of the Notes to be converted and pay or deliver, as the case may be, cash, shares of the Company’s common stock or a combination of cash and shares of the Company’s common stock, at the Company’s election, in respect of the remainder, if any, of the Company’s conversion obligation in excess of the principal amount of the Notes being converted. If the Lima Acquisition is not consummated on or prior to June 30, 2024 or if, before such time, the acquisition agreement with respect to the Lima Acquisition is terminated or the Company reasonably determines in good faith that the Lima Acquisition will not be consummated, the Company may, at its option, redeem all (but not less than all) of the Notes on a redemption date on or prior to September 30, 2024, in cash at a redemption price equal to 101% of the principal amount of the Notes to be redeemed, plus accrued and unpaid interest to, but excluding, the redemption date, plus a premium, if any.

The Notes will be offered only to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). The offer and sale of the Notes and any shares of the Company’s common stock issuable upon conversion of the Notes, if any, have not been, and will not be, registered under the Securities Act or the securities laws of any other jurisdiction, and unless so registered, the Notes and such shares, if any, may not be offered or sold in the United States except pursuant to an applicable exemption from such registration requirements.

This press release does not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any offer or sale of, the Notes (or any shares of the Company’s common stock issuable upon conversion of the Notes) in any state or jurisdiction in which the offer, solicitation, or sale would be unlawful prior to the registration or qualification thereof under the securities laws of any such state or jurisdiction.

About Enovis Corporation

Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company’s shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV.

Forward-Looking Statements

Some of the statements contained in this press release that are not historical facts are forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The Company intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 21E of the Exchange Act. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Statements other than statements of historical fact are statements that could be deemed forward-looking statements, including statements regarding: the ability to consummate and realize benefits from the Lima Acquisition; the impacts of the completed spin-off of ESAB Corporation (“ESAB”) into an independent publicly traded company (the “Separation”); the expected financial and operating performance of, and future opportunities for, the Company following the Separation; the impact of the COVID-19 global pandemic; projections of revenue, profit margins, expenses, tax provisions and tax rates, earnings or losses from operations, impact of foreign exchange rates, cash flows, synergies or other financial items; plans, strategies and objectives of management for future operations including statements relating to potential acquisitions, compensation plans or purchase commitments; developments, performance, industry or market rankings relating to products or services; future economic conditions or performance, including the impact of increasing inflationary pressures; the outcome of outstanding claims or legal proceedings; potential gains and recoveries of costs; assumptions underlying any of the foregoing; and any other statements that address activities, events or developments that the Company intends, expects, projects, believes or anticipates will or may occur in the future. Forward-looking statements may be characterized by terminology such as “believe,” “anticipate,” “should,” “would,” “could,” “may,” “likely,” “intend,” “plan,” “will,” “expect,” “estimate,” “project,” “positioned,” “strategy,” “targets,” “aims,” “seeks,” “sees,” and similar expressions. These statements are based on assumptions and assessments made by the Company’s management as of the date of this press release in light of their experience and perception of historical trends, current conditions, expected future developments and are subject to risks, uncertainties and other factors, including but not limited to: the risk that the Company may not be able consummate the Lima Acquisition on the anticipated terms or at all, the risk that the Company’s assumptions with respect to the Offering and capped call transactions may be incorrect, and other risks, uncertainties and other factors set forth in the Company’s reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors,” as well as the other risks and uncertainties set forth in the Company’s other filings with the SEC. In addition, these statements are based on assumptions that are subject to change. Any such forward-looking statements are not guarantees of future performance and actual results, developments and business decisions may differ materially from those envisaged by such forward-looking statements. This press release speaks only as of the date hereof. Enovis disclaims any duty to update the information herein, excepts as required by law.

Investor Relations Contact

Kyle Rose

Vice President, Investor Relations

Enovis Corporation

+1-917-734-7450

investorrelations@enovis.com

Media Contact

Katie Sweet

Vice President, Corporate Communications

Enovis Corporation

Katie.sweet@enovis.com